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Canada is getting older. 
According to Statistics Canada, the share of our population 
made up of older adults will grow from just under 15% in 
2010 to more than 25% in 2036. As this subgroup grows 
larger, there will be a significant impact on many aspects 
of our society, including a greater burden placed on our 
healthcare system. And that burden will be much heavier if 
the increasingly prevalent issue of substance use by older 
adults is not addressed.
The issue is, however, difficult to comprehend fully. When 
most people think of someone with a substance use 
disorder, an older adult does not immediately come to 
mind. When an older adult suffers a fall or experiences 
declining physical or mental health, we are quick to assume 
it’s the result of “getting older” and might not consider the 
possibility of substance use as a contributing factor.
To find a path forward that recognizes the needs of this 
growing population and responds effectively, we need 
to set our assumptions aside and look to the evidence. 
We need to build a more thorough understanding of 
what’s happening to people during this stage of life and 
why they might be more susceptible to experiencing 
harms associated with substance use (both licit and illicit 
substances) and problematic substance use.
In that sense, there are interesting parallels between this 
topic and the one featured in our previous report in this 
series, which explored cannabis use during adolescence. 
Much like youth, older adults experience significant 
physiological, psychological and social change. It’s a 
period of rapid, dynamic and difficult transitions. Taking 
a closer look at the unique elements of later life and how 
they relate to substance use, as we do in this report, is 
key to developing new and more tailored strategies for 
reducing the harms of alcohol and drugs on older adults. 
Since 2005, the series now known as Substance Use in 
Canada has highlighted alcohol- and drug-related issues 
that are in need of greater attention. For this seventh 
edition, we began with two questions: How can we help 
people age in a healthy way? and How can we ensure 
they have the supports they need to sustain a good 
quality of life in their later years?
Getting the answers to those questions begins by having 
a dialogue about substance use by older Canadians. 
It is with that in mind that this report calls for greater 
awareness and understanding of the issue among 
healthcare providers and caregivers — and facilitates that 
understanding through an in-depth exploration of the 
latest evidence on “successful aging,” the prevalence of 
substance use among older Canadians, the consequences 
of substance use in this vulnerable population, and other 
critical topics. It also emphasizes the need for a complete 
continuum of age-specific care, including substance use 
guidelines and treatment services tailored to the specific 
needs of this demographic, backed by improved training 
and education on how to detect and assess problematic 
substance use in older adults.
Through the evidence presented in this report, we are hoping 
to jumpstart a national conversation about substance use 
by older adults. And as with any conversation, the words 
we use are critically important. For this reason, we changed 
the title of this series to Substance Use in Canada from the 
previous Substance Abuse in Canada, reflecting a similar 
change we made to the name of our organization. The 
intent is to take every opportunity to move the language 
used away from stigma and toward greater sensitivity to all 
those affected by substance use disorders, including older 
adults. Understanding and language matter — especially 
if they help lead to better policies, practices and programs 
for older Canadians.
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About Substance Use in Canada
Since 2005, Substance Use in Canada (formerly Substance 
Abuse in Canada) has shone a spotlight on key contemporary 
issues related to substance use and identified specific areas 
for action in both policy and practice. Each report in the 
series is intended for a broad audience that includes policy 
makers, program development personnel, researchers, 
educators and health professionals. Health journalists are 
also an important audience as they can help raise the public 
profile of the issues discussed and help create the impetus 
for change.
This seventh Substance Use in Canada report explores 
alcohol and drug use in older adulthood (age 65 and older). 
Specifically, it:
• Considers the impact of the aging population and 
increasing problematic substance use among 
older adults on health outcomes and the Canadian 
healthcare system;
• Identifies gaps in knowledge about the harms 
associated with substance use and their impacts 
on healthy aging; and
• Summarizes the best available evidence on 
effective ways to prevent, detect, assess and  
treat problematic substance use in the older  
adult population. 
As the older adult population continues to grow so will the 
total number of older adults who use alcohol and other 
drugs, making it increasingly important to understand the 
needs of older adults and how the Canadian healthcare 
system can adapt to meet them. 
This report is not a systematic review. Instead, it provides 
a broad, high-level overview of this important health issue, 
drawing on neuroscience and an understanding of the 
behavioural and social context that shapes older adults’ 
substance use. It aims to give decision makers, policy 
makers, nurses, geriatricians, researchers and others 
working with older adults the opportunity to consider 
the evidence as they develop and employ more effective 
prevention and intervention programs to address substance 
use among older adults. 
Canadians have several misperceptions when it comes to 
substance use among older adults. Some don’t think it’s an 
issue at all. Others believe it’s too late to improve the quality 
of life of someone who uses substances in older age. Why 
try to get somebody to quit smoking after 50 years? Isn’t 
the damage already done?
Nothing could be further from  
the truth. 
We know that older adults do use substances: prescription 
and non-prescription, legal and illegal. Problematic 
substance use can develop gradually, becoming noticeable 
only later in life. And although prevalence of substance use 
is much lower among older adults than other age groups, 
they are at elevated risk for experiencing harms associated 
with non-prescription substance use.
Most importantly, we know quality of life can be improved 
significantly by addressing problematic substance use, 
regardless of a person’s age. Older adults can indeed live 
long, healthy and productive lives while in recovery.
Unfortunately, addressing the issue of substance use 
in older adults has proven to be difficult for a number of 
reasons. Too often, the symptoms of impairment are 
dismissed by clinicians as the symptoms of old age. The 
social isolation experienced by many older adults results in 
fewer opportunities for monitoring by friends and family. As 
their social networks continue to grow smaller, many older 
adults are hesitant to even broach the topic of substance 
use with family or caregivers, not wanting to bring conflict 
into their few remaining relationships. 
From a research perspective, we are also challenged by 
the lack of evidence specific to Canada. We still need to 
learn more about how substance use affects healthy aging. 
We also need to look more closely at the effectiveness of 
age-specific screening and treatment options. 
Foreword Introduction
The Series to Now
Current Challenges and Choices examined a variety of 
topics, including the prevention of alcohol problems, 
alternative sanctions for cannabis use and possession, 
drug-impaired driving, and the abuse and diversion of 
prescription medication. 
Focus on Youth looked at the prevalence of substance 
use and its associated harms among young people, 
exploring the underlying neurobiology of substance 
use in adolescence and identifying existing gaps in 
youth-centric services. 
Concurrent Disorders focused on the co-occurrence of 
mental health and substance use problems, examining 
the interconnections between addiction and mental 
illness, the costs of concurrent disorders for the 
healthcare system, and why treating these complex 
cases requires new and innovative approaches.
Licit and Illicit Drug Use during Pregnancy addressed the 
medical and obstetrical consequences of problematic 
drug use and dependency in pregnant women, as 
well as the short- and long-term effects that prenatal 
exposure to drugs can have on a child’s development.
Childhood and Adolescent Pathways to Substance Use 
Disorders explored influences during childhood and 
adolescence that can affect problematic substance use 
later in life, as well as the implications an understanding 
of those influences has for prevention and treatment.
The Effects of Cannabis Use during Adolescence 
reviewed the effects of youth cannabis use, looking 
specifically at the drug’s impact on health and brain 
development, as well as the interventions currently 
available for treating cannabis use disorder.
That’s where this report comes into play. It pulls together 
the evidence that currently exists, and sheds light on areas 
that need more research. It identifies the current gaps in 
Canada’s healthcare system, as well as potential tools or 
resources to help fill them. 
At the Canadian Institutes of Health Research Institute of 
Neurosciences, Mental Health and Addiction, an important 
part of our mandate is to focus on research into substance 
use. While typically this has centred around younger 
populations, we now know that substance use is far more 
common among older adults than previously thought. We 
also know that the issue can be addressed and we can’t 
afford to wait. As Canada’s population continues to age, 
the time for action is now. 
We need to put in place, as soon as possible, systems and 
strategies to promote healthy aging. To do so, we must 
improve our understanding of older adults’ unique needs 
with respect to substance use. We have to reduce the 
stigma that surrounds substance use so that older adults 
engage in the conversation and seek support. And, finally, 
we have to follow through and ensure older adults, their 
families and caregivers know how to access the services 
and supports they need. 
Samuel Weiss, Ph.D., FRSC, FCAHS 
Scientific Director, Institute of Neurosciences,  
Mental Health and Addiction 
Canadian Institutes of Health Research
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more severely among older adults. For example, older 
Canadians are more often nicotine-dependent than the 
general population. 
For cannabis and other illicit drugs, the data suggest a 
cohort effect. As younger generations of Canadians are 
more likely to use and be exposed to these substances, 
there will likely be an increase in their use (and related 
health issues) in the decades to come as the younger 
cohort enters older adulthood.
Chapter 3: The Aging Brain and Substance Use
As the population ages, a deeper knowledge of how the 
aging process changes the brain will be critical to better 
understanding the impact of substance use on older 
adults’ health. 
After discussing how the brain’s function, structure and 
compensatory processes change with age, this chapter 
presents a detailed examination of the impact of aging on 
pharmacodynamics: the actions drugs have on the body. 
It explores the age-related changes that affect several 
neurotransmitter systems as well as the neuroendocrine 
and homeostatic systems. It also reviews the impact 
of aging on pharmacokinetics (the actions of the body 
on drugs), looking at how drug absorption, distribution, 
metabolism, and excretion and elimination processes 
change in older adulthood.
In some cases, pharmacodynamic and pharmacokinetic 
changes associated directly with aging can increase the 
likelihood of harmful drug–drug interactions or toxicity. In 
addition, problematic drug use places additional stress 
on the body’s systems (which are already more vulnerable 
with age) and reduces individuals’ ability to deal with the 
consequences of the aging process.
Chapter 4: Consequences of Alcohol and Drug 
Use in Older Adults
Age-related physiological changes to the nervous, 
gastrointestinal, respiratory and renal systems all result 
in diminished function, making older adults more 
vulnerable to the effects of substance use. This heightened 
level of vulnerability also significantly increases the risk of 
adverse outcomes that place a greater burden on 
Canada’s healthcare system and social services. 
This chapter provides an overview of some of the harmful 
consequences of substance use among the aging population, 
including hospitalization, falls, vehicular accidents, cognitive 
impairment, depression, substance withdrawal and death, 
including by suicide. Mortality rates are much higher among 
older adults who have substance use disorders. 
Because the use of alcohol and medication, whether 
prescribed or misused, causes greater harm in older adults 
than illicit drugs, this chapter focuses on how the use of 
alcohol, opioids, benzodiazepines and cannabis can result 
in adverse health outcomes. Alcohol’s accessibility and 
prevalence of use make it the substance of greatest risk, 
with the widest range of harms, for older adults. More older 
adults in Canada are hospitalized each year for alcohol-
related issues than for heart attacks. 
The chapter concludes with a discussion of the social 
consequences of substance use, which include elder abuse, 
homelessness, family breakdown, crime and social isolation.
Chapter 5: Considerations for Co-occurring 
Health Conditions
Many older adults with psychiatric disorders use illicit drugs 
or misuse prescription drugs, which can ultimately worsen 
the severity of and prognosis for their mental illness. Certain 
physical health problems in older adults can also be worsened 
by problematic substance use. When older adults have co-
occurring psychiatric disorders and medical problems, they 
are at much greater risk of developing a substance use 
disorder (SUD) or experiencing harmful interactions between 
prescription and non-prescription medications.
This chapter presents evidence on the prevalence of 
and contributing factors behind some of the psychiatric 
disorders that commonly co-occur with SUDs, including 
schizophrenia, mood and anxiety disorders, post-traumatic 
stress disorder, and Alzheimer’s and Parkinson’s diseases. 
It also looks at how SUDs (and their lack of treatment) 
can worsen physical health issues such as coronary heart 
disease, diabetes, insomnia and chronic pain. 
As demand grows for integrated physical health, mental 
health and addictions services for older adults, there is 
need for more research focused on older adults with 
substance use disorders and co-occurring physical or 
mental illnesses. 
Chapter-by-Chapter Summary
Chapter 1: Substance Use and Successful 
Aging: Key Issues and Considerations
The global population is aging dramatically, with older 
adults representing the fastest-growing segment of society. 
In Canada, the number of older adults increased from 
2.7 million in 1986 to 4.8 million in 2010. By 2036, 
approximately 25% of Canada’s population will be 65 years 
of age and older.
This chapter explores the concept of “successful 
aging,” highlighting the importance of specific lifestyle 
and psychological factors that help people adapt to the 
physical, cognitive and emotional changes associated 
with older adulthood. Maintaining social contacts, pursuing 
stimulating activities and cultivating a sense of purpose 
in life are all key to successful aging. The absence of 
these factors appears to increase the risk of problematic 
substance use: social isolation, sudden lifestyle changes 
(such as retirement) and declining physical health are 
some of the main reasons why older adults use alcohol, 
prescription drugs and other substances. 
Strategies and interventions designed to promote successful 
aging could hold the key to reducing problematic substance 
use among older adults, with patients, caregivers and 
healthcare providers all having important roles to play in 
ensuring positive aging outcomes.
Chapter 2: Epidemiology of Psychoactive 
Substance Use among Older Adults
This chapter summarizes the most recent epidemiologic 
data on substance use among Canadians aged 55 and 
older, looking at their prevalence of use for five categories 
of psychoactive substances: tobacco, alcohol, prescription 
drugs (pain relievers, sedatives and stimulants), cannabis 
and other illicit drugs. 
While older Canadians generally use these substances less 
frequently than younger Canadians, patterns of daily use are 
more common among older adults for prescription drugs 
and especially alcohol, with daily drinking and drinking 
that exceeds low-risk drinking guidelines both peaking in 
the 55 and older age group. In addition, the health-related 
problems associated with substance use are experienced 
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Several of the terms used throughout this report have clinical definitions, which are provided below. The Canadian Centre 
on Substance Use and Addiction no longer uses the term “substance abuse,” as it is generally accepted that this term is 
stigmatizing and does not reflect the current consensus on the subject. However, some of the sources cited in the report 
do use “substance abuse” and variations on the term as clinical indicators and outcomes. Whenever the sources use these 
terms, they are reflected in the text of the report by being included in quotation marks to indicate they come from another 
source. These terms are left intact to preserve the integrity of the original research being cited.
Addiction:1 A health condition characterized by compulsive 
drug use, despite harmful consequences. Someone 
suffering from addiction is unable to consistently abstain from 
substance use, even when it causes physical, psychological, 
social or economic harms. Other symptoms include craving 
for the substance and diminished recognition of problems 
with one’s behaviour and relationships.
Substance dependence:2 A physiological dependence 
on a psychoactive substance developed after prolonged 
use, where an individual experiences withdrawal symptoms 
when the substance is abruptly discontinued. Dependence 
can occur without the psychological and behavioural 
symptoms associated with addiction, such as compulsive 
use and craving. 
Substance misuse:3 The use of a psychoactive substance 
in a way that increases the risk of harmful consequences 
for the person misusing the substance. Substance misuse 
can be defined specifically as the use of a prescription 
medication by someone other than the person to whom the 
medication is prescribed or in a manner or for a purpose 
contrary to what is medically intended.  
Substance use: “Substance” includes all legal and illegal 
drugs or psychoactive substances, including alcohol and 
tobacco. Because of this breadth of application, the term 
is often modified.
Substance use disorder:4 A cluster of cognitive, 
behavioural and physiological symptoms related to the 
use of a psychoactive substance and experienced by an 
individual who continues to use the substance despite the 
symptoms. A substance use disorder is characterized by 
a maladaptive pattern of use that continues despite harms 
to the individual’s physical or mental health, or the welfare 
of others. A disorder can also result in adverse social 
consequences related to substance use, such as failure 
to meet work, family or school obligations, interpersonal 
conflicts or legal problems. 
Chapter 6: Detection, Screening and Assessment
Most people who misuse substances never receive the 
treatment they need for a number of reasons, the most 
notable being a lack of detection. Some symptoms of 
substance use can be masked by other physical ailments, 
making it difficult for clinicians to identify them. At the same 
time, friends, family and caregivers might attribute an older 
adult’s symptoms simply to getting older and therefore not 
seek treatment. 
Several substance use screening tools and approaches 
are reviewed in this chapter, looking at their ease of use 
and ability to accurately detect problematic substance use 
in older adults. Ultimately, the best approaches are those 
that are tailored to reflect the unique sensitivities of older 
adults. Also discussed are the importance of conducting 
more comprehensive assessments of older adults, the 
challenges inherent to diagnosing SUDs in older adults, and 
the atypical presentations of substance use in older adults 
that clinicians must consider when making a diagnosis. 
The chapter concludes by highlighting the need for better 
training of healthcare professionals and students on the 
prevention and detection of SUDs in older adults, with a 
brief discussion of some of the more innovative programs 
and curricula in this field.
Chapter 7: Substance Use Treatment  
for Older Adults
When age-specific treatment services are available, older 
adults are more likely than younger adults to complete 
treatment programs — with comparable or better treatment 
outcomes, including reduced (or eliminated) substance use 
as well as improvements to overall health and quality of life. 
This chapter explores some of the pharmacological options 
available to clinicians for treating acute intoxication and 
withdrawal among older adults, providing guidelines and 
best practices for addressing symptoms related to alcohol, 
opioid, benzodiazepine, nicotine and cannabis disorders 
and dependence. It also offers advice on the use of 
inpatient residential treatment (to prevent continual access 
to alcohol and drugs) and outpatient treatment (to connect 
patients with resources in their community).
Also addressed are the many behavioural treatment options 
available to build social support, improve self-esteem and 
develop ways to cope with substance use, including brief 
interventions, motivational interviewing, case and care 
management, and contingency management. Addiction 
treatment in primary care settings is also covered in this 
chapter, emphasizing the importance of offering a continuum 
of care that includes linkages to community resources.
Chapter 8: A Call to Action
Summarizing the key findings presented in the previous 
chapters, this final section of the report outlines the 
immediate actions that can be taken to address the 
issue of under-diagnosis and under-reporting of SUDs in 
older adults, which, in turn, will improve treatment outcomes 
and reduce the harms associated with substance use in 
older adults.
This chapter calls for greater awareness of the growing 
issues associated with substance use by older adults, 
noting that more research and policy focused specifically 
on this population is required to shift ageist societal 
attitudes on substance use. Increasing awareness also 
means delivering more training and education to healthcare 
professionals and students, helping them improve the 
skills and capacity for detecting and diagnosing SUDs in 
older adults. 
Finally, the report advocates developing clinical guidelines 
and recommendations for the diagnosis and treatment of 
SUDs that are tailored to the unique needs of older adults, 
which will require more precise understanding of the stages 
of development within older adulthood. There is a need to 
improve the availability and accessibility of age-specific 
treatments and care — and to effectively communicate 
information about those services to the general public, 
healthcare professionals, decision makers and older adults. 
Terminology Notes
1 American Society of Addiction Medicine. (2011). Public policy statement: definition of addiction. Retrieved from www.asam.org/advocacy/find-a-
policy-statement/view-policy-statement/public-policy-statements/2011/12/15/the-definition-of-addiction
2 National Institute on Drug Abuse. (2014). Media guide. Retrieved from www.drugabuse.gov/publications/media-guide/dear-journalist
3 World Health Organization. (2015). Lexicon of alcohol and drug terms. Retrieved from www.who.int/substance_abuse/terminology/who_lexicon/en/
4 American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders, (5th ed.). Washington, D.C.: American Psychiatric 
Publishing.
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CHAPTER AT A GLANCE
• Older adults represent the fastest growing segment of society. In Canada, the  
aging population is expected to grow faster than in most other developed countries. 
• Rates of substance use and substance use disorders among older adults are 
projected to increase over the next few decades.
• Risk factors for substance use among older adults stem from difficulties adjusting to 
the lifestyle changes and challenges experienced during aging, including the loss of 
meaningful work-related activities (e.g., retirement), social isolation and the presence 
of chronic medical conditions.
• Not all older adults follow the same trajectory in normal aging declines, with some 
individuals displaying what is known as “successful aging.”
• Older adults who age successfully appear to possess positive psychological traits 
and lifestyles, such as optimism, adaptability and social engagement, that make 
them more resilient to the challenges of older adulthood.
• By incorporating successful aging strategies into their lives and work, patients, 
caregivers and healthcare providers might be able to help prevent problematic 
substance use among older adults. 
CHAPTER
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estimates the share of Canada’s gross domestic product 
(GDP) directed toward aging-related health and long-
term care will rise by 1.9% from 2010 to 2025 (Canadian 
Institute for Health Information, 2011). In absolute terms, 
this is equivalent to a $30.9-billion increase in healthcare 
expenditures, or $905 per Canadian. 
As older adults represent a fast-growing, economically 
significant population, determining strategies for promoting 
successful aging will be essential to ensuring positive aging 
outcomes and controlling healthcare costs (see Chapter 2 
for more discussion on that topic). Before reviewing 
the research on successful aging, it is first necessary 
to describe how the typical aging process unfolds. 
1.3 How the Typical Aging Process 
Affects Health
Aging into older adulthood is associated with changes 
across multiple health domains, especially those related to 
physical, cognitive and emotional health. 
1.3.1 Physical Health
Non-communicable and chronic diseases are highly 
prevalent among older adults. Arthritis and rheumatism 
are the most common chronic conditions, affecting 44% 
of the older adult population in Canada. Cardiovascular 
disease is also highly prevalent; in 2009, 23% of Canadian 
older adults reported some form of heart disease and 56% 
reported a diagnosis of high blood pressure. A significant 
percentage of older Canadian women also suffer from 
osteoporosis (29%). In addition, older Canadian adults 
make up a disproportionate number of new cases of 
cancer, with 39% of all new cases in 2006 diagnosed 
among Canadians age 65–79 and another 17% diagnosed 
among Canadians 80 years and older. Finally, many older 
Canadians report conditions affecting their hearing and 
vision, such as cataracts and glaucoma (Public Health 
Agency of Canada, 2010).
1.3.2 Cognitive Health
Subtle declines in cognitive abilities occur as a person 
advances into older adulthood, with numerous studies 
exploring the specificity of these deficits across distinct 
cognitive processes and domains. Crystallized intelligence, 
which involves knowledge that is overlearned and 
familiar (e.g., vocabulary, general knowledge), remains 
largely stable through the sixth (age 50–60) and seventh 
(age 60–69) decades of life. In contrast, fluid 
intelligence — that is, the ability to process and learn new 
information, reason and solve problems, and attend to and 
manipulate the environment — declines gradually over the 
course of adulthood (Salthouse, 2012). 
Most prominent among the changes seen in fluid 
intelligence are declines in the speed with which cognitive 
activities and motor responses are performed (termed 
processing speed). Processing speed typically peaks 
between the ages of 20 and 29, then gradually declines 
throughout the rest of adulthood and into older adulthood 
(Salthouse, 2010). Declines in processing speed can affect 
other cognitive domains, including memory (Luszcz & 
Bryan, 1999). 
Declines in complex attention (e.g., dividing attention 
between multiple tasks) and executive functioning (e.g., 
self-monitoring, planning, organizing, reasoning, problem 
solving) are also prominent among older adults, with these 
abilities typically beginning to subside during the seventh 
decade (Salthouse, 2010; Salthouse, Fristoe, Lineweaver, 
& Coon, 1995). The neurological basis of these cognitive 
changes is complex, primarily involving reductions in grey 
and white matter volume as well as reduced white matter 
tract integrity (Harada, Natelson Love, & Triebel, 2013). 
1.3.3 Emotional Health
In contrast to physical and cognitive health, subjective 
well-being and psychological health might improve in older 
adulthood. Several studies have reported that mental health 
follows a U-shaped curve over the course of development, 
with declines in mental health occurring in early adulthood 
and into middle adulthood followed by subsequent 
improvement in later adulthood (Blanchflower & Oswald, 
2008; Jeste & Oswald, 2014; Stone, Schwartz, Broderick, 
& Deaton, 2010). Similarly, large-scale epidemiological 
studies have reported lower levels of mental illnesses in 
older adults (de Graaf, ten Have, van Gool, & van Dorsselaer, 
2012; Hasin, Goodwin, Stinson, & Grant, 2005). 
Other research has looked more specifically at emotional 
domains. The findings suggest that happiness, enjoyment 
and the inverse of sadness all exhibit U-shaped patterns 
over development. Stress and anger decline linearly with 
age, while worry remains elevated into middle age and then 
declines in older adulthood (Stone et al., 2010; Goncalves 
& Byrne, 2013).
1.1 Introduction
The global population is aging dramatically, with older 
adults now the fastest growing segment of society. People 
face a number of challenges as they age, from social 
isolation to an increase in chronic medical conditions. 
Difficulties adjusting to these challenges place older adults 
at heightened risk of problematic substance use (Arndt & 
Schultz, 2015).
Given these realities, the number of older adults with 
problematic substance use is projected to increase over 
the next few decades (Jeste et al., 1999; Patterson & Jeste, 
1999). This increase is concerning because problematic 
substance use among older adults is associated with 
negative physical, cognitive and emotional health 
outcomes, all of which can lead to higher healthcare costs 
(Koh, Gorney, Badre, & Jeste, 2016). 
Research on “successful aging” has highlighted the 
importance of specific lifestyle and psychological factors in 
helping people adapt to the challenges of older adulthood 
(Harmell, Jeste, & Depp, 2014). These factors might also 
hold the key to reducing rates of substance use among 
older adults.
1.2 Demographic Trends in Aging
The aging population represents an unprecedented 
demographic trend: there are now more older adults and 
a greater proportion of older adults relative to the total 
population than at any time in history (Bloom, Canning, 
& Fink, 2010). Worldwide, the number of individuals 
over the age of 60 increased from 200 million in 1950 to 
approximately 760 million in 2011, with the percentage 
of older adults increasing from 8% to 11% of the overall 
population (Beard et al., 2012). 
The aging trend is likely to continue for the next several 
decades. Current estimates project that the number of 
individuals over the age of 60 worldwide will reach two 
billion by 2050, representing 22% of the overall population 
(Beard et al., 2012). The world’s population is expected to 
increase 3.7 times from 1950 to 2050; during that same 
period, the population of individuals age 60 and older will 
increase by a factor of 10 (Bloom, Boersch-Supan, McGee, 
& Seike, 2011). 
Canada has not been excluded from this growth in the 
number of older adults. Between 1986 and 2010, the 
number of older adults rose from 2.7 million to 4.8 million, 
increasing the proportion of older adults to the general 
population from 10% to 14% (Canadian Institute for Health 
Information, 2011). As of 2011, 14.4% of the Canadian 
population was 65 years and older — making the percentage 
of older adults in Canada slightly higher than the worldwide 
average (Statistics Canada, 2011). 
By 2036, approximately 25% of Canada’s population will be 
65 years of age and older (Statistics Canada, 2007). In fact, 
Canada’s aging population is expected to grow faster than 
most other developed countries, with current projections 
stating it will take just 33 years for the number of people 
age 65 and older to increase by 10%. In comparison, the 
United States is expected to take nearly 50 years to realize 
this same percentage increase (Canadian Institute for 
Health Information, 2011).
1.2.1 Causes and Consequences of the Global 
Aging Trend
There appear to be three main reasons for the 
disproportionate growth of the aging population (Canadian 
Institute for Health Information, 2011): 
• Life expectancy has increased substantially over 
the past century, largely due to economic and 
healthcare advances. Worldwide, the average  
life expectancy has risen from 48  years in 1950 
to 68 years in 2010 — and is predicted to reach 
76 years by 2050. 
• Fertility rates have declined, resulting in a 
decrease in the proportion of younger individuals 
relative to the overall population. In 1950, the 
fertility rate was five children per woman; it has 
since fallen to approximately 2.5 children per 
woman. The fertility rate is expected to further 
decline over the coming decades, decreasing  
to 2.2 children per woman by 2050.
• The large cohorts of children born after World  
War II (the “baby boomers”) are shifting population 
structures as they age. 
Given that older adults are frequent users of healthcare 
services, it is unsurprising that these aging trends have 
contributed to rising healthcare costs. Between 1998 
and 2008, healthcare expenditures increased by 7.4% in 
Canada, with the aging of the population accounting for 11% 
of this increase. Projecting into the future, the Organisation 
for Economic Co-operation and Development (OECD) 
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appearing in 91% of definitions of successful aging, 
followed by engagement (51%), well-being (49%), personal 
resources (25%) and extrinsic factors (6%). This research 
suggests successful aging is a complex, multidimensional 
construct that involves more than simply the absence of 
disability or disease.
Due to the lack of consensus on a definition, the prevalence of 
successful aging has been difficult to estimate precisely. Depp 
and Jeste (2006) reported a mean proportion of successful 
aging of 35.8%, but noted that prevalence depended 
substantially on the operational definition used. Inclusion of a 
disability/physical function dimension had the largest impact 
on prevalence: studies that included this dimension reported 
a mean prevalence of 27.2% whereas those that excluded 
it reported a mean prevalence of 63.8%. Similarly, Cosco 
and colleagues (2014) reported a wide range of prevalence 
estimates, noting that the number of constructs included 
in the operational definition of successful aging affected 
prevalence estimates substantially. Operational definitions 
including only a single construct reported a mean prevalence 
of 32.5% whereas those including four constructs yielded a 
prevalence of 23.3%.
1.4.2 A Qualitative Perspective  
on Successful Aging
An alternative approach to defining successful aging has 
focused on the perspectives of older adults themselves. 
These studies have consistently found that older adults 
emphasize the importance of psychological well-being over 
physical and cognitive functioning in describing successful 
aging. For instance, von Faber and colleagues (2001) 
reported that while older adults acknowledge the impact 
of physical and cognitive limitations, they perceive their 
ability to adapt to and make the best of these changes as 
more crucial.
Maintaining social contacts was also seen as a key 
component of successful aging. Knight and Ricciardelli 
(2003), for example, found that older adults highlighted 
the ability to adjust to losses and limitations as central 
to successful aging. Again, older adults noted that while 
health-related issues could pose challenges to continuing 
previously enjoyed activities, learning to adjust to these 
challenges and finding activities better suited to their 
current capabilities was more central to success in aging.
Spotlight: Successful Aging  
Evaluation study
The Successful Aging Evaluation (SAGE), a 
community-based study of dementia-free adults 
in San Diego County, California, examined the 
physical, cognitive and mental health of individuals 
between the ages of 20 and 100. Participants 
were selected by random digit dialing, with 
oversampling of individuals older than 75 years. 
After controlling for relevant demographic factors 
(gender, education, marital status), analyses 
revealed that both cognitive and physical health 
declined while mental health improved in older age 
groups relative to younger groups. Specifically, 
physical and cognitive health exhibited non-linear 
worsening, with accelerated declines beginning 
around age 70. Mental health, on the other hand, 
improved linearly with age. This pattern represents 
a paradoxical trend in aging: despite worsening 
physical and cognitive health, older adults report 
superior mental health relative to younger cohorts 
(Thomas et al., 2016).
1.4 What Is Successful Aging?
While most individuals age in accordance with the physical, 
cognitive and emotional health trends described above, 
a minority of older adults exhibits a more favourable 
progression in some, if not all, of these three domains. In 
their seminal review, Rowe and Kahn (1987) argued that 
many of the declines observed in typical aging are due 
not to the aging process but rather result from exogenous 
factors such as lifestyle choices. They also suggested 
that the aging process could be improved by focusing 
on individuals who exhibit superior aging. Consistent with 
this proposal, twin studies suggest that longevity and 
functioning in older adulthood are only 20–30% heritable, 
suggesting a key role for exogenous factors (Gurland, Page, 
& Plassman, 2004). The concept of successful aging was 
proposed to identify individuals who have demonstrated 
favourable aging outcomes, and to highlight the relevant 
behaviours and strategies they used to promote such 
outcomes (Fiocco & Yaffe, 2010).
1.4.1 Defining Successful Aging
The term “successful aging” was introduced into biomedical 
literature in the 1970s and 1980s. Rowe and Kahn (1987) 
articulated the most influential early model of successful 
aging, which had three components: freedom from disease 
and disability; high cognitive and physical functioning; and 
social and productive engagement. This model was then 
incorporated into the MacArthur Foundation Research 
Network on Successful Aging study, which followed 1,000 
older adults and was the first large-scale longitudinal study 
of successful aging.
Despite the influence of Rowe and Kahn’s definition, there is 
currently no consensus on how to define successful aging. 
Depp and Jeste (2006) reviewed 28 studies on successful 
aging and identified 29 distinct definitions. Consistent with 
Rowe and Kahn’s definition, most of the conceptualizations 
of successful aging identified by Depp and Jeste were 
multidimensional. The most common dimensions identified 
were, in order of frequency, disability/physical functioning 
(26/29 definitions), cognitive functioning (13/29), life 
satisfaction/well-being (9/29), social/productive engagement 
(8/29), presence of illness (6/29), longevity (4/29), self-rated 
health (3/29), personality (2/29), environment/finances (2/29) 
and self-rated successful aging (2/29). 
A more recent review identified 105 operational definitions 
of successful aging across 84 studies (Cosco, Prina, 
Perales, Stephan, & Brayne, 2014). These definitions were 
categorized into five broad constructs: 
• Physiological (physical function/disability, cognitive 
function, illness/disease presence, health status, 
longevity, mental health); 
• Well-being (affective status, life satisfaction/ 
well-being); 
• Engagement (active life/social engagement,  
support system); 
• Personal resources (personal resources, 
independence/autonomy); and 
• Extrinsic factors (environment/finances). 
The authors of this review also found that the majority 
of definitions were multidimensional, with the average 
definition incorporating 2.2 of these broad constructs. 
Physiological constructs were the most frequently included, 
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Reichstadt and colleagues (2010) conducted qualitative 
interviews with older adults to determine their conceptions 
of successful aging. They found older adults describe 
successful aging as a balance between two seemingly 
opposing tendencies: self-acceptance/self-contentment and 
self-growth/engagement. Self-acceptance was described 
as having a realistic self-appraisal and comfort with one’s 
past experiences and current circumstances, while self-
growth involved an active engagement in life, including 
pursuing novel activities, maintaining social relationships, 
fostering a positive attitude and contributing to others’ 
well-being. Taken together, studies exploring the subjective 
experience of older adults highlight important psychological 
and behavioural components of successful aging that are 
often not captured by objective definitions.
1.4.3 Success Factors
Given their differing definitions, it is not surprising 
that objective and subjective prevalence estimates of 
successful aging differ widely. For instance, Strawbridge 
and colleagues (2002) compared Rowe and Kahn’s 
criteria directly to self-rated successful aging in a sample 
of 867 older adults aged 65–99 years. While Rowe and 
Kahn’s criteria yielded a successful aging prevalence of 
18.8%, self-rated successful aging was much higher at 
50.3%. Presence of disease and disability emerged as the 
most prominent rate-limiting factor of objectively defined 
successful aging. 
In contrast, many older adults considered themselves 
to be successful agers despite having chronic medical 
conditions. A similar pattern was documented by Vahia and 
colleagues (2010) in a study of 1,979 women over age 60. 
Respondents were asked to rate themselves on a scale from 
1 (not successfully aging) to 10 (successfully aging). Nearly 
90% of older women rated themselves with a score of 7 or 
higher despite only 15% of the sample reporting absence of 
disease and only 38% reporting freedom from disability (see 
also Montross et al., 2006; von Faber  et al., 2001).
These findings suggest successfully aging older adults 
might possess positive psychological traits that render them 
resilient to the challenges of aging. Across two longitudinal 
studies, older adults with a more positive self-perception of 
aging exhibited superior functional health and survival over 
time (Levy, Slade, & Kasl, 2002; Levy, Slade, Kunkel, & Kasl, 
2002). Giltay and colleagues (2004) found that dispositional 
optimism, defined as the “general expectation that good 
things rather than bad things are likely to happen in the 
future,” was predictive of decreased all-cause mortality, with 
optimism being particularly protective against cardiovascular 
mortality among men. Having a purpose in life is also 
important for older adults: those with a stronger sense of 
“meaning” exhibited better physical health, leading to lower 
levels of mortality over a period of five years (Krause, 2009). 
Consistent with these findings, older adults themselves 
tend to emphasize psychosocial factors as central to aging 
successfully. Reichstadt and colleagues (2007) conducted 
focus group interviews with 72 older adults between 
the ages of 60 and 99. Participants identified 33 factors 
relevant to successful aging, which could be grouped into 
four broad categories:
1. The importance of one’s attitude and ability  
to adapt to change; 
2. A sense of security and stability in life, often related 
to issues involving one’s living environment, social 
supports and financial resources;
3. Engagement in life, including pursuing stimulating 
activities, contributing to others’ well-being and 
cultivating a sense of purpose; and
4. Physical health and wellness, although it should 
be noted that participants conveyed mixed 
opinions on their necessity for successful aging.
Additional correlates of successful aging outside of positive 
psychological traits have also included factors related to 
age and physical health. In their review, Depp and Jeste 
(2006) reported that age (closer to age 60), freedom from 
arthritis or diabetes, absence of hearing problems, better 
activities of daily living and being a non-smoker were the 
most predictive factors of successful aging. Moderate 
support was also found for exercise/physical activity, 
better self-rated health, lower systolic blood pressure, 
fewer medical conditions and the absence of depression, 
while limited support was found for higher income, greater 
education, current marriage and white ethnicity. 
At age 60, Patrice was involved in a car accident that significantly impaired his mobility 
and resulted in chronic back pain, forcing him to retire early from his job at an automotive 
manufacturing plant. As many of Patrice’s closest friends were his co-workers, he felt isolated 
and lonely after retiring. While he had drunk alcohol in modest amounts throughout his life, he 
started drinking more frequently after retirement — both to cope with the pain and to assuage 
his feelings of boredom and loneliness. At first, Patrice drank only a beer or two per day; over 
time, that increased to five or six beers per day. 
Concerned over Patrice’s alcohol intake and thinking he may be depressed, his wife 
encouraged him to see a doctor; however, Patrice refused. When Patrice’s wife passed away 
when he was 64 he became even more withdrawn, often going days without showering. 
Worried about his well-being, Patrice’s two sons insisted he see a doctor, to which he 
eventually agreed. 
During the appointment, the doctor discussed a plan to reduce Patrice’s substance use and 
improve his mood. When Patrice mentioned that most of his former co-workers had now 
retired, he was encouraged to reconnect with them. Patrice’s oldest son also asked Patrice to 
move in with him, saying he was struggling to find daycare for his daughter and could use the 
help. Finally, the doctor recommended Patrice see a therapist to discuss his sadness, monitor 
his alcohol use and develop behavioural strategies to cope with his chronic pain.
Six months later, Patrice is living with his son. He enjoys caring for his granddaughter, saying 
it makes him feel useful again. He reconnected with several former co-workers and served 
as an important support when the wife of his best friend passed away. And while Patrice 
remains skeptical about therapy, he enjoys having somebody to talk to about his wife. Today, 
Patrice drinks only a beer or two per occasion and only in social contexts. Although he’s still 
frustrated by his functional limitations, he knows there are many positive things in his life and 
he shouldn’t focus so much on the bad things outside his control.
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1.5 Why Older Adults Use  
Alcohol, Prescription Drugs  
and Other Substance
Prevalence of substance use among older adults can be 
difficult to estimate because current diagnostic criteria might 
not be appropriate for this population (Arndt & Schultz, 
2015). Older adults most frequently report problematic use 
of alcohol, nicotine and prescription medications, although 
rates of cannabis use have increased in recent years 
(Simoni-Wastila & Yang, 2006). 
While older adults do not report high levels of problematic 
psychoactive drug use, nearly one in four reports having 
used a psychoactive medication with an abuse potential 
(Simoni-Wastila & Yang, 2006). The baby boomer generation, 
particularly individuals between the ages of 50 and 64, report 
using more illicit and non-medical drugs than older cohorts. 
Taking these two trends together, current projections 
estimate that the number of older adults with substance 
use disorders will rise considerably in the future (Wu & 
Blazer, 2011). In the U.S., the number of older adults with 
a substance use disorder is projected to double between 
2002–2006 and 2020 (Han, Gfroerer, Colliver, & Penne, 
2009). There is no corresponding estimate for the increase 
of older adults with a substance use disorder in Canada. 
1.5.1 Lifestyle Changes
Numerous lifestyle changes and challenges specific to older 
adulthood could contribute to substance use. Retirement 
is a near-universal phenomenon among older adults that 
brings significant changes to one’s life, including the loss 
of meaningful work-related activity, a reduction in social 
contacts and an increase in leisure time. Among some 
older adults, these changes can increase depression and 
reduce well-being, especially when retirement is abrupt 
or perceived as happening too early (Szinovacz & Davey, 
2004). While some studies have reported unemployment 
as being associated with increased substance use among 
older adults (Bryant & Kim, 2012), others have not found 
this association (Lin  et  al., 2011). It is likely that there is 
not a direct relationship between retirement and substance 
use; rather, one’s social network might play a key role in 
the association between retirement and substance use. 
Individuals with limited social networks independent 
of work could exhibit higher rates of post-employment 
substance use (Kuerbis & Sacco, 2012).
1.5.2 Physical Health
Physical health among older adults might also affect 
substance use. Several studies have reported that healthier 
older adults are more likely to use alcohol problematically 
(Bryant & Kim, 2012; Merrick et al., 2008; Platt, Sloan, & 
Costanzo, 2010). Others have found the opposite pattern, 
with less healthy individuals more likely to report problematic 
alcohol use (St. John, Montgomery, & Tyas, 2009). Overall, 
there appears to be a subset of healthy older adults who 
drink excessively; however, once their health declines they 
may limit their alcohol use (Arndt & Schultz, 2015). The 
one notable exception to this trend is among older adults 
with medical conditions causing chronic pain. They might 
rely on alcohol to reduce pain, leading to more alcohol use 
problems (Moos, Brennan, Schutte, & Moos, 2010). 
The association between physical health and non-medical 
prescription drug use is clearer. Research has consistently 
identified poor general medical condition and having 
chronic or multiple physical illnesses as risk factors for the 
non-medical use of prescription drugs (Sarkar, Parmar, 
& Chatterjee, 2015). Medical illnesses such as chronic 
pain, insomnia and anxiety increase the likelihood of 
exposure to prescription drugs with abuse potential, 
especially benzodiazepines, opiate analgesics and skeletal 
muscle relaxants (Culberson & Ziska, 2008). In the majority 
of cases, non-medical use of prescription drugs is 
unintentional among older adults (Sarkar et al., 2015).
1.5.3 Social Isolation
Finally, social isolation is a known risk factor for substance 
use. Social isolation can be divided into two types: 
objective social isolation, in which an individual possesses 
few social contacts; or perceived social isolation, in which 
the individual might have a typical level of social contact but 
has less social contact than they desire. Perceived social 
isolation is also known colloquially as “loneliness.” 
Rates of clinically significant loneliness rise substantially in 
older adulthood, with estimates reaching as high as 40% 
(Pinquart & Sorensen, 2001; Weeks, 1994). Importantly, 
loneliness is associated with a greater propensity to abuse 
alcohol and can serve as both an initiating and maintaining 
factor in alcohol abuse (Akerlind & Hornquist, 1992). On 
the other hand, objective social isolation, especially due to 
living at home alone, appears to contribute to a greater 
likelihood of non-medical use of prescription drugs among 
older adults (Jinks & Raschko, 1990; Sarkar et al., 2015). 
Mechanisms underlying this association are currently 
unclear and deserve further examination. 
Marriages can also undergo substantial changes in older 
adulthood that can lead to social isolation, with widowhood 
being the most significant. Research has consistently 
demonstrated an association between marital status 
and substance use. Compared to those who are married, 
single older adults are more likely to use alcohol (Blazer & 
Wu, 2009; Lin et al., 2011; Merrick et al., 2008; Moore et al., 
2009), cannabis (Blazer & Wu, 2009) and nicotine (Blazer 
& Wu, 2012).
1.6 How Patients, Caregivers  
and Providers Can Promote 
Successful Aging
Risk factors for problematic substance use overlap 
considerably with the processes relevant to successful aging. 
Older adults see successful aging as the ability to accept 
and adapt to the medical and social challenges of older 
adulthood (Knight & Ricciardelli, 2003; Reichstadt  et  al., 
2010; von Faber et al., 2001). Maintaining social contacts, 
pursuing stimulating activities and cultivating a sense of 
purpose in life are also seen as important components of 
successful aging (Reichstadt et al., 2010; von Faber et al., 
2001). The flip side of each of these factors appears to 
increase risk of problematic substance use. More specifically, 
limited social contact and limited social networks (Akerlind 
& Hornquist, 1992; Jinks & Raschko, 1990; Kuerbis & 
Sacco, 2012; Sarkar et al., 2015), reductions in meaningful 
activity (Bryant  &  Kim, 2012; Kuerbis & Sacco, 2012), 
and the presence of and difficulties adjusting to chronic 
medical conditions (Sarkar  et  al., 2015; St John  et  al., 
2009), especially chronic pain (Culberson & Ziska, 2008; 
Moos  et  al., 2010), contribute to problematic substance 
use among older adults. This correlation suggests that 
interventions designed to promote successful aging 
could also reduce problematic substance use  —  with 
patients, caregivers and healthcare providers each having 
an important role to play in cultivating the elements of 
successful aging.
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1.6.1 Patients
As there are several modifiable lifestyle factors that 
contribute to both successful aging and substance use 
among older adults, a multifactorial approach is warranted. 
Such an approach should focus on three goals: reducing 
physical illness; increasing social engagement; and 
improving psychological well-being.
There is a wealth of research demonstrating that physical 
activity reduces the risk of cardiovascular disease, metabolic 
disease and osteoarthritis during aging (Harmell  et  al., 
2014). Increased physical activity also appears to improve 
cognitive function and reduce the risk of cognitive decline 
among older adults (Brown, Peiffer, & Martins, 2013). To 
achieve these health benefits, the American College of 
Sports Medicine recommends at least 150 minutes of 
moderate weekly physical activity (i.e., 30 minutes per day, 
five days per week) (Chodzko-Zajko et al., 2009).
As mentioned earlier, social withdrawal and loneliness 
increase in older adulthood, largely due to physical decline 
and retirement (Pinquart & Sorensen, 2001; Weeks, 1994). 
Limited social engagement has been shown to affect self-
reported health, cognitive functioning and depression, as 
well as alcohol and prescription drug abuse among older 
adults (Akerlind & Hornquist, 1992; Jinks & Raschko, 1990; 
Sarkar et al., 2015). Interventions to reduce social isolation 
among older adults should focus on improving social 
skills, enhancing social supports, increasing opportunities 
for social contact and restructuring maladaptive social 
cognition (Masi, Chen, Hawkley, & Cacioppo, 2011). 
Increasing positive psychological traits is also a 
promising strategy to promote successful aging and 
reduce substance use among older adults. Resilience, 
optimism and adaptability appear to be especially 
important psychological contributors to successful aging 
(Engberg  et  al., 2013; Jeste  et  al., 2013). Although no 
structured interventions have been conducted to promote 
these positive psychological traits, it has been suggested 
that increasing levels of social support, enhancing self-
efficacy and structuring tasks to an individual’s ability level 
might enhance these traits (Southwick & Charney, 2012). 
1.6.2 Caregivers
Caregivers can play a key role in promoting successful 
aging and reducing substance use by encouraging social 
engagement and promoting healthy lifestyle behaviours. 
To increase social engagement, caregivers should provide 
activities that are deemed meaningful and enjoyable by 
their loved one. These activities should be consistent 
with the individual’s level of ability or, if beyond their level 
(e.g., because of physical disability), structured in a way 
that allows the individual to successfully engage in them. 
Older adults often report social activities (particularly those 
involving family and friends) and opportunites to contribute 
to the well-being of others as especially important to 
successful aging (Reichstadt, Sengupta, Depp, Palinkas, 
& Jeste, 2010).
Caregivers can also help promote an active lifestyle. 
Moderate exercise or even a simple walking program can 
help improve cardiovascular fitness and cognitive functioning 
(Erickson et al., 2011). Engaging in activities that stimulate 
cognition, such as board games, card games and crossword 
puzzles, might also help reduce the risk of cognitive decline 
(Hughes, Chang, Vander Bilt, & Ganguli, 2010).
1.6.3 Healthcare Providers
Healthcare providers can play a crucial role in monitoring 
successful aging and substance use among their patients. 
They should promote and monitor programs intended 
to increase physical activity, social engagement and 
psychological well-being. This task will require discussion 
with both patients and their caregivers to determine 
the appropriateness of successful aging strategies, the 
effectiveness of these strategies and the need for potential 
modification. Providers should also make sure to inquire 
beyond physical health when speaking with patients and 
caregivers, as psychological factors appear to be just as 
important (if not more important) than physical health in 
positive aging and substance use outcomes.
At the same time, providers must be aware of potential 
limitations in the decision-making capacity of older 
adults with physical dependence on substances. Many 
individuals with a physical dependence exhibit impairments 
on decision-making tasks, typically characterized by a 
preference for actions associated with short-term gains 
with reduced consideration for long-term losses and a 
greater likelihood of selecting risky actions (Bechara & 
Damasio, 2002; Lane & Cherek, 2000). These decision-
making deficits can be further exacerbated in older adults 
because of declines in cognition associated with aging 
(Harada et al., 2013). 
As there is considerable heterogeneity in decision-making 
capacity among individuals with a physical substance 
dependence, conclusions about decisional capacity should 
not be drawn strictly from an individual’s diagnosis (Jeste & 
Saks, 2006). When questions about capacity to consent to 
treatment arise, providers are advised to consider use of a 
structured instrument to assess treatment-related decision-
making capacity, such as the MacArthur Competence 
Assessment Tool — Treatment (Grisso, Appelbaum, & Hill-
Fotouhi, 1997) or the Hopkins Competency Assessment 
Tool (Janofsky, McCarthy, & Folstein, 1992).
1.7 Conclusion
Many risk factors for substance use among older adults 
stem from difficulties adjusting to socio-environmental 
challenges specific to older adulthood including retirement, 
social withdrawal, widowhood and chronic medical 
conditions. Research among successful agers has revealed 
numerous strategies for coping with these challenges — 
and these strategies for successful aging might also 
provide a robust preventative approach to substance use 
among older adults.
With the increasing use of psychoactive drugs and the aging 
of the baby boomer generation, problematic substance use 
is projected to increase over the coming years (Han et al., 
2009). To develop more effective interventions, policy 
makers, clinicians and allied healthcare workers will need a 
more thorough understanding of the prevalence of specific 
psychoactive substances, as well as the risk and protective 
factors for problematic substance use among older adults.
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CHAPTER AT A GLANCE
Tobacco 
• Males are more likely than females to smoke tobacco; however, this gender difference  
is smaller in the 55 and older age group than in younger age groups.
• While older Canadians smoke tobacco at a lower frequency than younger Canadians, those 
who do are smoking larger quantities of cigarettes and are more often dependent on nicotine.
Alcohol 
• The frequency of daily or almost daily alcohol use peaks in the 65–74 age group,  
where it is almost three times as high as in the 15–54 age group.
• More than 13% of Canadians age 55 and older report a pattern of problematic binge drinking. 
Prescription Drugs
• While the frequency of prescription opiate use is lower in the 55 and older age group compared 
to younger age groups, a pattern of daily use is seen more frequently among older adults. 
Cannabis
• As age increases, cannabis use and dependence tend to decrease. This pattern is consistent 
with a cohort effect, meaning cannabis use among older adults could increase in future 
generations as the current cannabis-using cohort ages. 
• The frequency of cannabis use for medical purposes is lower among older adults despite  
an increase in the indicators for such use (e.g., chronic pain). 
Other Drugs
• The frequency of illicit drug use is lower in the 55 and older age group compared to younger 
age groups.
• The pattern of lifetime illicit drug use suggests a possible cohort effect, raising concerns  
that illicit drug use could increase in future generations of older Canadians. 
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Dr. Scott B. Patten
Professor, Department of Community Health Sciences, University of Calgary
26 Canadian Centre on Substance Use and Addiction 
Substance Use In Canada—Improving Quality of Life: Substance Use and Aging 
Canadian Centre on Substance Use and Addiction 27
Substance Use In Canada—Improving Quality of Life: Substance Use and Aging 
2.1 Introduction
This chapter summarizes recent epidemiologic data 
on substance use among older Canadians, with an 
emphasis on providing the best available evidence about 
the prevalence of psychoactive substance use within the 
55 and older age group. 
The estimates reported in this chapter come from two 
Statistics Canada surveys: the 2012 Canadian Community 
Health Survey — Mental Health (CCHS-MH) and the 2015 
Canadian Tobacco, Alcohol and Drugs Survey (CTADS). 
• The CCHS-MH was the first national survey 
to include a diagnostic measure for assessing 
substance use disorders (Statistics Canada, 
2012). A total of 25,113 Canadians aged  
15 years and older were surveyed in 2012, with 
face-to-face interviews used whenever possible. 
The survey used a Canadian adaptation of the 
Composite International Diagnostic Interview,  
a fully structured psychiatric diagnostic tool.
• The CTADS is a biennial survey of smoking, 
alcohol and drug use trends (Statistics Canada, 
2016). Throughout 2015, computer-assisted 
telephone interviewing was used to collect data 
from 15,154 Canadians aged 15 years and older. 
Starting from a random sample of telephone 
numbers, one or two respondents from each 
number were then selected based on household 
composition. An equal number of respondents 
were chosen from each province. 
Additional information about both surveys can be found at 
www.statcan.gc.ca. 
2.1.1 How Prevalence Is Reported
There are several types of prevalence. The most common 
is point prevalence: the proportion of a population having 
an attribute (e.g., cannabis use) at a point in time. However, 
some estimates provided in this chapter use period 
prevalence: the proportion of a population with an attribute 
at any time during a specified interval (e.g., one week, one 
month, one year).
In addition to overall prevalence estimates for the general 
Canadian population, sex- and age-specific estimates 
are also provided. While the focus of this report is on the 
older adult population (defined here as 55 years and older), 
prevalence estimates for younger age groups are often 
presented for context.
Two types of estimates of psychoactive substance 
use are reported in most of the analyses that follow. 
First, the frequency of use of each specific substance is 
described. Second, estimates of relevant clinically defined 
entities (problematic use, dependence and other clinical 
syndromes characterized by a pathological pattern of use) 
are also reported. The prevalence of substance use and 
substance use disorders are reported here as percentages 
along with their associated 95% confidence intervals (CI). 
That is, it is 95% certain that the true prevalence falls 
somewhere within lower and upper confidence limits 
provided for each estimate.
Spotlight: Challenges in data  
collection and analysis
Data collected by Statistics Canada are usually 
available in two formats: public-use micro-data 
files (PUMFs) and master files. PUMFs include 
safeguards to protect the confidentiality of survey 
respondents; master files retain a higher level of 
detail but can be accessed only by approved 
personnel in a secured environment and only 
when analyses cannot be carried out using 
PUMFs. For this reason, all of the estimates 
reported in this chapter are derived from PUMFs. 
As the CCHS-MH and CTADS are national surveys, 
data collection by simple random samples is 
not feasible. Instead, geographical areas are 
selected first, then households, then individuals 
in those households. This method produces 
two complications for statistical analysis. First, 
people living in the same geographical region are 
somewhat similar to one another, meaning the 
amount of variability in the population could be 
underestimated. Second, if only one person is 
selected from a household, that means members 
of larger households have a lower probability  
of being selected than those of smaller 
households. Such factors must all be accounted 
for in the analysis. In addition, to ensure estimates 
can be made for smaller provinces, Statistics 
Canada must deliberately oversample those 
provinces, requiring further adjustments to be 
made in the analysis. 
2.2 Tobacco 
According to the most recent CTADS results, 12.9% of 
Canadians are smokers (9.3% are daily smokers and 3.7% 
are occasional smokers). Within the general population, 
smoking occurs at a higher frequency in males (15.6%) 
than females (10.4%). This trend is observed in most age 
groups as well. 
Among males between the ages of 15 and 54, the 
prevalence of smoking is 17.6% (95% CI 15.4–19.7) 
versus 10.9% (95% CI 9.0–12.8) for females in the same 
age range. In the 55 and older age group, 11.8% (95% 
CI 8.9–14.7) of males are smokers, similar to the female 
prevalence of 9.3% (95% CI 7.0–11.6). The widely held 
belief that smoking is far more prevalent in males than 
females appears not to apply to older adults. It might also 
be that any protective effect against smoking associated 
with being female becomes smaller as people grow older.
Overall, 10.5% (95% CI 8.7–12.3) of Canadians in the 
55 and older age group are smokers, compared to 14.3% 
(95% CI 12.9–15.6) of those under the age of 55. Yet 
while the overall frequency of smoking is lower in older 
Canadians, there is evidence to suggest the health-related 
challenges facing older adults who smoke are more severe. 
For example, older Canadians are smoking more cigarettes 
than younger Canadians. The CTADS records the number 
of cigarettes smoked in the week prior to the survey. As 
shown in Figure 1, the mean number of cigarettes smoked 
in the 15–54 age group was 67; among those aged 55–64, 
it was 91. The estimates for the 65–74 and 75 and older 
age groups are also higher than for the 15–54 age group. 
Figure 1. Mean number of cigarettes smoked in the 
preceding week, by age group
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Older Canadians are also more likely to be nicotine-
dependent (i.e., having a physical dependence to nicotine 
after prolonged use and experiencing withdrawal symptoms 
when use is discontinued) than younger Canadians. This 
fact is an important indicator because different approaches 
to smoking cessation are needed for people with physical 
dependence. For example, they likely need more intensive 
treatments (such as evidence-based counselling or nicotine-
replacement therapy) than non-dependent smokers. A good 
indicator of physical dependence to nicotine is the time to 
one’s first cigarette after waking up. Among older adults, 
20.4% (95% CI 12.8–27.9) can go more than 60 minutes 
before having their first cigarette of the day. In comparison, 
nearly one-third (28.9%; 95% CI 22.6–35.2) of those in the 
15–54 age group are able to delay smoking by more than 
60 minutes.
2.2.1 Interprovincial Differences  
in Smoking Prevalence
Figure 2 presents province-specific estimates stratified 
by age group. As expected, smoking rates are generally 
lower among older Canadians when compared to the 15–
54 age group. The provinces with the lowest frequencies 
of smoking in the 55 and older age group tend to have a 
larger gap in prevalence between the two age groups, while 
those with the highest frequencies of smoking among older 
adults (Newfoundland and Labrador, Quebec, Alberta) tend 
to have smaller differences. This finding could suggest that 
some provinces are more effective than others at helping 
people quit smoking.
There are many possible explanations for these 
interprovincial differences in smoking prevalence, including 
different policies for the age at which tobacco products 
can be legally purchased. Four provinces allow 18-year-
olds to purchase tobacco products: Quebec, Manitoba, 
Saskatchewan and Alberta. Not surprisingly, these 
provinces have a higher frequency of smoking in the 15–54 
age group: a combined 15.2% (95% CI 12.7–17.7) versus 
13.6% (95% CI 11.7–15.5) in the other provinces (although 
the overlapping confidence intervals means the difference 
might not be statistically distinct). What is more surprising is 
that the same trend is seen in the older age groups, where 
the prevalence of tobacco use in the provinces that allow 
purchase at age 18 is 14.0% (95% CI 10.7–17.3) compared 
to 8.2% (95% CI 6.2–10.2) in the others. Here, the non-
overlapping confidence intervals indicate a statistically 
distinct difference. To assess the robustness of this finding, 
the same estimates were calculated using the 2013 CTADS 
dataset, which showed effects in the same direction.
2.3 Alcohol 
The CTADS asks all respondents how often they drank 
alcoholic beverages during the past 12 months. Compared 
to younger Canadians, those in the 55 and older age group 
are more likely to not drink at all: 28.8% (95% CI 26.3–31.3) 
versus 20.1% (95% CI 18.5–21.7) of those under the age 
of 55. However, the responses regarding daily or almost 
daily drinking represent a reversal of this pattern, with 
11.0% (95% CI 9.1–12.9) of respondents aged 55 and 
Figure 2. Frequency of smoking, by province and age group
older drinking every day compared to just 4.0% (95% 
CI 3.2–4.8) of those between the ages of 15 and 54. 
The frequency of daily or almost daily alcohol use peaks in the 
65–74 age group, where it is almost three times as high as 
in the 15–54 age group.
What’s in a drink?
The CTADS methodology is built upon the 
definition of a “standard drink,” which is equal to 
one 341 millilitre (mL) serving of beer or cider, one 
142 mL glass of wine, or one straight or mixed 
drink containing 43 mL of liquor or spirit.
This pattern of daily drinking is a concern given that Canada’s 
Low-Risk Alcohol Drinking Guidelines recommend non-
drinking days every week to diminish the habit-forming 
effects of alcohol (Canadian Centre on Substance Use and 
Addiction, 2017). Similar to the pattern seen for smoking, 
while the frequency of alcohol consumption is slightly 
lower in older adults than in the general population, the 
problems associated with its use occur more frequently 
and are more severe. 
2.3.1 Binge Drinking
Another drinking pattern associated with health risks is 
binge drinking, which is defined as five or more drinks on 
any one occasion for males and four or more drinks on any 
one occasion for females. In the CTADS, all respondents 
who report past-year drinking are asked how often they 
had five or more drinks in a single occasion during the past 
12 months. (The frequencies reported here represent the 
frequency of past-year binge drinking only among those 
who report any drinking in the past year.) 
The estimated overall prevalence of past-year binge drinking 
in the Canadian population is 44.7%, with prevalence higher 
in males (52.0%) than females (37.7%). The frequency of 
binge drinking among older adults is lower than that of the 
15–54 age group; among respondents aged 55 and older, 
27.5% (95% CI 25.1–30.0) report past-year binge drinking 
compared to 54.0% (95% CI 51.8–56.2) in the younger 
age group. 
Because binge drinking includes a heterogeneous pattern of 
alcohol consumption, it cannot be fully captured by past-year 
frequency. The CTADS therefore collects complementary 
information on the frequency of binge drinking. A pattern 
of binge drinking that occurs at a monthly frequency (or 
more) is considered especially problematic. Among older 
Canadians, the estimated prevalence of monthly (or more 
frequent) binge drinking is 13.2% (95% CI 11.3–15.0), which 
is lower than that of the 15–54 age group but still quite high.
A facsimile of the low-risk drinking guidelines was created 
for this analysis by using past-week drinking data and 
combining the overall maximum weekly consumption 
(10 drinks for females and 15 for males) with a requirement 
that more than two drinks for females and more than three 
for males not occur on four of seven days of the week. 
Based on this model, the prevalence of “risky” drinking 
among older adults is 10.2% (95% CI 8.4–12.0). 
Rates of binge drinking across all age groups have increased 
over time, with a recent time-series analysis finding that 
the increase has occurred at a similar rate among older 
Canadians (both male and female) as for any other age 
group (Bulloch, Williams, Lavorato, & Patten, 2016). 
2.3.2 Problematic Alcohol Use
Binge drinking is a major health issue for Canadians aged 
55 and older. Not only is this pattern of drinking in itself 
associated with harmful effects (such as an increased risk 
of falls), it is more strongly associated with alcohol use 
disorders in older adults. 
In the general Canadian population, across all ages, both 
alcohol abuse and alcohol dependence are more prevalent 
in males than females.1 The overall prevalence of past-year 
alcohol abuse is 2.2% (95% CI 1.7–2.7), with a prevalence 
of 3.4% (95% CI 2.6–4.2) in males and 1.1% (95% CI 
1 The CCHS-MH was conducted in 2012 and therefore uses definitions from the fourth edition of the Diagnostic and Statistical Manual of Mental 
Disorders, or DSM-IV (American Psychiatric Association, 2000), rather than DSM-5 (American Psychiatric Association, 2013). The DSM-IV 
terminology includes “alcohol abuse” and “alcohol dependence” whereas DSM-5 includes mild, moderate and severe “substance use disorders.” 
While the less-stigmatizing term “problematic alcohol use” is used elsewhere in this report, this chapter uses “alcohol abuse” because it was a 
specific clinical diagnosis at the time the data were collected. The DSM-5 definition of “mild substance use disorder” roughly aligns with the DSM-IV 
definition of “alcohol abuse.”
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0.6–1.6)M in females.2 The overall prevalence of past-year 
alcohol dependence is 0.9% (95% CI 0.6–1.4)M. 
Due to the similarity of the age- and sex-specific patterns, 
the two categories (abuse and dependence) are presented 
here under a single label: alcohol use disorders. 
Alcohol-related Interference in Daily Life
The CCHS-MH asks respondents whether they have 
encountered problems due to their drinking in their home 
responsibilities, school attendance, ability to work at a job, 
and ability to form and maintain close relationships and 
social life. As shown in Figure 3, Statistics Canada derived 
an “interference rating” representing the average value of 
the relevant ratings for each respondent.
Figure 3. Mean interference ratings, by sex and age group
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Although the interference ratings do not show the same 
age or sex differences evident in the prevalence data, 
it is notable that females report higher alcohol-related 
interference in their daily lives than males. Also, the mean 
level of interference does not decline very much with 
increasing age. This finding reinforces a theme repeatedly 
seen in these data sources: while the prevalence of 
problematic patterns of substance use tends to be lower 
in older adults (and particularly in females), the severity or 
impact of such use is not necessarily lower when compared 
to the younger age groups. 
Relationship Between Binge Drinking and Alcohol 
Use Disorder
While the CCHS-MH also assesses binge drinking, its 
definition of the term is simply five or more drinks on any 
one occasion (i.e., the lower threshold of four or more 
drinks for females is not applied as it is in the CTADS). By 
this definition, the frequency of binge drinking across all age 
groups in Canada is 20.9%, slightly lower than the 22.1% 
reported by the CTADS. The inclusion of binge drinking in 
the CCHS-MH allows for an examination of the relationship 
of binge drinking to alcohol use disorders in different age 
groups. This distinction is important because, by definition, 
alcohol use disorders refer to pathological patterns of 
alcohol use (e.g., loss of control over use) associated 
with substantial distress, dysfunction or danger to health 
(American Psychiatric Association, 2013). 
Questions often arise concerning the extent to which binge 
drinking is indicative of psychopathology. For example, 
while occasional binge drinking is associated with certain 
risks (e.g., violence, accidents), it does not always indicate 
the occurrence of substance use disorder. Consistent 
with this idea, only 7.6% (95% CI 6.3–8.9) of the total 
CCHS-MH sample reporting at least one episode of past 
year binge-drinking qualifies for an alcohol use disorder. 
Among older adults, this frequency is even lower at 4.7% 
(95% CI 2.0–7.2)M.
Still, the association of binge drinking with alcohol use 
disorders is strong irrespective of age. In the 15–24 age 
group, the weighted odds ratio for the association of 
alcohol use disorders with at least monthly binge drinking 
is 19.6, meaning that the odds of an alcohol use disorder 
being present are nearly 20 times higher than that of non-
binge drinkers. This association gets even stronger with 
age. In the 55–64 age group, the odds ratio is 24.3 and in 
the 65 and older age group it is 64.3. While binge drinking 
declines with age, the seriousness of its associated 
problems does not.
2 Because the CCHS-MH and CTADS are conducted using random samples, it is possible that repeating the survey with another random sample 
would lead to different results. While the degree of such random variation is small, it can increase when estimates are made for subgroups of the 
population, such as the 55 and older age group, meaning some precision might be lost. Statistics Canada provides measures of variability (called 
“coefficients of variation”) that can be used to quantify an estimate’s vulnerability to random error. Estimates presented here with a superscript “M” 
indicate the need for caution in their interpretation due to their coefficients of variation.
2.4 Prescription Drugs 
The CTADS addresses three categories of prescription 
drug use: pain relievers, stimulants and sedatives. The 
pain reliever category focuses on opiates, the type of drug 
of main concern. However, as some opiates (e.g., heroin) 
are not available by prescription in Canada, these are 
discussed in the subsequent section on “other illicit drugs.” 
For similar reasons, some stimulants (e.g., cocaine) are 
also discussed in that section. 
2.4.1 Pain Relievers
When the CTADS asks about prescription use of pain 
relievers, it specifically refers to products that contain 
opioids such as codeine, morphine or related drugs (i.e., not 
regular Tylenol®, Advil®, aspirin, etc.). While most of these 
products require a prescription, some codeine products 
are available over the counter. Among all respondents, the 
weighted frequency of those who have ever used such pain 
relievers is 42.6% (95% CI 40.7–44.5). Among those in the 
55 and older age group, 43.9% (95% CI 40.8–47.0) have 
used pain relievers, similar to the 41.8% (95% CI 39.8–43.8) 
reported in the 15–54 age group. The frequency of use is not 
appreciably higher in males (43.1%) than females (42.1%).
In the context of the current opioid epidemic and its 
related regulatory changes, it is important to assess the 
lifetime exposure to preparations containing oxycodone. 
Consequently, the CTADS asks about past-year use of these 
preparations. Among the overall population, the frequency of 
reported use of oxycodone-containing preparations is 2.3% 
(95% CI 1.7–2.9). The frequency of use is nearly identical for 
the 15–54 year range (2.4%; 95% CI 1.7–3.0) as it is for the 
55 and older age range (2.1%; 95% CI 1.2–2.9)M and also 
when comparing males (2.4%) and females (2.2%). 
In examining the frequency of opiate use among people 
who use them, a bimodal distribution pattern emerges 
(as illustrated in Figure 4), with peaks at either end of the 
frequency scale: minimal use (i.e., one to two times in past 
year) and daily or almost daily use. Interestingly, the modal 
(most frequent) value differed by age group. While minimal 
use of opiates is the modal pattern in the 15–54 age group, 
daily or near-daily use is the most frequent pattern in the 
55 and older age group — even with post-surgical use of 
opiates excluded from the analysis. 
To provide context for the very high frequency of daily or 
near daily use (35.7%; 95% CI 25.1–46.4)M among older 
adults reporting opiate use, it is helpful to consider that the 
overall prevalence of daily or nearly daily opiate use in the 
entire older adult population is only 1.1% (95% CI 0.6–1.5)M.
Figure 4. Frequency of opiate use (among those reporting 
use), by age group
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Note: Intermediate categories (e.g., monthly) are included in the 
denominators of the reported proportions but are not reported 
separately due to large coefficients of variation.
2.4.2 Sedatives
Although the term “sedative” has referred traditionally to 
benzodiazepines and related “z-drugs” such as zopiclone, 
it now encompasses many different medications that have 
sedative effects, including those designed to help people 
sleep, calm down or relax their muscles. The CTADS 
asks about the use of various sedatives or anti-anxiety 
medications, specifically mentioning products that can 
be obtained from a doctor such as diazepam, lorazepam, 
alprazolam and clonazepam.
The pattern of past-year use of these substances in 
the general population differs from other drug classes: 
prevalence of use is higher in females (13.5%; 95% CI 
11.9–15.1) than males (7.3%; 95% CI 6.0–8.6), and 
higher in older adults (14.6%; 95% CI 12.5–16.6) than 
younger adults (8.3%; 95% CI 7.1–9.5). The prevalence of 
use in older females is especially high at 18.7% (95% CI 
15.6–21.8), approximately twice that of older males (10.0%; 
95% CI 7.2–12.8)M. About half of the older adults taking 
sedatives do so on a daily or almost daily basis, amounting 
to 7.7% of the older adult population (95% CI 6.1–9.2).
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2.4.3 Stimulants
The CTADS also collects data on stimulant use, asking 
respondents about their use of products such as Ritalin®, 
Concerta®, Adderall® and Dexedrine® that are prescribed by 
doctors to help with attention or concentration problems.
Approximately 1.1% (95% CI 0.7–1.4)M of the Canadian 
population has used stimulants in the past year. The 
frequency of use is much higher in younger age groups, 
with the highest frequency occurring in the 15–24 age 
range (4.5%; 95% CI 2.7–6.3)M. The frequency of stimulant 
use in older adults is very small: about 0.2% but ultimately 
too low to support an adequately precise estimation. 
2.5 Cannabis 
Epidemiological information about cannabis use is available 
from both the CCHS-MH, which assesses cannabis 
use disorders (subdivided into the categories of abuse 
and dependence), and the CTADS, which measures the 
frequency and quantity of cannabis use. 
In the CTADS, respondents are asked about lifetime use 
of marijuana (specifically, marijuana, hashish, hash oil or 
any other preparation of the cannabis plant), as well as 
use on more than one occasion and use within the past 
12 months. Despite the commonly held opinion that 
cannabis use is everywhere, only 44.5% (95% CI 
42.9–46.1) of respondents have used cannabis at some 
point during their lives. Among males, a slight majority 
report lifetime use (52.0%; 95% CI 49.4–54.5) compared 
to 37.2% (95% CI 34.9–39.5) for females. Approximately 
one-third of older adults (32.6%; 95% CI 29.7–35.5) have 
used cannabis while more than half of those in the 15–54 
age range (50.9%; 95% CI 48.8–53.0) report using it. 
As shown in Figure 5, this pattern of lifetime cannabis use 
is suggestive of a cohort effect, with younger generations 
of Canadians having a higher probability of exposure to 
cannabis. If there was no cohort effect (i.e., if the probability 
of using cannabis remained stable over time), older 
respondents would likely report similar rates of lifetime 
exposure to those in the younger ager groups. However, 
it appears that respondents born before 1980 were less 
likely to be exposed to cannabis than those born later. This 
cohort effect could predict an increase in cannabis-related 
issues among older Canadians as the more recent birth 
cohorts enter the 55 and older age group. 
Figure 5. Lifetime cannabis use, by age group
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Note: The estimate for the 75 and older age group should be 
interpreted with caution due to a marginal coefficient of variation.
Among respondents reporting lifetime use, 84.1% have 
used cannabis multiple times, with similar frequencies found 
in males (86.4%) and females (81.1%), as well as in the 
15–54 (85.8%) and 55 and older (79.3%) age groups. About 
one-third (33.5%) of those who have ever used cannabis 
did so within the past year, which translates to 12.1% (95% 
CI 10.9–13.3) of the general population. Overall, 14.7% of 
males and 9.6% of females have used cannabis within the 
past year. The frequency of past-year use is higher among 
15–54 year olds (16.8%; 95% CI 15.2–18.4) than in the 
older adult age group (3.5%; 95% CI 2.4–4.6). 
In the CTADS, respondents who report the use of cannabis 
are asked whether they consider their use to be medicinal. 
Despite having more issues for which medical cannabis 
is likely to be used (e.g., chronic pain), the frequency of 
self-reported medical cannabis use is not higher among 
older adults. Overall, only 7.7% (95% CI 5.8–9.6) of 
respondents use cannabis for medical purposes. The 
frequency of medical cannabis use is nearly twice as high 
in the 15–54 age group (8.6%; 95% CI 6.8–10.3) than 
in the 55 and older age group (4.95%; 95% CI 2.5–7.4)M. 
2.5.1 Cannabis Use Disorders
In addition to using cannabis less frequently, older 
Canadians have a lower prevalence of cannabis use 
disorders. In the overall population, the lifetime prevalence 
of cannabis use disorders (as assessed by the CCHS-MH) 
is 6.8% (95% CI 6.0–7.6), with higher lifetime prevalence 
found in males (9.9%) than in females (3.9%). When looking 
across age groups, lifetime prevalence is higher in the 
15–54 age range (8.9%; 95% CI 7.8–10.0) than in the 55 
and older age group (2.6%; 95% CI 1.6–3.5)M. 
As these estimates are for lifetime prevalence, the apparent 
effect of age could again represent a cohort effect. It does 
not necessarily mean that these problems decline with age, 
but rather that those currently afflicted with a cannabis use 
disorder tend to have been born more recently. As these 
individuals age, the prevalence of cannabis use disorders 
in older adults is likely to increase. Although it was not 
possible to estimate the prevalence of past-year cannabis 
use disorder in the older adult age group, among the 
overall population, past-year prevalence is 1.3% (95% CI 
0.9–1.7), which is decidedly lower than the lifetime 
prevalence of 6.8% — suggesting that a large proportion 
of people recover from their disorder. 
Another possible explanation for declining lifetime 
prevalence with age is recall bias. If people forget or for 
other reasons do not report cannabis use from earlier in 
their life as they get older, declining lifetime prevalence 
estimates could occur. As a way of exploring this issue, 
lifetime prevalence of alcohol dependence was assessed 
to see if the same appearance of a cohort effect was 
evident. In this analysis, the lifetime prevalence of alcohol 
dependence was higher in the 15–54 age group (3.4%; 
95% CI 2.6–4.2) than in the 55 and older age group (2.2%; 
95% CI 1.3–3.1), suggesting possible recall bias. However, 
the observed difference does not occur to the same extent 
as is seen with cannabis.
2.6 Other Illicit Drugs
Because respondents might be unwilling to disclose 
information about illegal activities, it can be difficult for 
surveys like the CTADS and CCHS-MH to collect accurate 
data on the use of illicit substances such as cocaine, 
ecstasy and methamphetamine. 
In most cases, the frequencies of recent use (i.e., past 
12 months) reported by the CTADS are too low to produce 
age-stratified estimates; however, it is possible to estimate 
lifetime use of several drugs and groups of drugs. As 
shown in Figure 6, the frequency of use of many illicit 
drugs is lower in older adults relative to younger adults. 
The pattern of higher frequency of exposure in the younger 
age group suggests a possible cohort effect, indicating a 
potential increase in illicit drug use in future generations of 
older Canadians.
Figure 6. Lifetime use of selected drugs, by age group
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Note: The methamphetamine estimate for the 55 and older age group 
should be interpreted with caution due to a marginal coefficient of 
variation. The ecstasy estimate for the 55 and older age group cannot 
be reported due to the very high coefficient of variation.
The CCHS-MH provides estimates of the prevalence of 
drug abuse and dependence for drugs other than alcohol 
and cannabis. Defined in this way, the lifetime prevalence 
of drug abuse or dependence is 4.0% (95% CI 3.3–4.7) in 
the overall Canadian population. As expected, prevalence 
is higher in males (5.1%) than females (3.0%). Lifetime 
prevalence is also higher in the 15–54 age group (4.9%; 
95% CI 4.0–5.8) than in the 55 and older age group (2.1%; 
95% CI 1.3–2.9), a pattern consistent with a cohort effect 
but for which recall bias is another possible explanation. 
2.7 Limitations of the Analysis
As mentioned earlier, this analysis is based on data from 
Statistics Canada PUMFs. Determination of the standard 
errors associated with estimates arising from these files 
is difficult, requiring the use of approximate coefficients 
of variation. More accurate variance estimation would 
be possible using master file data. Access to the master 
files would also support more elaborate analyses, such 
as the ability to make statistical adjustments using 
multivariable analysis. 
This analysis is also limited by its reliance on a small 
number of cross-sectional data sources, collected within 
a few years of each other. Pooling estimates from many 
34 Canadian Centre on Substance Use and Addiction 
Substance Use In Canada—Improving Quality of Life: Substance Use and Aging 
Canadian Centre on Substance Use and Addiction 35
Substance Use In Canada—Improving Quality of Life: Substance Use and Aging 
different surveys would allow for an assessment of trends 
over time. For example, while the lower rates of lifetime 
exposure reported in older adults suggest a possible 
cohort effect, serial cross-sectional estimates would be 
needed to differentiate between age and cohort effects 
(Keyes, Utz, Robinson, & Li, 2010). Longitudinal data with 
repeated measures would also help address the potential 
issue of recall bias among older adults. 
The available data sources also have inherent limitations. 
For example, the CTADS asks about “sedatives,” which is a 
much broader and non-specific class of medications than 
just benzodiazepines. It might also include over-the-counter 
preparations such as antihistamines that are marketed for 
their sleep-inducing properties, for example. For many 
years, the frequency of use of benzodiazepines (and related 
z-drugs) in the general Canadian population was about 
3% (Kassam & Patten, 2006). While this frequency of use 
appears to have decreased in recent years (Patten et al., 
2016), any diminishment of benzodiazepine use may 
have been offset by an increase in the use of sedating, 
second-generation antipsychotics during this same period. 
Unfortunately, it was not possible to delve deeper into this 
issue using the available data sources. 
Finally, it is difficult to compare these data to international 
data because available reports use different age 
classifications. A recent report summarizing findings from 
the 2015 U.S. National Survey on Drug Use and Health 
(Bose et al., 2016) used 26 and older as its oldest age group. 
Similarly, estimates for older adults are inconspicuous in the 
2016 European Drug Report (European Monitoring Centre 
for Drugs and Drug Addiction, 2016). More than anything 
else, this illustrates that older adults have sometimes been 
neglected in surveillance activities.
2.8 Conclusion
Substance use is an important issue for older Canadians. 
While the prevalence of substance use is generally lower 
in older adults than in the 15–54 age group, it is still quite 
high. More notably, patterns of substance use are often 
more pronounced and problematic in older adults. For 
example, indicators of nicotine dependence are more 
prominent among older adults who smoke. Also, daily 
drinking or drinking that exceeds the low-risk drinking 
guidelines both peak in the 55 and older age group. These 
findings have important implications for understanding 
the effects of alcohol on the aging brain (explored in 
Chapter 3) and the consequences of substance use in 
older adults (explored in Chapter 4).
Even though self-reported use of other substances (such 
as cannabis and cocaine) tends to be lower in the 55 and 
older age category, this pattern could be indicative of a 
cohort effect, where younger Canadians have had greater 
exposure to some of these drugs — meaning increasing 
prevalence of use in older adults will likely be seen in the 
decades to come as the younger cohort ages. 
The possibility of a cohort effect is particularly important as 
it relates to the legalization of cannabis. While the current 
data suggest a possible cohort effect, a period effect 
might also occur. A period effect occurs when an event (in 
this case, cannabis legalization) affects people of all ages 
when it occurs; in contrast, a cohort effect affects just one 
particular generation, with the effect moving from one age 
group to the next as that generation grows older.
Canada is fortunate to routinely conduct surveys like 
the CTADS and CCHS-MS that contributed data to 
this analysis. However, these surveys are designed for 
surveillance, using only a brief telephone or face-to-face 
interview for data collection. They also do not specifically 
focus on older adults. The ongoing Canadian Longitudinal 
Study on Aging will be a valuable source of information for 
more deeply exploring the causes and consequences of 
substance use in older adults. 
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The Aging Brain and 
Substance Use
03
CHAPTER AT A GLANCE
• Aging is associated with cognitive and functional changes that can make the brain 
more vulnerable to the effects of drugs. 
• With aging, the brain experiences changes that force it to compensate for functional 
declines or disease states. Substance use can jeopardize these compensatory 
changes, making the brain more vulnerable to declines or disease.
• Many neurotransmitter systems change with age, which can alter how a drug acts on 
the brain — and reduce the ability of older adults to adapt to the physiological effects 
of drugs. 
• Age-related changes can affect drug absorption, distribution, metabolism and 
excretion. Declining kidney function and reduced liver performance among older 
adults have the greatest impact on the ability to eliminate drugs from one’s body. 
• Older adults tend to have more physical illnesses and be prescribed more 
medications. Exposed to more drug combinations and with less capacity to avoid 
the adverse effects of substance use, older adults are at increased risk for potentially 
harmful drug–drug interactions.
• Substance use among older adults puts additional stress on vulnerable body 
systems and reduces the ability to deal with the consequences of the aging process. 
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Case examples of drug interactions in older adults
Example 1: If an individual takes stimulants (whether prescribed or illicit) or the opiate methadone, and is also prescribed 
citalopram for depression or anxiety disorder, they will be exposed to two drugs that prolong QT interval (a measure of the 
heart’s electrical cycle), which is associated with increased risk of cardiac arrhythmias. Because the metabolic activity of the 
liver enzyme CYP2C19 declines with age, it will lead to a progressively greater plasma concentration of citalopram for any 
given dose. It is plausible that there could be an additional pharmacokinetic component to this pharmacodynamic interaction. 
Example 2: The antiemetic agent Gravol® (dimenhydrinate), which is prone to problematic use due to its deliriant effects, 
has anticholinergic properties because it is an antagonist of muscarinic cholinergic receptors. It therefore has the potential 
to have a negative impact on cognition in tandem with the natural loss of anticholinergic function that comes with aging — 
especially if an individual is taking other drugs that also have anticholinergic effects. These include many drugs commonly 
taken by older adults such as drugs for incontinence (e.g., tolterodine), several antipsychotic medications (e.g., olanzapine) 
and some older antidepressants (e.g., imipramine, amitriptyline, paroxetine).
Example 3: Older adults who are taking drugs associated with postural hypotension, such as alpha-adrenergic blockers 
(e.g., prazosin) and tricyclic antidepressants, may be at increased risk of experiencing side effects due to the age-related 
weakening of the baroreceptor reflex as well as a progressive failure of a homeostatic mechanism. Use of opiates such as 
morphine can worsen this problem because some of these drugs are also associated with postural hypotension.
3.1 Introduction
With more than 600 million people around the world 
currently aged 65 or older — and more than twice this 
number of older adults expected by 2050 (He, Goodkind, 
& Kowal, 2016) — a deeper knowledge of how the aging 
process changes the brain is critical to building a better 
understanding of the impact external factors such as 
substance use can have on the health of older adults.
3.2 Impact of Aging on the Brain
3.2.1 Age-related Changes in Brain Function
Cognitive Function
As healthy adults grow older, some cognitive functions 
gradually decline while others remain stable or improve 
over time. Vocabulary and verbal skills, for example, tend 
to remain stable into the eighth decade of life (Hedden & 
Gabrieli, 2004; Wisdom, Mignogna, & Collins, 2012) and, 
in some studies, have even been shown to improve with 
age (Park & Reuter-Lorenz, 2009; Singh-Manoux  et  al., 
2012). Substance use can affect these functions: studies 
assessing the impact of drugs on language found that 
alcohol and stimulants improve verbal flow (Higgins & 
Stitzer, 1988, 1989), while other drugs, such as ketamine, 
impair language and can cause a disordered thought 
process (Adler, Goldberg, Malholtra, Pickar, & Breier, 1998; 
Adler et al., 1999).
In contrast to vocabulary and verbal skills, perceptual 
speed, reasoning and memory all tend to decline as a 
person grows older, beginning as early as 20 years old 
(Hedden & Gabrieli, 2004; Wisdom et al., 2012; Salthouse, 
2010). Such declines can have significant implications 
on the impact of drugs on processing speed, which is a 
fundamental cognitive process that affects performance 
in almost all other domains. Cannabis use, for example, 
is associated with impaired processing speed, though not 
during the acute intake phase (Kelleher, Stough, Sergejew, 
& Rolfe, 2004). 
Attention and Memory
Complex attention processes such as selective and divided 
attention also decline with age (Carlson, Hasher, Connelly, 
& Zacks, 1995; Salthouse, Fristoe, Lineweaver, & Coon, 
1995). Selective attention is critical to a person’s ability to 
focus on a task in the presence of noise or other distractors; 
divided attention allows a person to multitask. Drugs such 
as amphetamine, cocaine and nicotine have been shown 
to enhance attention in the short term (Mattay et al., 1996; 
Del Olmo, Higuera-Matas, Miguens, Garcia-Lecumberri, 
& Ambrosio, 2007; Kenney & Gould, 2008). This acute 
improvement in attention raises the question as to whether 
the aging process makes older adults more susceptible 
to becoming physically dependent on these drugs due 
to their enhanced effects on cognitive function. Not all 
drugs provide such improvement, however; chronic 
exposure to alcohol, amphetamine and cannabis tends to 
be associated with deficits in complex forms of attention 
(Moriyama, Muramatsu, Kato, Mimura, & Kashima, 2006; 
Dalley et al., 2005; Pope, Gruber, & Yurgelun-Todd, 2001).
Another cognitive function that declines with age is working 
memory (Salthouse, Mitchell, Skovronek, & Babcock, 1989), 
which is the ability to store and manipulate information in 
the short term (Baddeley, 1996). There is also evidence 
to suggest that working memory is negatively affected by 
chronic exposure to alcohol (Moriyama  et  al., 2006) and 
nicotine (Kenney & Gould, 2008). 
Declarative memory (i.e., the conscious ability to recall specific 
facts or events) can be subdivided into two categories:
• Episodic memory, which is the ability to recall 
specific events experienced over the course of 
one’s life; and
• Semantic memory, which is the ability to recall 
facts and knowledge obtained over the course  
of one’s life. 
While older adults experience a gradual decline in both 
episodic and semantic memory, the decline in semantic 
memory occurs much later in life (Ronnlund, Nyberg, 
Backman, & Nilsson, 2005). The decline of both episodic 
and semantic memories can be exacerbated by any drug 
that impairs declarative memory (Blagrove  et  al., 2011). 
Cocaine and ecstasy, for example, impair declarative 
memory by interfering with the ability to store and recall 
memories (Tronson & Taylor, 2013).
In contrast to the declines seen in declarative memory, 
procedural memory tends to remain stable as adults age. 
Procedural memory refers to the memory of performing 
certain tasks (e.g., riding a bicycle, buttoning up a shirt) 
that do not require conscious recollection but are instead 
recalled and carried out subconsciously. Despite these 
memories remaining stable over time, there is evidence 
to suggest drugs such as cocaine and ecstasy negatively 
affect procedural memories (van Gorp  et  al., 1999; 
Blagrove  et  al., 2011). Chronic use of such drugs could 
deprive older adults of the stability of procedural memory 
in later life.
Executive Function
Aging is also associated with declines in executive 
functions, which include abilities for abstract thinking, 
planning, shifting tasks, reasoning, impulse control and 
problem solving (Fuster, 2009). Declines in executive 
function cause older adults to become more cognitively 
rigid (Oosterman  et  al., 2010) and also contribute to a 
deficit in inductive reasoning (Singh-Manoux et al., 2012). 
Several drugs have been shown to have a negative impact 
on executive functions, including cannabis, cocaine and 
opioids (Pope  et  al., 2001; Kelley, Yeager, Pepper, & 
Beversdorf, 2005; Lyvers & Yakimoff, 2003). The effects 
of these drugs could exacerbate age-related declines in 
executive functions.
3.2.2 Age-related Changes in Brain Structure
In parallel with the changes made to the brain’s functions, 
the aging process is also associated with structural 
changes in the brain that are thought to mediate the 
functional changes observed in the later stages of life.
Grey Matter 
One of the most apparent age-related structural changes 
is the decline of grey matter in the older adult brain. While 
neuronal death could contribute to reductions in grey 
matter, these reductions are likely the result of reductions 
in synaptic densities (Terry & Katzman, 2001; Uttara, 
Singh, Zamboni, & Mahajan, 2009). In the healthy aging 
brain, reductions in grey matter are observed early on in 
the prefrontal cortex (West, 1996); in contrast, people with 
Alzheimer’s disease show early reductions in grey matter 
in the entorhinal cortex (Raz, 2000; Terry, 2000; Resnick, 
Pham, Kraut, Zonderman, & Davatzikos, 2003; Raz, 
Rodrigue, Head, Kennedy, & Acker, 2004).
What are grey and white matter?
Grey matter is a major component of the central 
nervous system. It is composed of neuronal cell 
bodies and synapses. Grey matter has a very light 
grey colour, which comes from capillary blood 
vessels and neuronal cell bodies.
The other major component of the central 
nervous system, white matter is composed 
mostly of myelinated axons. White matter is 
named for its light appearance, the result of the 
fatty myelin sheathe that insulates the electrical 
communication between neurons.
The susceptibility of the prefrontal cortex to age-related 
structural changes results in changes in the frontostriatal 
system, which includes a decrease in dopaminergic, 
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noradrenergic and serotonergic neurotransmission (Raz, 
2000; Volkow  et  al., 2000). These three neurochemical 
systems are central to the mechanisms of action of several 
substances, both medicinal and recreational. Substance 
use in older adults can modify these neurotransmitter 
systems, exacerbating the structural changes that occur 
as a consequence of aging. For example, chronic cannabis 
use has been associated with reductions in bilateral 
orbitofrontal gyri volumes (i.e., a symmetrical size reduction 
in the orbitofrontal cortex; Filbey et al., 2014). In another 
study, decreases in grey matter volumes were observed 
in women who were previously dependent on stimulants 
(cocaine, amphetamines or methamphetamine) even after 
being abstinent for an average of more than one year 
(Regner et al., 2015). 
White Matter
Aging is associated not only with decreases in grey matter 
volume but also with changes in white matter integrity and 
connectivity. While white matter disruption in the aging brain 
occurs in nearly every cortical region, it is most prominent 
in the prefrontal cortex and corpus callosum (Head et  al., 
2004). Some of the changes in white matter integrity and 
connectivity have been associated with age-related declines 
in executive function (O’Sullivan et al., 2001). For example, 
decreases in white matter integrity have been observed 
in the brain structures related to memory formation, such 
as the para-hippocampal region, with such decreases 
associated with a decline in memory (Rogalski et al., 2012). 
Other studies have observed disruptions in white matter 
integrity in individuals who use drugs such as alcohol, 
cannabis and heroin (Jacobus et al. 2013; Liu et al., 2008). 
These disruptions occur in the frontolimbic system of the 
brain, the same system that is susceptible to aging. 
3.2.3 Age-related Changes  
to Compensatory Processes
Although the brain experiences a number of declines as it 
ages, evidence has shown that the prefrontal cortex plays 
a compensatory role in response to age-related memory 
declines (Gutchess  et  al., 2005; Davis, Dennis, Daselaar, 
Fleck, & Cabeza, 2008; Rosano et al., 2012). In a healthy 
adult, the frontal lobes are part of the frontostriatal axis 
that is affected by the typical aging process; in contrast, 
it is the temporoparietal axis that is affected in disease 
states such as Alzheimer’s disease (Buckner, 2004; Head, 
Snyder, Girton, Morris, & Buckner, 2005; Fjell et al., 2014). 
Patients with mild cognitive impairment — a clinical state 
that typically precedes Alzheimer’s disease — who have 
high prefrontal cortical function continue to perform well on 
measures of episodic memory. Their strong performance 
is associated with prefrontal cortical thickness rather than 
temporal lobe thickness (Chang  et  al., 2010), suggesting 
that the frontostriatal axis has beneficial effects on memory-
related tasks. Furthermore, prefrontal cortical function in 
patients with mild cognitive impairment is a predictor of their 
progression to Alzheimer’s disease (Gomar  et  al., 2011). 
Patients with Alzheimer’s disease have cerebral blood-flow 
deficits in the temporal and parietal lobes during the early 
stages of the disease; these deficits are seen only in the 
frontal lobes during the later stages of the disease (Jagust, 
Budinger, & Reed, 1987; Rapoport, 1991; Brown  et  al., 
1996; Jagust, Eberling, Reed, Mathis, & Budinger, 1997). 
There is also evidence for the engagement of the prefrontal 
cortex to compensate for the effects of cognitive aging. 
Among healthy older adults, the prefrontal cortex shows 
overactivation on one side of the brain (i.e., a loss of 
symmetrical activity) in response to a cognitive task 
(Cabeza, 2002; Reuter-Lorenz & Cappell, 2008; Cappell, 
Gmeindl, & Reuter-Lorenz, 2010; Schneider-Garces et al., 
2010; Tyler et al., 2010). Cognitive training in older adults 
can result in structural changes in the frontal lobes, 
increasing their potential to compensate for cognitive 
decline (Anguera  et  al., 2013). The ability of the frontal 
lobe to change and adapt has also been demonstrated 
in a study where the frontal cortices of older adults were 
electrically stimulated through artificial means and the 
stimulation normalized the pattern of brain activity to what 
is typically observed among younger adults (Meinzer, 
Lindenberg, Antonenko, Flaisch, & Floel, 2013). Finally, the 
ability of the frontal cortices to compensate is supported 
by the fact that with aging there is mostly dendritic (but not 
neuronal) loss in the frontal lobes (Bennett et al., 2006).
The prefrontal cortex’s ability to compensate, along 
with other mechanisms of compensation, could 
delay the manifestation of Alzheimer’s disease among 
highly educated individuals, despite the high levels of 
neurodegeneration taking place within their brains (Stern, 
2002; Brickman  et  al., 2008; Rentz  et  al., 2010; Jagust 
& Mormino, 2011; Brickman et al., 2012; Stern 2012). If 
substance use exacerbates declines in prefrontal cortical 
function, it is likely that substance use will accelerate 
cognitive decline in older adults and advance progression 
to Alzheimer’s disease among high-risk individuals. 
3.3 Impact of Aging on Pharmacodynamics
Aging is directly associated with changes in 
pharmacodynamics (the actions drugs have on the 
body) and pharmacokinetics (the actions of the body on 
drugs). However, much of the complexity in determining 
the consequences of substance use in older adults comes 
from two further consequences of advancing age. 
First, older adults might have less capacity to deal with 
change beyond the expected age-related pharmacodynamic 
and pharmacokinetic changes, which involve multiple organs 
and bodily systems (Klotz, 2009). This loss of capacity to 
deal with change is in part because of the aging process 
and partly due to the greater likelihood of illness and disease. 
Second, older adults are, in general, prescribed more 
medications than their younger counterparts, increasing 
the risk of harmful drug–drug interactions (Davies, Eayrs, 
Pratt, & Lennard, 2004; Kennerfalk, Ruigómez, Wallander, 
Wilhelmsen, & Johansson, 2002; Pizzuti, Caffari, Binkin, & 
Gruppo Argento, 2006). In the United States, for example, 
persons over the age of 65 account for 13% of the population 
but receive approximately one-third of all drug prescriptions 
(Avorn, 1995). 
3.3.1 Age-related Changes  
to Neurotransmitter Systems
Pharmacodynamic changes influence the relationship 
between the concentration of drugs circulating in the body 
and the behavioural responses caused by those drugs 
(Bowie & Slattum, 2007). Drug pharmacodynamics can 
be altered through age-related changes in the function of 
neurotransmitter systems, such as the number of available 
receptors and the receptors’ affinity to neurotransmitters 
(Singh & Bajorek, 2015; Bowie & Slattum, 2007). 
Age-related pharmacodynamic changes can also be 
mediated by allied hormonal systems and homeostatic 
mechanisms. These age-related changes affect many 
neurotransmitter systems, including monoamine (e.g., 
dopamine, noradrenaline, serotonin) neurotransmitters and 
the cholinergic system (Rehman & Massoon, 2001).
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Monoamine Neurotransmitters
The dopaminergic system shows pronounced changes 
with aging, most notably in the tuberoinfundibular pathway, 
which is one of the four major dopamine pathways in the 
brain. Age-related declines in dopamine D2 receptors 
have also been reported in other brain regions, including 
the caudate, putamen, substantia nigra and globus 
pallidus (Morgan, May, & Finch, 1987). Because dopamine 
neurotransmission in these regions controls physical 
movement, the age-related declines in dopamine receptors 
might explain the increased sensitivity of older adults to 
drug-induced movement disorders. Such disorders are 
common with conventional antipsychotic agents that act 
specifically on the dopamine system. 
Important age-related changes have also been observed 
in the noradrenaline system, with evidence showing age-
related reduction of neuronal density in the locus coeruleus, 
the principal site for norepinephrine synthesis in the brain 
(De Kosky & Palmer, 1987). 
Finally, several imaging studies have reported small age-
related reductions in the availability of serotonin receptors, 
which help regulate mood and anxiety. These reductions 
were shown in the 5-HT1A receptors (Moller, Jakobsen, & 
Gjedde, 2007) and 5-HT2 receptors (Adams et al., 2004), 
although the ramifications of these age-related changes 
are not clear. 
Cholinergic System
Aging is associated with decreased acetylcholine levels as 
well as a decreased number of acetylcholine receptors in the 
caudate, putamen, hippocampus and frontal cortex (Rinne, 
1987). These changes cause older adults to become more 
sensitive to anticholinergic drugs (e.g., Benadryl®). As a 
result, drugs with anticholinergic activity are more likely to 
cause obvious deficits, such as cognitive impairment, in the 
older adult population.
GABA System
Many anxiolytic (anti-anxiety) and hypnotic drugs act on 
the gamma-aminobutyric acid (GABA) system by binding 
to the GABA-benzodiazepine receptor. (GABA is the 
primary inhibitory neurotransmitter in the brain and works 
to reduce neuronal excitability throughout the nervous 
system.) Traditional benzodiazepines, such as diazepam, 
alprazolam, lorazepam and clonazepam, produce their 
anxiolytic effects by activating the GABA system. The 
1990s saw the introduction of a newer class of “z-drugs” 
(e.g., zopiclone, zaleplon, zolpidem) that produce a 
hypnotic effect through the activation of the GABA system. 
There are also some non-benzodiazepine anxiolytic drugs, 
such as pregabalin, buspirone and hydroxyzine, which 
work through non-GABA related systems to treat anxiety. 
Similarly, there are non-benzodiazepine drugs used to 
promote sleep, such as antihistamines and trazodone, 
which do not exert their effect through the GABA system. 
The use of benzodiazepines can be risky for older adults. 
For example, older adults who take benzodiazepines are 
approximately 50% more likely to fracture a hip than those 
who do not (Cumming & Le Couteur, 2003). Alcohol, like 
benzodiazepines, acts primarily on the GABA system 
but has additional effects on other systems such as the 
dopamine system and N-methyl-D-aspartate (NMDA) 
receptors. The common mechanism of action between 
alcohol and benzodiazepines is important when considering 
drug–drug interactions and the synergistic effects of drugs 
that converge on the GABA system. Many of the harms 
associated with benzodiazepine use are worsened in the 
presence of alcohol because both drugs target the same 
receptors and neurotransmitter systems. 
Many studies have shown that increased sensitivity to a 
specific drug (such as benzodiazepines) can be explained 
by pharmacokinetics. For example, Greenblatt and 
colleagues (1991) reported that increased sedation and 
impairment on psychomotor performance and memory 
were related to triazolam plasma concentrations, which 
are greater in older adults. However, a minority of studies 
have suggested that benzodiazepine sensitivity might 
be increased independently of pharmacokinetic factors. 
A study using alprazolam showed that the drug was 
maintained at a similar concentration in both young and 
older participants (Bertz  et  al., 1997), with this effect 
possibly explained by changes in GABA-benzodiazepine 
receptor density rather than alterations in the binding 
affinity of the GABA-benzodiazepine receptor.
Opioid System
The majority of pain relievers prone to problematic use act 
on the opioid system. Although there is little information 
in the literature on age-related changes in the functioning 
of the opioid system, such as alterations in receptor 
sensitivity or density, the pharmacodynamic effects in 
older adults are important. Older adults often receive 
prescription opioids to mediate pain. While pain relief is 
mediated through the activation of mu-opioid receptors in 
the central nervous system, opioid use inevitably activates 
mu-opioid receptors in the periphery. Activation of peripheral 
mu-opioid receptors, such as those in the gastro-intestinal 
system, leads to the commonly observed problem of 
constipation among older adults, with those aged 80 and 
older particularly vulnerable to this side effect (Chokhavatia, 
John, Bridgeman, & Dixit, 2016).
Cannabinoid System
Tetrahydrocannabinol, the main psychoactive component 
of cannabis, acts on a specific receptor system that has 
affinity for naturally occurring endocannabinoids. Evidence 
on the age-related pharmacodynamic changes occurring 
in the endocannabinoid system — and the potential risks 
of cannabis use in older adults — is sparse and further 
study is required. However, one area that has received 
attention is the effects of cannabis on memory impairment 
in younger populations (Ranganathan & D’Souza, 2006). 
These findings can be extrapolated to older adults with 
greater vulnerability to cognitive decline, suggesting that 
this population could be at a relatively greater risk of 
memory problems when using cannabis regularly. 
Adenosine System
Caffeine, the primary stimulant in coffee, exerts its effects by 
antagonizing the adenosine receptor, leading to the release 
of monoamines and acetylcholine. There is limited evidence 
to suggest differences in the pharmacodynamic effects 
of caffeine between younger and older adults. However, 
differences such as a greater caffeine-induced rise in blood 
pressure and a greater impact on calcium metabolism have 
been noted in older adults (Massey, 1998). 
3.3.2 Age-related Changes  
to the Neuroendocrine System
Many neuroendocrine changes have been described in 
older adults, including decreased levels of testosterone, 
aldosterone, growth hormone, thyroid stimulating hormone, 
oxytocin and melatonin (Rehman & Massoon, 2001). In 
contrast, reports suggest that luteinizing hormone, follicle-
stimulating hormone and antidiuretic hormone show 
increased blood concentrations in older adults (Deslypere 
& Vermeulen, 1984). 
3.3.3 Age-related Changes  
to Homeostatic Mechanisms
Important pharmacodynamic changes in older adults are 
linked to declines in homeostatic systems, which help 
control water balance, posture, circulatory responses and 
thermoregulation (Bigos, Bies, & Pollock, 2013). Changes 
to these systems might interfere with the ability to adapt to 
the physiological effects of medication. For example, aging 
is associated with a decrease in baroreceptor responsivity, 
meaning orthostatic hypotension (i.e., a drop in blood 
pressure when moving from sitting to standing) is more likely 
to occur when using medications such as prazosin and 
tricyclic antidepressants. The co-prescription of diuretics 
might also worsen orthostatic hypotension through a 
reduction of fluid volume. 
Other examples of impairments in homeostatic mechanisms 
include a reduction in peripheral parasympathetic nervous 
system responses (e.g., the “rest-and-digest” response), 
which are dependent on acetylcholine and muscarinic 
cholinergic receptors; and an increased risk of syndrome 
of inappropriate antidiuretic hormone secretion when 
prescribed antidepressants. 
In general, the failure of homeostatic mechanisms creates 
vulnerabilities that might be worsened by standard drug 
treatment as well as problematic substance use. For example, 
the increased risk of falls in older adults is multifactorial 
in origin, with some of the contributing factors including 
poor control of posture and orthostatic responses. There 
are associations with the use of prescribed medications, 
including most psychotropic drugs, that might be worsened 
by problematic use of substances such as benzodiazepines 
and alcohol. 
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3.4 Impact of Aging on 
Pharmacokinetics
In contrast to pharmacodynamics, pharmacokinetics 
describes the actions of the body on drugs. Once a drug 
gains access to the blood stream (the absorption process), 
it must travel to the intended site of action and elsewhere 
(the distribution process) and then be removed from the 
body (the elimination and excretion process). A minority 
of drugs are excreted directly by the renal system without 
being changed or modified. However, most drugs are first 
converted to more polar compounds (the metabolism 
process) before they can eventually be excreted in the form 
of metabolites. 
3.4.1 Absorption Process
Aging is associated with a variety of pharmacokinetic 
changes. Some principally affect the absorption process, 
either by enhancing or limiting it. For example, the reduction 
in gastric motility and decrease in the available luminal 
surface that occurs with aging tends to reduce levels of 
drug absorption (Singh & Bajorek, 2015). 
Some drugs, such as codeine, ionize in an acidic 
environment and will normally be present in the stomach 
in the ionized state. Age-related reductions in gastric acid 
secretion are associated with reduced codeine ionization, 
making the molecule more lipid-soluble and improving its 
absorption in the stomach. Furthermore, reduced first-pass 
metabolism — the process by which orally administered 
drugs get broken down in the liver before having any 
opportunity to influence other organs — means that some 
drugs, such as morphine, have greater bioavailability in older 
adults. At the same time, several studies have found that in 
healthy individuals the absorption of many drugs (such as 
lorazepam) is unchanged with age (Greenblatt et al., 1991). 
3.4.2 Distribution Process
An increase in body fat often seen among older adults 
increases the volume of distribution and might increase 
the half-life of fat-soluble drugs (Klotz, Avant, Hoyumpa, 
Schenker, & Wilkinson, 1975). Furthermore, reductions 
in body water associated with aging increase the serum 
concentration of drugs such as ethanol and morphine. 
Other age-related changes include a reduction in serum 
albumin (the most common protein in human blood 
plasma), which increases the amount of highly protein-
bound drugs. 
3.4.3 Metabolism Process
The vast majority of prescription and non-prescription 
drugs require metabolic transformations before they can 
be excreted or eliminated. Metabolism consists of two 
phases: the alteration of functional groups, which most 
commonly occurs in the liver where cytochrome P450 
(CYP) enzymes catalyze transformations such as oxidation 
or reduction; followed by the addition of functional groups 
(e.g., conjugation with sulphate or glucuronic acid). The 
first phase of metabolism is more susceptible to age-
related changes than the second phase. For example, the 
first phase is reduced in the presence of liver disease or 
reductions in hepatic volume, which is observed in healthy 
aging, leading to greater plasma concentrations of drugs 
such as diazepam and alprazolam. 
Many studies have reported that the activity of specific 
liver enzymes, such as CYP3A4 and CYP2D6, is largely 
unaffected by healthy aging. However, the rate of CYP3A4-
mediated metabolism is dependent on hepatic blood 
flow, so reports that benzodiazepines metabolized by this 
enzyme are cleared more slowly in older adults could be 
attributable to the progressive decline in liver perfusion 
due to aging. The CYP2C19 enzyme, which is important 
in the metabolism of citalopram and escitalopram, appears 
to be susceptible to an age-related decline in functioning 
(Jin et al., 2010), with advancing age being associated with 
a reduced ability to metabolize both drugs. 
What is cytochrome P450?
Cytochrome P450 (CYP) refers to a family of 
many distinct enzymes present in the liver and 
other sites (e.g., gut, brain) that are important 
in the metabolism of most drugs. CYP enzymes 
most commonly involved in drug metabolism 
include CYP2D6, CYP3A4, CYP1A2, CYP2C19, 
CYP2C9, CYP2B6 and CYP2E1. 
Many pharmacokinetic drug interactions occur 
when one or more CYP enzymes is less able to 
metabolize drugs due to being inhibited (either 
through the presence of a drug competing for 
metabolism or a drug that shuts down enzyme 
activity), or metabolizes drugs more extensively 
than usual (through the presence of a drug that 
induces the activity of the enzyme). 
For further details, refer to Davies & Nutt, 2007.
Overall, the effect of age-related changes on CYP-mediated 
metabolism is much smaller than that of co-prescribed 
medications, which can have profound effects on inhibiting 
the activity of a specific enzyme, or of known genetic 
polymorphisms, such as the impact of being a “poor” 
CYP2D6 metabolizer (Kirchheiner & Seeringer, 2010). 
Individuals with a poor metabolizer genotype with respect 
to CYP2D6 might have elevated plasma concentrations 
of drugs metabolized by this enzyme unless alternative 
metabolic pathways are available. 
3.4.4 Excretion and Elimination Process
Regarding excretion, it is likely that the liver and kidneys will 
function sub-optimally with advancing age. In other words, 
aging is associated with hepatic or renal impairment, 
slowing the metabolism and excretion of drugs. (It should 
also be noted that a reduction in cardiac output, such 
as occurs in heart failure, will reduce blood flow to both 
the liver and the kidneys, slowing the elimination of drugs 
through both routes.)
Declining renal function is the most consistent finding of all 
pharmacokinetic changes directly associated with aging. A 
reduction in glomerular filtration rate, which is considered 
the best test to measure kidney function and determine 
stages of kidney disease, occurs each year over the age 
of 40 (Wildiers, Highley, de Bruijn, & van Oosterom, 2003). 
However, approximately one-third of older adults show no 
change in renal function up to age 89 (Lindeman, Tobin, 
& Shock, 1985). Reduced renal function is an especially 
important issue for drugs that are exclusively excreted renally, 
such as lithium, gabapentin and pregabalin. Depending on 
the extent of the renal impairment, consumption of these 
drugs requires adjustments to dosing. 
Codeine and its active metabolite, morphine, rely substantially 
on renal excretion for elimination, making their use in patients 
with renal impairment problematic. Long-term use of 
morphine should not occur in people with moderate or severe 
renal failure due to the potential for metabolites to accumulate. 
While less than 20% of oxycodone is excreted renally, dose 
reductions can still be required in cases of renal impairment.
3.5 Impact of Pharmacokinetic 
Changes in the Metabolism of  
Drugs Prone to Problematic Use
3.5.1 Opioids
Several commonly prescribed antidepressants are inhibitors 
of liver enzymes that play a key role in the metabolism of 
drugs prone to problematic use. The selective serotonin 
reuptake inhibitors (SSRIs) paroxetine and fluoxetine, the 
selective norepinephrine reuptake inhibitor (SNRI) duloxetine 
and the dopaminergic antidepressant bupropion are all 
relatively strong inhibitors of the CYP2D6 liver enzyme, which 
metabolizes methadone and hydrocodone (Flockhart, 2016). 
When methadone or hydrocodone are used at the same 
time as SSRIs, SNRIs or dopaminergic antidepressants, 
their metabolism will likely be slowed, resulting in higher 
concentrations of the drug than expected. This deficit in 
metabolism is associated with increased potential for toxicity 
and adverse effects. Begre and colleagues (2002) described 
an interaction between methadone and paroxetine where the 
antidepressant caused an increase in the concentration of 
methadone plasma.
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For some opioids, such as codeine and tramadol, 
metabolism by CYP2D6 to active analgesics (e.g., codeine 
to methadone and tramadol to o-desmethyltramadol) is 
essential for the intended therapeutic effects. A recent 
study reported that rates of falls within 28 days after 
initiating codeine or tramadol in people concurrently 
prescribed a CYP2D6 inhibitor occurred less frequently 
than in those who were not (Möller, Laflamme, & Söderberg 
Löfdal, 2015). In other words, the presence of a CYP2D6 
inhibitor in these circumstances prevented the formation 
of the active analgesic and reduced the incidence of the 
associated side effects. 
Several antidepressant drugs inhibit the CYP3A4 liver 
enzyme. Examples include fluoxetine (through its long-
lasting active metabolite, norfluoxetine) and fluvoxamine 
(Nemeroff, DeVane, & Pollock, 1996). CYP3A4 is involved 
in the metabolism of more prescribed drugs than any 
other enzyme. Fentanyl, methadone, some of the 
benzodiazepines (including alprazolam, diazepam and 
triazolam), and the z-drugs zaleplon and zolpidem are all 
metabolized by CYP3A4. Higher blood concentrations of 
any of the above drugs can be expected when they are 
co-prescribed with a CYP3A4-inhibiting antidepressant, 
increasing the risk for adverse effects. 
The case of the analgesic agent tramadol is of particular 
interest (Brown & Davies, 2016). Tramadol is a “pro-drug” 
in that its analgesic effect depends on it being converted 
by CYP2D6 to an active metabolite, O-desmethyltramadol. 
In the presence of a CYP2D6 inhibitor (such as paroxetine, 
fluoxetine or duloxetine) or in a person whose genetics 
determine they are a poor metabolizer of this enzyme, 
conversion can be blocked so that little or none of the 
metabolite is produced and little analgesic effect is achieved. 
In this circumstance, tramadol metabolism must rely on 
other pathways, including one dependent on CYP3A4. 
Sometimes these pathways are also blocked — for example, 
a person taking the antibiotic erythromycin would have 
inhibition of the CYP3A4 enzyme — meaning the tramadol 
itself would be present at higher concentrations for longer 
periods. However, tramadol has some pro-serotonergic 
activity. When taken in combination with a serotonergic 
antidepressant, such as paroxetine or fluoxetine, there have 
been several reports of serotonin syndrome: a dangerous 
condition characterized by autonomic instability, tachycardia, 
diaphoresis and agitation that carries a risk of death. 
3.5.2 Tobacco
Tobacco smoking is associated with a risk of drug 
interactions because it induces the CYP1A2 liver enzyme. 
That is, it causes an increased rate of metabolic activity 
through the production of greater quantities of the enzyme. 
While the impact of substances that inhibit specific liver 
enzymes on other substances can be limited, if the latter 
can be metabolized by an alternative enzyme, the effect of 
inducers can be more profound in that a sudden increase 
in metabolizing capacity can result in a marked reduction of 
co-prescribed drug concentration. 
It is thought that CYP1A2 induction arises not from 
nicotine (Hukkanen, Jacob, Peng Dempsey, & Benowitz, 
2012), but rather from the polyaromatic hydrocarbons 
released by smoking. Because several important drugs 
are metabolized by CYP1A2 (notably the antipsychotic 
drug clozapine), the onset of smoking is associated with 
increased metabolism and thereby a reduction in exposure 
to clozapine, potentially compromising the therapeutic 
effect. Conversely, if an individual who smokes cigarettes 
and takes clozapine is made to stop (e.g., on admission 
to a hospital where smoking is not permitted), the lost 
induction effect can be associated with an increase in 
clozapine plasma concentration and increased potential for 
side effects and toxicity. 
Because caffeine is partially metabolized through CYP1A2, 
smoking cessation can, by the same mechanism, result 
in increased exposure to caffeine and increased likelihood 
of toxicity. 
3.5.3 Cannabis
The enzymes CYP3A4 and CYP2C9 metabolize 
tetrahydrocannabinols (Watanabe, Yamaori, Funahashi, 
Kimura, & Yamamoto, 2008). Because the activity of CYP3A4 
can be induced by several psychotropic drugs, including 
carbamazepine and St John’s wort (Flockhart, 2016), it is 
possible that individuals using these drugs might have less 
response from a specific exposure to cannabis than would 
be expected in the absence of the inducer. However, the 
literature relating to clinical observations of CYP-based 
interactions with cannabis is not well developed.
3.5.4 Alcohol
CYP enzymes play only a minor role in the metabolism of some 
substances prone to problematic use. Alcohol dehydrogenase 
is the most important enzyme in the metabolism of ethanol, 
for example, with the CYP2E1 enzyme playing a role only if a 
large amount of alcohol has been consumed. Although it is 
not clear whether the activity of both enzymes declines with 
age in the absence of other changes, the usual age-related 
factors of reduced hepatic perfusion and reduced liver size 
apply to reduce the clearance of alcohol. A further issue is 
that alcohol dehydrogenase is known to be present in the 
gastric mucosa, where it effects a first-pass metabolism that 
reduces the exposure to alcohol of other organs. With aging, 
the alcohol dehydrogenase in the gastric mucosa is known 
to reduce markedly so that the extent of the protective first-
pass metabolism is reduced (Meier & Seitz, 2008).
3.6 Conclusion
Aging is associated with changes in organ function and 
the failure of compensatory mechanisms, both at the 
level of the brain and its peripheral systems. In some 
cases, pharmacodynamic and pharmacokinetic changes 
associated directly with aging can increase the likelihood 
of harmful drug–drug interactions or toxicity. However, in 
many cases, these changes are of secondary importance 
compared to the increased burdens of physical illness and 
exposure to multiple prescribed medications, both of which 
are increasingly common in older adults. 
Problematic drug use places additional stress on 
vulnerable systems and reduces the ability to deal with the 
consequences of the aging process. This increased stress 
and reduced ability can result in an increased risk of harms 
and consequences associated with substance use among 
older adults, which is discussed in the next chapter. 
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Consequences of Alcohol and 
Drug Use in Older Adults
04
CHAPTER AT A GLANCE
• Changing physiology makes older adults more vulnerable to the physical effects  
of substances, resulting in significantly increased risk of adverse outcomes.
• The use of alcohol and medication, whether prescribed or misused, causes greater 
harm in older adults than illicit substances. Alcohol represents the greatest risk and 
range of harms among older adults.
• There is a strong association between substance use and falls, accidents, cognitive 
impairment, depression and suicide among older adults. 
• Older adults are often hospitalized as a result of adverse events related to the use of 
opioids, alcohol and other substances. Mortality rates are significantly higher in older 
adults with substance use disorders.
• Older adults may experience social consequences of substance use, such as abuse, 
homelessness, family breakdown, crime and social isolation.
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4.1 Introduction
Older adults represent a highly vulnerable population 
because of their high rates of frailty, comorbidities and 
diminished physiological reserves (Davies & O’Mahony, 
2015). With substance use among older adults on the 
rise, Canada will likely see an increase in morbidity, 
including substance-related emergency department visits 
and hospitalizations — resulting in a significant burden 
on the country’s healthcare system and social services. 
Some of the harmful consequences of substance use 
among the aging population include hospitalization, death, 
falls, accidents, acute and chronic cognitive impairment, 
depression, suicide and substance withdrawal. There are 
also the social consequences of substance use that need 
to be considered.
As an individual grows older, every major organ system 
undergoes physiologic change. As discussed in the previous 
chapter, the pharmacodynamic and pharmacokinetic 
changes to the nervous system, gastrointestinal system 
(especially the liver), respiratory system and renal system 
all result in diminished function, making older adults more 
vulnerable physiologically to the effects of substance use. 
Aging is also associated with a high prevalence of physical 
and psychiatric comorbidities. A large study of primary care 
patients reported multimorbidity in 81.5% of those over 
age 85 (Barnett et al., 2012), with a Scottish study finding 
the most common conditions in multimorbid primary care 
patients over age 75 to be hypertension (61.9%), ischemic 
heart disease (31.2%) and pain (23.6%) (McLean  et  al., 
2014). Other conditions reported included chronic renal 
disease, depression, diabetes, constipation, stroke, thyroid 
disease and hearing loss. Violan and colleagues (2014) 
carried out a systematic review of rates of multimorbidity 
in 39 primary care studies, all of which found a significant 
positive association between multimorbidity and age along 
with additional associations with lower socioeconomic 
status, female gender and mental disorders.
4.2 Hospitalization and Death
A recent study from Sweden examined “drug abuse”-
associated mortality, finding that the mortality hazard 
ratio (i.e., the comparative risk of death) is 11.3 times 
higher for drug abusers than for those without a history 
of drug abuse — and substantially higher for non-medical 
than medical causes (Kendler  et  al., 2017). Concomitant 
smoking and alcohol use explains only a small proportion 
of the excess mortality associated with the specific drugs 
that were studied. The mortality hazard ratio is highest for 
individuals who use opiates, followed by individuals who use 
sedatives, cocaine/stimulants and cannabis. The authors 
note that excess mortality stems from both indirect and 
direct causes, with direct effects being strongest in middle 
to middle-late adult life. Another study by Kendler and 
colleagues (2016) focused on alcohol use disorder (AUD), 
finding a mortality hazard ratio of 5.83 and also noting the 
direct effect of AUD becomes progressively more important 
later in life and with longer duration of the disorder.
While the subsequent sections of this chapter focus on 
harms described broadly under the term “substance use,” 
there are select substance-specific findings that stand out. 
Although these intersect with the harms categorized later 
in this report, it is a useful preface to highlight unique and 
prominent harms among older adults, especially in the 
context of hospitalization and mortality rates. 
4.2.1 Alcohol
Given its accessibility and prevalence of use, alcohol 
represents the greatest risk and range of harms among older 
adults. An Australian report on alcohol- and drug-related 
harms in adults aged 65–74 identified liver cirrhosis and 
hemorrhagic stroke as the major causes of death among this 
age group (Chikritzhs & Pascal, 2005). Falls, supraventricular 
cardiac dysrhythmias and alcohol dependence are significant 
alcohol-related causes of hospitalization. A recent Canadian 
Institute for Health Information (2017) report found that peak 
rates of hospitalization caused entirely by alcohol are highest 
for men between the ages of 55 and 69 and for women 
between the ages of 45 and 59. According to the report, 
in 2015–2016, alcohol-caused hospitalizations exceeded 
hospitalizations caused by heart attacks in Canada.
Excessive drinking puts older adults at increased risk of 
coronary heart disease, hypertension and stroke (Substance 
Abuse and Mental Health Services Administration, 1998). 
There is also evidence of a causal association between 
alcohol consumption and a number of gastrointestinal 
cancers (including liver cancer) as well as breast cancer 
(Boffetta & Hashibe, 2006).
Older adults who chronically use alcohol problematically 
are more vulnerable to the development of alcoholic 
liver disease (ALD). Symptoms and signs of ALD and its 
complications in older adults are similar to those seen in 
patients of all ages (Seitz & Stickel, 2007 ). However, up to 
79% of individuals with ALD who are 60 years and older 
suffer complications such as cirrhosis (Kim, Kisseleva, & 
Brenner, 2015). Of the older adults with alcoholic cirrhosis, 
40% develop hepatitis, which has a related mortality rate 
of 15 to 25%. Additional consequences of cirrhosis include 
portal hypertension, ascites and esophageal varices, with 
or without upper gastrointestinal bleeding. As a result, half 
of older adult patients with cirrhosis die within one year of 
their diagnosis (Smith, 1995). 
That said, in a 2013 study of the global burden of alcoholic 
liver disease, Rehm and colleagues (2013) reported that 
the overall impact of alcoholic liver cirrhosis is actually the 
greatest in the middle-aged group: 62.1% of all deaths from 
alcohol-attributable liver cirrhosis occurred among people 
aged 35–64 versus 33.0% among those 65 and older.
In the United Kingdom, an analysis of hospital admissions 
and deaths found that while older adults are less likely 
to exceed the recommended drinking guidelines, those 
who meet the definition of “moderate” drinking (weekly 
intake of 21 units for men and 14 for women) are more 
likely than younger adults to be admitted to hospital for an 
alcohol-related condition (Wadd & Papodopoulos, 2014). 
During that study’s timespan (2002 to 2010), alcohol-
related hospital admission rates increased the most among 
those between the ages of 55 and 74.
Although the National Institute on Alcohol Abuse and 
Alcoholism in the United States recommends that healthy 
people older than 65 consume no more than one drink per 
day, limits appropriate to age have not been established for 
older adults in most countries (National Institute on Alcohol 
Abuse and Alcoholism, n.d.). Such limits should be lower 
than those for younger people because of age-related 
changes in metabolism, advancing ill health and increased 
sensitivity to the effects of alcohol.
4.2.2 Opioids
In a study of older adults,  opioids accounted for 9.2% 
of emergency department visits and hospitalizations 
related to adverse drug events, ranking third behind anti-
coagulants and anti-neoplastic agents. More than 20% of 
these presentations resulted in hospitalizations (Bayoumi, 
Dolovich, Hutchison, & Holbrook, 2014). 
In Canada, adults 65 and older had the highest opioid-
related hospitalization rates in 2014–2015 (Canadian 
Institute for Health Information, 2016), with accidental 
poisonings, especially during therapeutic use, accounting 
for the highest proportion of hospitalizations (55%) in this 
population. Older adults accounted for nearly a quarter of 
all hospitalizations for opioid poisoning during this period, 
even though this age group represents only 16% of the 
Canadian population. A previous Canadian report noted 
a 142% increase between 2006 and 2011 in the number 
of days spent in the hospital due to opioid use disorders 
among older adults (Young & Jesseman, 2014). 
Hospitalization and mortality related to opioid therapeutic 
use has been associated with increased comorbidity 
and age. Vision and memory problems can develop with 
age, increasing the risk of overconsumption of prescribed 
medications, especially for patients with complex medical 
regimens. Problematic opioid use — specifically, opioid use 
disorder (OUD) — can worsen outcomes in people with pre-
existing medical conditions. A 2000–2011 study of older 
adults in the United States explored the impact of opioid 
use on older adult medical conditions with respect to 
mortality. During this period, adults aged 50 and older with 
OUD were more likely to die from any cause than younger 
adults with OUD. Furthermore, HIV- and liver-related deaths 
were higher among older people with OUD compared to 
same-age peers without OUD (Larney et al., 2015).
4.2.3 Benzodiazepines and Sedative-Hypnotics
Among older adults, the use of benzodiazepines and 
sedative-hypnotics poses a serious risk of adverse effects, 
including impaired cognitive functioning (Zhang, Zhou, 
Meranus, Wang, & Kukull, 2016), reduced driving skills 
(Meuleners  et  al., 2011) and increased risks of falls 
(Diem et al., 2014). Specifically, the risks of falls is greater 
when using benzodiazepines with a longer half-life 
(Woolcott et al., 2009). Long-acting benzodiazepines can 
pose particular risks in older adults because of age-related 
changes in pharmacokinetics and pharmacodynamics 
(Madhusoodanan & Bogunovic, 2004).
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In both French and British outcome studies, benzo-
diazepines appear to be associated with an increased 
risk of death, with a mortality rate for those exposed to 
these drugs 1.2 to 3.7 times higher than those who have 
not been exposed (Palmaro, Dupouy, & Lapeyre-Mestre, 
2015). However, it is unclear if this association is causal 
or whether these drugs are prescribed more frequently to 
people who are already at higher risk of dying (Markota, 
Rummans, Bostwick, & Lapid, 2016). 
A large U.S. population-based cohort study suggested no 
increase in risk (or a minor increase, at most) of all-cause 
mortality associated with benzodiazepine initiation (Patorno, 
Glynn, Levin, Lee, & Huybrechts, 2017). Also, a Finnish 
retrospective cohort study of mortality associated with the 
use of benzodiazepines and related drugs among people 
aged 65 years and older initially reported an increased 
mortality hazard. However, after adjusting for age, sex, 
antipsychotic drug use and diagnostic confounders, the 
use of these drugs was found not to be associated with 
excess mortality (Gisev, Hartikainen, Chen, Korhonen, & 
Bell, 2011).
4.2.4 Cannabis
Compared with other drugs, the disease burden related 
to cannabis appears to be relatively small (Degenhardt & 
Hall, 2012). Fischer and colleagues (2015) attempted to 
calculate cannabis-attributable mortality and morbidity 
in Canada, based on epidemiological data, using a 
comparative risk assessment. Focusing on motor vehicle 
accidents, cannabis use disorders, mental health (in 
particular, psychosis) and lung cancer, they found motor 
vehicle accidents and cannabis use disorders far outweigh 
the others in terms of morbidity (number of cases). They 
also reported that motor vehicle accidents and lung cancer 
are the only domains where cannabis-attributable mortality 
is estimated to occur. However, there does not appear to 
be any data specific to older adults. 
A four-year Danish study of individuals entering treatment 
for cannabis use disorders found that the standardized 
mortality ratios are highest for accidents (8.2) and 
suicide (5.3), followed by homicide/violence and natural 
causes (Arendt, Munk-Jørgensen, Sher, & Jensen, 2013).
4.3 Falls 
Approximately 20 to 30% of community-dwelling older 
Canadians experience at least one fall each year (Public 
Health Agency of Canada, 2014). Most falls are the result 
of multiple factors that combine and overwhelm an older 
adult’s ability to maintain or regain balance. Attention to the 
interplay of these factors as it pertains to alcohol and drug 
use might allow researchers to better isolate these risks 
for study and prevention. In a Taiwanese study of adults 
aged 65 years and older who were hospitalized for trauma 
following a fall, it was found that older adults have more 
severe injuries, worse outcomes and a higher mortality rate 
compared to younger adults (Rau et al., 2014).
The relationship between alcohol and falls has been widely 
studied but the literature is somewhat inconsistent as it 
relates to older adults (Choi  et  al., 2014). For example, 
Tait and colleagues (2013) reported an increased risk of 
falls in “abstainers” with depression, diabetes and, for 
women, musculoskeletal conditions. However, a cross-
sectional and longitudinal study of older adults in four 
U.S. communities found that consumption of 14 or more 
drinks per week is associated with an increased risk of falls 
(Mukamal  et  al., 2004). The authors suggest that cross-
sectional studies might fail to identify this risk of heavier 
drinking because older adults at risk for falls decrease their 
alcohol use over time, or because heavier drinkers at risk 
for falls tend not to enroll in cohort studies. Also, people 
who consume large amounts of alcohol and those who use 
opioids (especially when suffering with pain) are less likely 
to be moving around, which could reduce the incidence of 
falls. In a Swedish study, heavy alcohol consumption and 
use of sedatives or hypnotics was significantly associated 
with serious falls among women over the age of 60 
(Stenbacka, Jansson, Leifman, & Romelsjö, 2002). 
The risk of falls and fractures among older adults has been 
linked to the use of opioids for pain-related conditions 
(Papaleontiou  et  al., 2010; Rolita, Spegman, Tang, & 
Cronstein, 2013), primarily with a focus on early initiation 
and short-term use. A study in Quebec (Buckeridge et al., 
2010) found that, after adjusting for concurrent drug use and 
baseline risk factors, low- and intermediate-potency opioids 
were associated with a risk of injury. The use of codeine 
combinations was associated with the highest risk of injury, 
with a 127% greater risk per one adult dose increase. 
Woolcott and colleagues (2009) conducted a meta-analysis 
of the impact of nine medication classes on falls in older 
adults, noting an increased risk of falling associated with 
use of benzodiazepines, antipsychotics, antidepressants, 
sedative-hypnotics and nonsteroidal anti-inflammatory 
medication. Similarly, an Irish study of middle-aged and older 
adults found an association between benzodiazepine use 
and an increased risk of falls — along with an association 
between injurious falls and benzodiazepines when coupled 
with the concurrent use of multiple medications (Richardson, 
Bennett, & Kenny, 2015). A prospective study examining 
age-adjusted risk of falls also found an association between 
non-benzodiazepine sedative-hypnotics and an increased 
risk of any falls as well as recurrent falls. The same study 
also associated benzodiazepine use with a similar increase 
in age-adjusted risk of falling (Diem et al., 2014). 
In a 2014 study assessing the risk of falls in people with 
dementia, while the prevalence of falls was significant (17%), 
problematic substance use significantly enhanced the risk 
of falls with an odds ratio of 1.68 (Eshkoor et al., 2014).
4.4 Vehicular Accidents
While falls are the leading cause of injury among older adults 
in Canada, motor vehicle collisions are the leading cause of 
accidental deaths in the 65–74 age group (Public Health 
Agency of Canada, 2015). Falls and vehicular collisions 
together account for approximately 91% of all injury-related 
hospital admissions among older adults. 
It has long been established that driving under the influence 
of alcohol increases the risk of accident involvement 
(Borkenstein, 1964). In one study from the Fatality Analysis 
Reporting System in the United States, overall drug and 
alcohol use was determined to be considerably less 
common among fatally injured older adult drivers compared 
to middle-aged drivers (Zhu & Rudisill, 2014). Older drivers 
tested positive for medications more often than illicit drugs, 
with narcotics such as hydrocodone and sedatives often 
detected separately or in combination with medication. 
A recent study by Choi, DiNitto and Marti (2014) examined 
risk factors for older adults driving under the influence 
of alcohol or drugs. Of past-year users, 14.5% of those 
aged 50–64 and 6.2% of those in the 65+ age group self-
reported impaired driving. In both groups, the likelihood 
of driving under the influence significantly increased in the 
presence of higher frequency alcohol use, binge drinking, 
marijuana use and a major depressive episode. 
In a systematic review of medication use and collision 
risk, 15 medications (of a larger group of 53 medications 
investigated) were associated with an increased risk of 
vehicular collision, including 13 opioid and sedative-hypnotic 
medications, some of which are commonly used by older 
adults (Rudisill, Zhu, Kelley, Pilkerton, & Rudisill, 2016). 
Distinguishing the risk from ongoing use versus first-time 
use of medication could be useful in establishing harm in 
older adults. An analysis of sedative-hypnotic vehicle crash 
data (including benzodiazepines and the related “z-drugs” 
temazepam and zolpidem) showed that individuals 
newly using sedatives were at an increased risk of 
collision compared to non-users (Hansen, Boudreau, Ebel, 
Grossman, & Sullivan, 2015). These studies emphasize 
the need for additional approaches to preventing older 
adults from driving while under the influence, including the 
challenging issue of when to invoke mandatory reporting to 
the authorities, as is already required in some jurisdictions.
4.5 Cognitive Impairment 
Substance use and cognitive impairment have a complicated 
relationship in later life. Because cognitive decline is frequent 
in older adults as well as people who use substances, 
the extent to which substances lower the threshold or 
accelerate cognitive changes is of particular interest and 
relevance. An Australian study of 99 individuals between 
the ages of 50 and 71 attending drug and alcohol services 
reported that 40% of clients met the cut-off scores for more 
severe cognitive impairment (Lintzeris et al., 2016). The most 
frequently used substances among this group were alcohol 
(46%), benzodiazepines (40%) and cannabis (38%). 
Chapter 3 of this report contains a detailed account 
of aging-related declines in brain function, structure 
and compensatory processes, as well as changes to 
neurotransmitter systems, neuroendocrine function and 
homeostatic mechanisms.
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4.5.1 Acute Cognitive Changes
Acute cognitive changes can be precipitated by many 
substances, including a variety of prescribed medications, 
illicit drugs and alcohol. These changes can range from 
subtle to profound, as in cases of acute delirium, which can 
be precipitated by toxicity or substance withdrawal. Drugs 
with significant anticholinergic effects (e.g., psychotropic 
medications, antihistamines) are known to either precipitate 
delirium or the risk factors of delirium, especially in older 
adults (Tune, 2000). 
A systematic review found that delirium risk appears to be 
increased by benzodiazepines, opioids, dihydropyridines 
(calcium channel blockers) and possibly antihistamines 
(Clegg & Young, 2010). It is therefore recommended 
that people at risk of delirium avoid new prescriptions of 
benzodiazepines, or consider reducing or discontinuing their 
use of these medications when possible. The review also 
recommends opioids should be prescribed with caution for 
people at risk of delirium, tempered by the observation that 
untreated severe pain can itself trigger delirium.
In a study on the acute effects of alcohol use, alcohol was 
associated with poorer working memory performance 
in older adults (aged 55–70), but not in younger adults 
(Boissoneault, Sklar, Prather, & Nixon, 2014). Alcohol 
was also associated with poorer performance on a set-
shifting task (Trail Making Test – Part B) in older subjects. 
Cannabis can acutely affect short-term memory, attention 
and executive function (Lundqvist, 2010). Acute and chronic 
effects of substances can also affect driving ability especially 
among older adults, raising a critical public safety issue.
4.5.2 Cognitive Changes Associated  
with Long-term Substance Use
Alcohol
Excessive long-term use of alcohol can lead to damage 
to the structure and function of the brain (Harper, 2009), 
with a history of AUDs increasing the odds of developing 
severe memory impairment later in life (Kuz´ma et al., 2014). 
However, because alcohol-related dementia (ARD) does 
not have a distinct pathophysiological profile, it has received 
limited recognition as a distinct entity (Bowden, 2010). 
There remains considerable debate about the neurotoxicity 
from alcohol versus neurotoxicity from an associated 
cause (such as thiamine deficiency) or multiple causes. 
Confounding factors include common comorbidities such 
as psychiatric disorders, the use of other substances, 
head injury and increased vascular risk factors. Compared 
to people with Alzheimer’s disease, those with ARD tend 
to perform better on semantic tasks, but worse on visual-
spatial tasks (Ridley, Draper, & Withall, 2013). 
To stimulate research on ARD and improve the recognition 
of alcohol-related problems among older adults, Oslin and 
Cary (2003) developed diagnostic criteria for ARD, then 
studied 192 nursing home residents in an attempt to validate 
their criteria. (Table 1 below summarizes the criteria for 
classifying probable ARD.) Eighty-two percent of the study 
participants were diagnosed with some form of dementia, 
with 10% receiving a diagnosis of ARD. Those with ARD 
were less cognitively impaired, more often unmarried, 
and demonstrated a stabilization of both cognition and 
functional status. In contrast, those with Alzheimer’s 
disease and vascular dementia showed a general decline 
in both cognitive and functional status. Neuroimaging 
and neuropathological evidence of individuals diagnosed 
with ARD demonstrate prominent white matter loss and 
neuronal loss in the superior frontal association cortex, 
hypothalamus and cerebellum (Ridley et al., 2013). 
There is evidence that the frontal lobes of individuals with 
ARD appear particularly susceptible to damage. It is also 
possible that thiamine deficiency plays a significant role in the 
development of ARD. Individuals with AUDs have a very high 
risk of thiamine deficiency because of poor dietary nutrition 
and also because alcohol directly compromises thiamine 
metabolism. Thiamine deficiency can cause Wernicke’s 
encephalopathy, which is an acute neurological disorder 
characterized by ocular motor abnormalities, cerebellar 
dysfunction and altered mental state. Korsakoff syndrome, 
which is a syndrome of profound memory impairment, can 
also develop and appears to be related to additional damage 
to diencephalic and hippocampal circuitry.
Dementia and cognitive decline are linked to cardiovascular 
risk factors and there is some evidence to suggest alcohol 
might be protective in terms of reducing the risk of coronary 
artery disease and ischemic stroke. This protective effect 
could be related to alcohol’s inhibitory effect on platelet 
aggregation and a reduction of inflammatory markers, as 
well as by an alteration of the serum lipid profile (Hulse, 
Lautenschlager, Tait, & Almeida, 2005). 
A systematic review and meta-analysis by Peters and 
colleagues (2008) suggested that small amounts of alcohol 
may be protective against dementia, noting a risk ratio of 
0.63. (The reduced risk was specifically for Alzheimer’s 
disease, not for vascular dementia or general cognitive 
decline, but because of the heterogeneity of the data, these 
findings should be interpreted with caution.) Anstey and 
colleagues (2009) also carried out a meta-analysis of 15 
prospective studies. The pooled relative risks of Alzheimer’s 
disease, vascular dementia and any dementia for light to 
moderate drinkers compared to non-drinkers were all in the 
range of 0.72 to 0.75. These results suggest this group of 
alcohol drinkers had a reduced risk of dementia later in life 
compared to abstainers. However, it is unclear whether this 
reflects selection effects in cohort studies commencing in late 
life, a protective effect of alcohol consumption throughout 
adulthood or a specific benefit of alcohol in late life.
Cannabis
Very little research on the effects of cannabis has been 
carried out among adults over the age of 50, highlighting 
the urgent need to evaluate the impact of cannabis use on 
this population. 
In a systematic review of the effects of cannabinoids on 
human cognition, Broyd and colleagues (2016) found 
that verbal learning, memory and attention are most 
consistently impaired by both acute and chronic exposure 
to cannabis. They suggest that psychomotor function 
is most affected during acute intoxication, with some 
evidence for persistence in individuals who use cannabis 
chronically and after cessation of use. They also note that 
impaired verbal, memory, attention and some executive 
functions may persist even after prolonged abstinence.  
Table 1. Classification of probable alcohol-related dementia 
Criteria for the clinical diagnosis of probable ARD include the following:
• A clinical diagnosis of dementia at least 60 days after the last exposure to alcohol; and
• Signiﬁcant alcohol use, as deﬁned by a minimum average of 35 standard drinks per week for men and 28 for 
women, for a period greater than five years. The period of signiﬁcant alcohol use must occur within three years 
of the initial onset of cognitive deﬁcits.
The diagnosis of ARD is supported by the presence of any of the following:
• Alcohol-related hepatic, pancreatic, gastrointestinal, cardiovascular or renal disease  
(i.e., other end-organ damage);
• Ataxia or peripheral sensory polyneuropathy (not attributable to other speciﬁc causes);
• Stabilization or improvement of cognitive impairment after 60 days of abstinence;
• Neuroimaging evidence of improvement in ventricular or sulcal dilatation after 60 days of abstinence; or
• Neuroimaging evidence of cerebellar atrophy, especially of the vermis.
The following clinical features cast doubt upon the diagnosis of ARD:
• Presence of language impairment, especially dysnomia or anomia;
• Presence of focal neurologic signs or symptoms (except ataxia or peripheral sensory polyneuropathy);
• Neuroimaging evidence of cortical or subcortical infarction, subdural hematoma or other focal brain pathology; and
• Elevated score on the Hachinski Ischemia Scale.
Clinical features that are neither supportive nor cast doubt upon the diagnosis of ARD include:
• Neuroimaging evidence of cortical atrophy;
• Presence of periventricular or deep white-matter lesions on neuroimaging, in the absence of focal infarcts; and
• Presence of the apolipoprotein e4 allele.
Source: Oslin & Cary, 2003.
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Conversely, a recent report from the Canadian Centre on 
Substance Use and Addiction (CCSA) provides evidence to 
suggest continued chronic cannabis use does not produce 
severe or debilitating impairment of memory, attention, 
psychomotor and other cognitive functioning (McInnis & 
Porath-Waller, 2015). The report’s authors suggest the 
effects on these cognitive abilities are generally subtle. 
However, despite a large number of studies examining 
the impact of cannabis on various aspects of cognitive 
functioning, it is uncertain whether the effects of cannabis 
on cognition are reversible following cessation of the drug. 
The authors do note that there is emerging evidence that 
chronic cannabis use can affect brain development and 
functioning in areas that are important for cognitive and 
emotional processes, prompting concern about cannabis 
use in adolescents and young adults. Given the aging of the 
baby boomer generation, it is important to ask about early 
use of cannabis during clinical evaluation of this population.
Interestingly, it has been suggested that cannabinoids 
could have a positive impact on neurodegeneration. The 
cannabinoid system is emerging as an important factor 
in determining a neuron’s fate by providing protection to 
neurons through the activation of pro-survival pathways 
and the control of neurogenesis (Gowran, Noonan, & 
Campbell, 2011). While neurodegenerative illnesses are 
associated with toxicity of neurons due to their over-
activation, oxidative stress and neuroinflammation, certain 
cannabinoid molecules have been demonstrated to inhibit 
these events. However, there has not been any clinical 
research to support this concept.
Benzodiazepines
In a meta-analysis on the association between benzo-
diazepine use and dementia, Zhong and colleagues 
(2015) found that the risk of dementia is increased by 
approximately 50% in individuals who chronically use 
benzodiazepines compared to those who have never 
used these medications. Similarly, a systematic review 
of observational studies found that individuals who use 
benzodiazepines long-term have up to a two-fold increased 
risk of developing dementia compared to those who do not 
(Billioti de Gage et al., 2015). 
However, the observed association between benzo-
diazepine use and dementia may be due to confounding 
factors such as indication for use and reverse causation. 
For example, the prodromal symptoms of dementia (e.g., 
sleep disturbance, anxiety, depression) can occur for 
up to 10 years before a clinical diagnosis of dementia 
and may significantly contribute to the increased use 
of benzodiazepines. There are a number of different 
mechanisms that could underlie the potential influence 
of benzodiazepines on the development of dementia. As 
an example, due to neural compensation and cognitive 
reserve concepts, some people can cope with initial 
neurodegenerative lesions by using or developing alternative 
networks (Pariente, de Gage, Moore, & Bégaud, 2016). 
Lowering brain activation levels through benzodiazepine 
use could limit this capacity.
Opioids
Although there has been limited research on the potential 
for opioids to increase the risk of dementia, it has been 
suggested that opioids modulate the behaviour of 
microglia (a form of active immune defence of the central 
nervous system) — specifically, by promoting the initiation 
of programmed cell death — which might contribute to 
the development of neurodegenerative diseases (Hu, 
Sheng, Lokensgard, & Peterson, 2002). In a study of older 
adults who were not suffering from dementia, Dublin and 
colleagues (2015) concluded that people with the heaviest 
opioid or non-steroidal anti-inflammatory drug use have a 
slightly higher risk for dementia than those with little or no 
use. However, as these results could reflect a direct effect 
of chronic pain on cognition, there is little evidence of long-
term cognitive harm associated with opioids. 
4.6 Mood and Related Disorders
4.6.1 Alcohol
Older adults suffering from depression are three to four 
times more likely than non-depressed older adults to have 
an AUD, with AUDs prevalent in 15 to 30% of patients with 
late-life major depression (Devanand, 2002). At the same 
time, a high percentage of older adults with a diagnosed 
AUD have a history of depression. 
There are several possible causal relationships in the 
association between AUDs and major depression. An AUD 
might cause depression. Major depression might cause an 
AUD (via self-medication). There can also be a reciprocal 
causal relationship, where each disorder increases the risk 
of the other disorder simultaneously. Possible explanations 
for the factors and processes giving rise to these causal 
links include: 
• Alcohol misuse often leads to disruptions in 
family and social life, as well as physical health 
problems. While it can be argued that these 
difficulties are the source of the linkage between 
AUD and depression, studies that have tried to 
account for these factors found that the links 
persist even after controlling for social and 
environmental factors (Boden & Ferguson, 2011). 
• The disorders could be linked by genetic factors 
related to neurotransmitter functioning. 
• Alcohol could cause metabolic changes (e.g., 
reduced folate levels, alterations to circadian 
rhythms) that increase the risk of depression. 
• Many older adults drink alcohol in response to 
psychosocial triggers such as loneliness and 
depressed mood. 
In their examination of the literature on the association 
between AUDs and depression, Boden and Ferguson 
(2011) found that the presence of either disorder doubles the 
risk of the second disorder. They suggest the most plausible 
causal association is one in which the AUD increases the 
risk of major depression rather than vice versa. A systematic 
review by Sullivan and colleagues (2005) revealed a median 
prevalence of current or lifetime alcohol problems in people 
with depression of 16% and 30%, respectively. (In contrast, 
the general population has a prevalence of 7% and 16 to 
24%, respectively.) There is evidence that alcohol problems 
are associated with worse outcomes over the course of 
depression, with negative impacts on suicide and death risk, 
social functioning and healthcare use. There is also evidence 
that antidepressants can improve depression outcomes in 
people with alcohol dependence.
4.6.2 Opioids
A recent study of individuals with chronic pain who were 
treated with prescription opioids, medical cannabis or both 
found that patients who were prescribed opioids were 
significantly more likely to screen positive for depression 
and anxiety (Feingold, Goor-Aryeh, Bril, Delayahu, & Lev-
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Ran, 2017). Individuals in the group receiving both opioids 
and medical cannabis were also more prone to depression 
than those in the cannabis-only group. Similarly, newly 
emerging epidemiologic evidence suggests the incidence 
of depression following initiation of prescription opioid 
analgesics is high (Fischer, Murphy, Kurdyak, & Goldner, 
2016). In a study of two large patient cohorts, patients 
with remitted depression who were exposed to opioid 
analgesics were 77 to 117% more likely to experience a 
recurrence of depression than those who remained opioid-
free (Scherrer  et  al., 2016). There is also evidence of an 
association between major depression and non-medical 
use of prescription opioids (Fink et al., 2015). 
4.6.3 Benzodiazepines
Although benzodiazepines are widely believed to cause 
depression, there is a lack of evidence to substantiate 
this claim (Patten, 2008). However, in a study of the 
determinants of treatment-resistant depression, Parker 
and Graham (2015) reported that benzodiazepine use 
was significantly more frequent in the highest treatment-
resistant group. 
4.6.4 Cannabis
Various reviews and meta-analyses have found an 
association between heavy or problematic cannabis 
use and depression (Degenhardt, Hall, & Lynskey, 2003; 
Lev-Ran  et  al., 2014). For example, a report by Bersani 
and colleagues (2016) found that patients with cannabis 
use disorder present significantly more severe negative 
symptoms of depression when compared to patients 
without cannabis use disorder. They also note that cannabis 
use is frequent among depressed patients, which could lead 
to “amotivational syndrome,” which combines symptoms of 
affective flattening and loss of emotional reactivity. 
Unfortunately, the literature about the link between 
depression and cannabis use is almost exclusively focused 
on adolescents or younger adults with very little research 
related to older adults. Whether these results can be 
generalized to older adults is unclear. 
4.7 Suicide
The rate of completed suicide is disproportionately high 
in the older adult population, especially males. Substance 
use disorder (SUD), especially AUD, is the second most 
common type of psychiatric disorder associated with 
completed suicide in the older adult population, following 
only depression (Blow, Brockmann, & Barry, 2004). 
Drinking alcohol increases suicide risk through interactions 
with many age-related factors, including medical illness, 
negatively perceived health status and low socio-economic 
support. The acute use of alcohol is also associated with 
increased likelihood of a suicide attempt, particularly when 
large amounts are consumed (Borges et al., 2017). There 
is also evidence that the presence of an AUD significantly 
increases the risk of suicidal ideation, suicide attempt 
and completed suicide — suggesting that AUD could be 
an important predictor of suicide and premature death 
(Darvishi et al., 2015). A Swedish study of individuals aged 
70 years or older who had attempted suicide found a strong 
association between AUD and hospital-treated suicide 
attempts in both sexes, with AUD observed in 26% of cases 
versus just 4% in a comparison group (Morin et al., 2013). 
Alcohol misuse and comorbid psychiatric illness represent 
a potentially lethal combination that accounts for a large 
number of suicides in late life. However, because the 
relationship between alcohol use and late-life suicide is so 
complex, more research will be required to develop better 
detection and prevention strategies (Koh, Gorney, Badre, 
& Jeste, 2015).
A study of emergency department visits for drug-related 
suicide attempts among middle-aged adults (ages 45 to 
64) found a dramatic increase in the rate of such visits 
between 2005 and 2011 (Tesfazion, 2013). In 2011, the 
majority of the drug-related suicide attempts involved 
prescription drugs and over-the-counter medications 
such as anti-anxiety and insomnia medications (48%), 
analgesics (29%) and antidepressants (22%). More 
recently, Bohnert and colleagues (2017) studied SUDs 
and the risk of suicide mortality among American veterans. 
They found that a diagnosis of any current SUD and a 
specific current diagnosis of alcohol, cocaine, cannabis, 
opioid, amphetamine or sedative use disorder are all 
significantly associated with an increased risk of suicide 
in both males and females. Although the greater suicide 
risk among females was observed only among those with 
“any current SUD” and opioid use disorder, the correlations 
are significantly stronger for women than men, suggesting 
the presence of an SUD might be an especially important 
marker for women. The authors note that other co-
occurring psychiatric disorders might partially explain the 
associations between SUDs and suicide.
Arthur, 65, first started using prescription opiates after experiencing gallstone pain  
10 years ago. Although a surgeon had recommended a cholecystectomy, Arthur feared 
taking time off work without pay, opting instead to pursue supportive management for 
recurring episodes of pain with the help of his family doctor. 
Due to the ongoing difficulties with the pain — and the resulting missed days at work — 
Arthur was unable to continue his full-time job as a librarian. As a result, he had to move 
further outside the city for work, settling into a small third-floor apartment and taking up 
his current job as a part-time bookkeeper. When his family doctor retired a few years 
ago, Arthur was forced to see several different walk-in doctors for the prescription of his 
medication, hydromorphone, in addition to acquiring pills through people he knows. As 
he became more tolerant to the medication, his use gradually escalated over the years; 
today, Arthur admits to taking five 3-milligram (mg) tablets of long-acting hydromorphone 
each day. He first started inappropriately using in response to the many stressors in his 
life — the ongoing pain, financial issues, the death of his wife — but now uses regularly 
in the morning before going to work to prevent withdrawal. Arthur has been late for work 
or missed days because he ran out of hydromorphone, and has taken to dealing with his 
stress through illicit diazepam acquired through a friend: between three to five 10-mg 
tablets most days of the week. 
While he has no identified mobility issues, Arthur admits that living on the third floor is 
worrisome, especially when the elevator is out. He was eventually referred for help with 
suggestions of opiate maintenance therapy. He has never been on opiate maintenance 
therapy and has heard different stories about methadone in the community. He would 
like to know more about the consequences of his past use and how he can get support 
for the future.
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4.8 Substance Use  
and Drug Interactions
One of the most concerning harms related to substance 
use among older adults is the potential for interaction 
with medications and the resulting consequences. For 
example, the interaction of alcohol and medication can 
affect drug metabolism through the microsomal ethanol 
oxidizing system (MEOS). Chronic alcohol consumption 
induces greater enzymatic capacity in the MEOS as it 
works to keep alcohol levels in check. Older adults often 
take a large number of prescribed medications, which are 
also metabolized by the MEOS; following alcohol-induced 
enzymatic induction, the MEOS can become saturated 
with the metabolites of these medications, resulting in 
potentially toxic levels of metabolites in the liver (Moore, 
Whiteman, & Ward, 2007). In a cross-sectional analysis of 
older individuals in the Irish population, 72% of participants 
had been exposed to alcohol-interactive medications, 
with 60% of those reporting concomitant alcohol use 
(Cousins  et  al., 2014). Twenty-eight percent of those 
reporting antihistamine use identified themselves as heavy 
drinkers, nearly one-fifth combined heavy drinking with 
the use of anticoagulants/antiplatelets and cardiovascular 
agents, and 16% combined heavy drinking with central 
nervous system agents. 
Older adults may not receive adequate information about 
their medications and alcohol use, making it difficult for them 
to make an informed decision about concurrent use. In 
addition, many older adults do not discuss alcohol use with 
their healthcare providers and the written warnings found 
on the packaging of some over-the-counter medications 
might not reflect age-specific recommendations (Slattum & 
Hassan, 2017). Because many older adults use prescription 
or over-the-counter medications to help with poor sleep or 
pain, the use of alcohol to further manage sleep or pain 
issues increases the risk of harmful interactions. 
The consequences of drug–drug interactions are especially 
pronounced when examining opioid-related drug interactions. 
A study by the Canadian Institute for Health Information 
(2013) found that among older adults who had an adverse 
drug-related hospitalization, opioids was the third-most 
common drug class. Of these, the most common co-
occurring toxicity was with benzodiazepines (19%) followed 
by acetaminophen (14%), including both combination 
products and acetaminophen alone. The combination of 
opioids and benzodiazepines significantly increases the 
risks of harms such as overdose, respiratory depression and 
death (Karaca-Mandic, Meara, & Morden, 2017). 
To improve patient outcomes, Gudin and colleagues (2013) 
made strong recommendations for monitoring treatment 
adherence (e.g., through urine screening) and ruling out 
psychiatric comorbidity when screening for possible 
benzodiazepine–alcohol interactions is indicated.
4.9 Substance Withdrawal
Different substances present a spectrum of withdrawal-
related consequences. Among older adults, some of these 
consequences are aggravated by the unique physiological 
changes that occur later in life. However, as a general 
principle, an extra order of conservativism is appropriate 
because of the lower threshold for complications among 
older adults. 
In alcohol withdrawal, the risk of seizures and delirium 
is well-recognized and regarded as potentially fatal in 
older adults because of their physiological vulnerability. 
Sudden cessation, even with lower levels of alcohol use, 
is not advised and a gradual taper is recommended. One 
systematic review of alcohol withdrawal among older 
adults reported mixed results with respect to severity and 
duration compared to younger patients (Karounos  et  al., 
2013). Another study stressed the need for screening of all 
older adults for level of alcohol use when admitted to an 
acute care facility in order to avoid acute withdrawal and the 
development of delirium tremens (Letizia & Reinbolz, 2005). 
In light of the high degree of medical comorbidity and 
potentially increased severity and duration of alcohol 
withdrawal in older adults, inpatient elective withdrawal 
management is generally recommended (O’Connell, Chin, 
Cunningham, & Lawlor, 2003). Outpatient management 
might not be appropriate for older individuals who are 
frail, live alone with limited family support, or have multiple 
medical problems and prescribed medications (Liskow, 
Rinck, Campbell, & DeSouza, 1989). Because withdrawal 
management from any addictive substance in an outpatient 
setting could pose significant risks for older adults, it should 
be carefully supervised, ideally in a hospital. 
Benzodiazepine-assisted withdrawal is the mainstay of 
both alcohol and benzodiazepine withdrawal management. 
It should be undertaken with care in older adults because 
of their altered pharmacokinetics and increased sensitivity 
to the adverse effects of benzodiazepines (Hurt, Finlayson, 
Morse, & Davis, 1988; Sabioni, Bertram, & Le Foll, 2015). 
Short-acting benzodiazepines could prove less problematic 
with older adults, lessening the chances of sedation and 
harmful drug–drug interactions (Dufour & Fuller, 1995). 
Benzodiazepine withdrawal often requires careful tapering, 
with older adults experiencing greater insomnia and anxiety 
during withdrawal (Ashton, 2005; Authier et al., 2009). 
While opioid and cannabis withdrawal are encountered in 
clinical geriatric practice, they do not appear to have been 
extensively studied in the literature. It is generally regarded 
that the instability of blood pressure brought on by any 
withdrawal, independent of the features described above for 
alcohol and benzodiazepines, leave older adults vulnerable 
because of their underlying physiological state. CCSA has 
created a useful care pathway for older adults experiencing 
psychoactive prescription drug harms. It includes guidance 
on treating withdrawal from benzodiazepines and opioids, 
including medication-assisted withdrawal and psycho-
social interventions such as cognitive behavioural therapy 
(Canadian Centre on Substance Abuse, 2016).
Bonnet and Preuss (2017) recently reviewed the literature 
on cannabis withdrawal syndrome. They conclude that 
cessation from long-term and regular cannabis use 
precipitates a specific withdrawal syndrome (mainly mood 
and behavioural symptoms) of light to moderate intensity. 
There is very little information available on cannabis 
withdrawal in older adults, although there is a case report 
of suspected dronabinol withdrawal in a medically ill older 
adult patient (Muramatsu, Silva, & Ahmed, 2013).
4.10 Social Consequences
The literature on social consequences among older adults 
is somewhat limited. However, some information is available 
on abuse of older adults, family breakdown, homelessness, 
crime and social isolation/loneliness.
4.10.1 Abuse of Older Adults
Substance use, whether by the victim or the perpetrator, 
has long been associated with violence and abusive 
behaviour. In the United States, Jogerst and colleagues 
(2012) studied the association of state-reported domestic 
elder abuse with regional levels of substance abuse. They 
found that elder abuse investigations and substantiations 
are associated with various forms of substance abuse and 
because the measures of documented elder abuse are 
minimal, being able to associate substance abuse with elder 
abuse is a significant finding. 
A report by the World Health Organization (2011) notes the 
following links between alcohol and the abuse of older adults:
• Individuals with alcohol problems may be financially 
dependent on relatives, including older adults. 
This reliance can include funding their alcohol use, 
possibly leading to financial or material coercion.
• Caregivers who drink excessively might neglect 
their responsibilities to the older adults who depend 
on them.
• Impaired judgment and memory through harmful 
alcohol use by older adults can leave them more 
vulnerable to abuse.
• Caregivers can encourage older adults to drink to 
make them more compliant or exploit them financially.
• Older adults may use alcohol as a means of coping 
with abuse or neglect.
• Hazardous and harmful levels of alcohol use  
are risk factors for intimate partner violence.
Two Canadian studies were mentioned in the World Health 
Organization report, including a report from an outreach 
program for older adults with alcohol or other substance 
use problems, which found that 15 to 20% of its clients 
were suffering from psychological, physical or financial 
abuse (Bradshaw & Spencer, 1999). In addition, a study of 
older adult abuse case files from agencies across Canada 
reported that severe drinking bouts by the abuser led to 
harmful incidents in 14.6% of all older adult abuse cases 
(Pittaway & Gallagher, 1995). In a seven-city European study 
of alcohol use among people between the ages of 60 and 
84, it was found that psychologically abused older adults are 
more likely to use alcohol (Tredal et al., 2013). 
Some of the factors that might increase the risks of older 
adults suffering elder abuse include cognitive or physical 
impairment and social isolation. Gender is also important 
in some regions, where females are generally more at risk. 
Both older adult abuse and harmful alcohol use can lead 
to physical injury, financial problems, social withdrawal, 
malnourishment, depression and cognitive impairment.
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4.10.2 Family Breakdown
While a breakdown in family cohesion can contribute to 
substance use, the relationship can also work in the 
opposite direction, with substance use straining family 
relationships and leading to family dysfunction. The cravings 
associated with SUDs can lead to financial difficulties as 
well as irrational, violent or criminal behaviour, all of which 
place strain on the family. Individuals dealing with addiction 
can also become self-centred, selfish and oblivious to the 
needs of others around them. 
There is limited literature focused on older adults. A study 
by Moos and colleagues (2011) compared personal, 
family and social functioning of older husbands and wives, 
concordant or discordant for high-risk alcohol consumption. 
They concluded that high-risk and discordant alcohol 
consumption does not seem to be linked to decreased 
family functioning among older couples in long-term, 
stable marriages. However, a different study reported that 
discrepancies in alcohol consumption between spouses 
(as opposed to consumption levels) are more closely 
related to the probability of subsequent divorce, with 
couples comprising two abstainers or two heavy drinkers 
having the lowest rates of divorce (Ostermann, Sloan, 
& Taylor, 2005). A study from Norway reported similar 
findings: heavy drinking among men and women increases 
the risk of future divorce, with concordant abstainers and 
concordant heavy drinkers having a lower risk of divorce 
(Torvik, Røysamb, Gustavson, Idstad, & Tambs, 2013).
4.10.3 Homelessness
In a U.S. study of older homeless adults aged 50–69, 
30% had a history of binge drinking and 16.8% had 
a history of “drug problems,” based on an addiction 
severity index (Brown, Kiely, Bharel, & Mitchell, 2012). 
In a more recent study of homeless individuals aged 50 
and older, almost two-thirds of participants had moderate 
or greater severity symptoms for at least one illicit drug, 
while 25.8% had moderate or greater severity alcohol 
symptoms (Spinelli  et  al., 2017). The authors noted an 
association between a history of psychiatric hospitalization 
and moderate or greater illicit drug symptoms, and also 
linked the presence of major depressive symptoms with 
moderate or greater severity alcohol symptoms. 
In a study of homeless veterans in the United States, 21% 
had a complex mix of physical, mental and substance 
abuse conditions (Byrne et al., 2015). In another study of 
homeless veterans, 23% had a history of drug abuse and 
25% had a history of alcohol abuse (Van den Berk-Clark & 
McGuire, 2013).
4.10.4 Crime
According to a report from Correctional Service Canada 
(CSC), more than 50% of older offenders are first-time 
offenders (Uzoaba, 1998). Comparing data on older and 
younger offenders with respect to substance use, CSC 
found that older offenders are significantly more likely 
to have started drinking at an early age, drink regularly, 
combine alcohol and drugs, and drink to excess in social 
situations. They are also more likely to have a history of 
daily binges and view alcohol as a means of relieving stress. 
In another study of inmates of all ages in Canadian federal 
institutions, 41% had consumed alcohol at least once per 
week in the six months prior to arrest, with 24.5% using 
cannabis, 17.9% cocaine and 4.2% heroin during the same 
period (Brochu et al., 2001). An estimated 40% of crimes 
are associated with the consumption of psychoactive 
substances, with intoxication possibly playing a role in 
impairing cognitive functions, including disinhibition.
4.10.5 Loneliness and Social Isolation
The concept of loneliness is based on a person’s subjective 
evaluation of feeling without companionship, isolated or not 
belonging (Victor et al., 2002). Social isolation, which is an 
objective measure of the size and diversity of one’s social 
network and frequency of social interaction, is distinct from 
loneliness — although the two are associated (Coyle & 
Dugan, 2012). 
Akerlind and Hornquist (1992) reviewed the interplay 
between loneliness and alcohol abuse. Although the 
literature was sparse, they suggest loneliness may be 
a significant contributing and maintaining factor in the 
development of alcohol abuse. They also note an association 
between loneliness and a broad array of psychopathology. 
In contrast, Canham and colleagues (2016) recently 
reported on the association of alcohol use and loneliness 
among middle-aged and older adult drinkers aged 50 and 
above, with their results suggesting loneliness is associated 
with reduced alcohol use frequency — and no association 
between loneliness and at-risk or binge drinking. Possible 
explanations for the association between frequent alcohol 
use and decreased loneliness is that alcohol can cultivate 
an environment of friendship and togetherness; in certain 
settings, alcohol has been described as a “social facilitator.” 
However, future research is needed to explore whether 
there is a threshold level at which being lonely can lead to 
excessive alcohol consumption.
Regarding social isolation, the absence of close friends is 
associated with several mood and anxiety disorders (Chou, 
Liang, & Sareen, 2011). Similarly, the absence of frequently 
contacted members of a network (e.g., a religious group) is 
linked to alcohol abuse, alcohol dependence, drug abuse 
and nicotine dependence. 
4.11 Conclusion
Based on the limited evidence available, it is clear that 
substance use by older adults can lead to a number 
of harmful consequences. However, more research is 
required to understand the full impact of substance use 
among different subgroups of the older adult population, 
including those with significant comorbidities. Substance 
use guidelines for older adults are also needed to provide 
better guidance for care and harm reduction related to both 
short- and long-term substance use. The next chapter of 
this report focuses on substance use issues in older adults 
with significant medical and psychiatric comorbidities.
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CHAPTER AT A GLANCE
• A large proportion of older adults with psychiatric disorders, such as schizophrenia, 
bipolar disorder, depression and anxiety, use illicit drugs or prescription drugs for 
non-medical purposes.
• Physical health problems among older adults, such as cardiovascular disease,  
might be worsened by problematic substance use.
• Older adults who experience co-occurring psychiatric disorders and physical  
health problems (e.g., diabetes, stroke, insomnia, chronic pain) are at greater risk  
of developing substance use disorders. 
• Substance use disorders that co-occur with physical or mental illnesses might be 
related to chronic pain or insomnia, resulting in problematic substance use or harmful 
drug–drug interactions between prescription and non-prescription medications.
• As demand increases for integrated physical health, mental health and addiction 
services for older adults, there is a need for more research focused on older adults 
with substance use disorders and co-occurring physical or mental illnesses. 
• Preventive and integrated treatments are critical in addressing co-occurring health 
conditions in the older adult population.
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5.1 Introduction
By 2061, older adults are projected to make up as much as 
28% of Canada’s population (Statistics Canada, 2016). Yet 
while older adults have higher life expectancies than ever 
because of the latest advances in health care (Gfroerer, 
Penne, Pemberton, & Folsom, 2003), they still face a 
number of negative health outcomes as they age, including 
a greater risk of delirium and falls, as well as comorbid 
diagnoses such as diabetes, hypertension and dementia. 
At the same time, older adults have lower rates of 
substance use disorders (SUDs) than younger populations. 
Approximately 1.9% of adults aged 45 and older and less 
than 1% of those aged 65 and older have an SUD, much 
lower than the 11.9% prevalence rate observed among 
youth (Pearson, Janz, & Ali, 2013). There are also fewer 
numbers of older adults admitted into substance treatment 
programs (Kuerbis, Sacco, Blazer, & Moore, 2014). As 
such, there is a common misperception that older adults 
do not display problematic substance use. However, 
recent evidence suggests the prevalence of SUDs among 
the “baby boomer” generation compared to earlier 
cohorts of older adults is increasing (Gfroerer et al., 2003; 
Kuerbis et al., 2014). 
The baby boomers are a distinct population born between 
1946 and 1965, a period of shifting views toward alcohol 
and other drugs compared to the preceding cohort, known 
as the “greatest generation” (Ekerdt, De Labry, Glynn, 
& Davis, 1989; Gfroerer  et  al., 2003; Savage, 2014). The 
number of baby boomers with an SUD is expected to 
increase from 2.8 million in 2006 to 5.7 million in 2020 
(Han, Gfroerer, Colliver, & Penne, 2009). As shown in Table 1, 
the scope of SUDs in this population includes both licit and 
illicit substances, with alcohol being the most commonly 
reported SUD.
Table 1. Prevalence of SUDs in the older adult population (age 50 years and older)
SUD Prevalence (%) Reference
Alcohol 2–22 Kuerbis et al., 2014; Oslin, 2005
Benzodiazepines 11 Holroyd & Duryee, 1997
Cannabis 1.3–4.5 Blazer & Wu, 2009a, 2009b; Hasin et al., 2015; Wu & Blazer, 2014
Cocaine 2 Rivers et al., 2004
Hallucinogens 0.1 Blazer & Wu, 2009a
Heroin < 0.05 Blazer & Wu, 2009a
Methamphetamine 5 Klassen, Katzman, & Chokka, 2010
Nonmedical opioids 1.4 Blazer & Wu, 2009b
Stimulants < 1 Blazer & Wu, 2009a
Tobacco 13–14 Marinho, Laks, Coutinho, & Blay, 2010
(Holroyd & Duryee, 1997). Another study demonstrated 
that mood and personality disorders were most commonly 
associated with “alcohol abuse” in 21% of psychiatric 
inpatients aged 55 years and older (Speer & Bates, 1992). 
Goldstein and colleagues (1996) further supported this 
finding, demonstrating that alcohol use disorders were 
prevalent in 23 to 44% of elderly psychiatric inpatients. 
Despite this rising prevalence, there have been limited 
studies of SUDs in older adult psychiatric populations. 
However, some of the psychiatric disorders known to 
commonly co-occur with SUDs include schizophrenia/
psychosis, mood and anxiety disorders, Alzheimer’s/
Parkinson’s disease and other co-occurring SUDs.
5.2.1 Schizophrenia/Psychosis
Nearly 50% of patients with schizophrenia suffer from co-
occurring SUDs (Volkow, 2009), which is consistent with 
the rate of SUDs in the general population. However, the 
prevalence of co-occurring SUDs in older age cohorts is 
lower than in younger patients. Research has suggested 
that because schizophrenia typically appears between 
the ages of 18 and 24, older patients are more stable and 
less likely to have an addiction to drugs (Vanasse  et  al., 
2012). A recent study in Quebec found that patients with 
schizophrenia aged 65 years and older were less likely 
to use substances or have frequent visits to emergency 
departments than younger patients with schizophrenia 
(Ngamini-Ngui et al., 2014). These findings were in line with 
an earlier study from Montreal that found no consistent 
increase over time in yearly visits for treatment for SUDs in 
older schizophrenia patients (Chaput & Lebel, 2007). 
The co-occurrence of chronic schizophrenia is most 
commonly associated with SUDs specific to tobacco use 
(72 to 90%; Smith, Mazure, & McKee, 2014), cannabis 
use (20 to 65%; Koskinen, Lohonen, Koponen, Isohanni, 
& Miettunen, 2010; United Nations Office on Drugs and 
Crime, 2015) and alcohol use (20.6%; Koskinen, Lohonen, 
Koponen, Isohanni, & Miettunen, 2009). Studies have 
suggested that neurobiological vulnerability in patients with 
schizophrenia, as well as environmental stressors (e.g., 
substance use), can result in the relapse and continuation 
of psychotic symptoms co-occurring with drug use (Kozak, 
Barr, & George, 2017). Cognitive deficits have also been 
suggested to be more apparent in older patients with 
schizophrenia, resulting in greater “substance abuse” 
(Bowie, Serper, Riggio, & Harvey, 2005). 
SUDs co-occurring with medical or mental illnesses may 
be related to acute or chronic pain and insomnia, resulting 
in misuse, “abuse” or harmful drug–drug interactions 
with prescription and non-prescription medications 
(Kuerbis et al., 2014). The effects of cognitive impairment 
(e.g., mild cognitive impairment, dementia) on substance 
use and vice versa in people under 65 years of age have 
also been strongly related, particularly with cannabis 
(Lyketsos, Garrett, Liang, & Anthony, 1999). Furthermore, 
co-occurring psychiatric disorders in older adult cohorts 
have been strongly associated with certain SUDs (in 
particular, schizophrenia and tobacco use disorder). 
Yet there is limited research on SUDs in co-occurring older 
adult and psychiatric populations (Kuerbis  et  al., 2014). 
Most publicly funded substance treatment programs 
have focused on younger populations, with only 7% of 
admissions involving patients aged 50 and older (Substance 
Abuse and Mental Health Services Administration, 2000). 
Modifying the focus of treatment care primarily toward 
older populations will be critical to meeting the special 
needs of this subgroup of substance-using individuals. 
Addressing this co-occurrence is imperative given that, by 
2020, the 50 and older age groups will include all surviving 
baby boomer and post-baby boomer cohorts (those born 
between 1965 and 1970), which have high rates of illicit 
drug use (Substance Abuse and Mental Health Services 
Administration, 1996).
5.2 Clinical Aspects of Co-occurring 
Substance Use Disorders and Mental 
Illness in Older Adults
The current edition of the Diagnostic and Statistical Manual 
of Mental Disorders (DSM-5) defines “substance use 
disorder” as a psychiatric disorder (First, 2013). Notably, 
other psychiatric disorders often co-occur with SUDs, 
meaning older adults can experience SUDs in addition 
to other psychiatric disorders that might relate to mood, 
psychosis, anxiety or other SUDs. 
Since the 1990s, there has been evidence of increasing illicit 
substance use by older adults with comorbid psychiatric 
illnesses (Han  et  al., 2009; Patterson & Jeste, 1999; 
Simoni-Wastila & Yang, 2006). One study showed a 20% 
prevalence of SUDs in older adult psychiatric outpatients, 
mainly comprising alcohol, narcotics and benzodiazepines 
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Compared to other psychiatric disorders, bipolar disorder 
among older adults has the highest rate of comorbid 
alcohol use disorder, ranging from 13 to 25% (Dols et al., 
2014; Grey & Hall, 2016). Other common drugs misused 
among those with bipolar disorder include tobacco, 
benzodiazepines, cocaine, amphetamines, prescription 
opioids, illicit opioids and cannabis (Bhuvaneswaran, 
Hargrave, & Brown, 2017). Bipolar disorder and alcohol 
use disorder are highly co-occurring because of common 
risk factors that include greater impulsivity, fewer years 
of education, late age of diagnosis, greater depressive 
episodes and criminal behaviour (Aas et al., 2016). 
Treatment options for older adults with co-occurring 
bipolar disorder and SUDs are limited, but include various 
medications and behavioural therapies. For example:
• Sedative-hypnotic and benzodiazepine use 
can be treated with cholinesterase inhibitors, 
oxcarbazepine and phenobarbital. Although these 
treatment options have yet to be tested, they 
are promising given the efficacy for mood and 
improved cognitive function within this population 
(Lehmann & Forester, 2017). 
• Cocaine use disorder among older adults with 
bipolar disorder has been treated with citicoline, 
lamotrigine and quetiapine. However, treatment 
efficacy varies and has been shown to diminish 
over time (Brown et al., 2015). 
• Opioid use disorder among patients with bipolar 
disorder has been treated with office-supervised 
opioid treatment and methadone maintenance 
treatment (Lehmann & Forester, 2017). 
• Valproate maintenance has been used in patients 
with bipolar disorder and alcohol dependence. 
However, as this was investigated in a study with 
a mean age of 37.5, the suitability of valproate 
maintenance for older adults is not known 
(Salloum et al., 2005).
Researchers have also shown that detrimental long-
term effects of substance use on brain structure and 
function might manifest more strongly in older patients 
with schizophrenia compared to younger groups (Allen, 
Goldstein, & Weiner, 2001). Consequently, it has been 
suggested that premature mortality among patients with 
schizophrenia is highly associated with the secondary 
effects of drugs such as tobacco and cannabis, specifically 
the increased risk of cardiovascular disease and lung 
cancer (Olfson, Gerhard, Huang, Crystal, & Stroup, 
2015). Addressing this comorbidity is therefore important 
given that SUDs among those with schizophrenia are 
associated with worsened negative symptoms, cognitive 
deficits and the interference of functional recovery (Volkow, 
2009). Increasing healthcare costs each year among other 
psychosis disorders, such as bipolar disorder, also highlight 
the importance of addressing this comorbidity. 
5.2.2 Bipolar Disorder
There are few studies focusing exclusively on SUDs in 
aging patients with bipolar disorder (type I or II). However, 
the high prevalence of SUDs in those with bipolar disorder 
(9  to 29%) has attracted attention (Sajatovic, Blow, & 
Ignacio, 2006). The major concerns raised with co-occurring 
SUDs in older adults with bipolar disorder relate to the 
negative medical and functional consequences of excessive 
substance use, which can lead to a more severe course 
of illness (Lagerberg  et  al., 2010). Importantly, patients 
are more vulnerable to both physical and medication side 
effects due to age-related changes in pharmacokinetics, 
polypharmacy and multiple medical comorbidities (Lala & 
Sajatovic, 2012). Relative to patients with bipolar disorder 
alone, comorbid patients are also found to have increased 
rates of hospitalizations, suicides, mood instability, medication 
non-adherence, and greater manic and depressive episodes 
(Strakowski, DelBello, Fleck, & Arndt, 2000). End-stage 
complications of alcohol dependence and toxicity/overdose 
from opioids and stimulants have also been suggested to 
shorten lifespans by 10 to 12 years (Hjorthoj et al., 2015). 
5.2.3 Depression
Heavy drinking is strongly associated with mood disorders 
such as anxiety and depression among adults aged 65 and 
older (Kirchner et al., 2007; Loscalzo, Sterling, Weinstein, 
& Salzman, 2017). Alcohol also appears to be related to 
an increased risk of falls and medical morbidity in older 
patients, and is an independent predictor of suicide risk 
among this population (Dombrowski, Norrell, & Holroyd, 
2016; Waern, 2003). 
A longitudinal epidemiologic survey by the National Institute 
on Alcohol Abuse and Alcoholism found a four-fold increase 
of major depressive episodes among those with a history of 
alcohol dependence (Hasin & Grant, 2002). Another study 
found that older adults who reported depressive symptoms 
were at higher risk of problematic alcohol use, particularly 
at the younger end of the older adult age spectrum 
(Rodriguez, Schonfeld, King-Kallimanis, & Gum, 2010). 
Dombrowski and colleagues (2016) recently conducted a 
retrospective study collecting data over a 10-year period 
from 1,788 elderly psychiatric patients. Of those patients, 
11.7% had an SUD, with alcohol use disorder the most 
common (73.3%) and major depression the most frequent 
comorbid diagnosis (26.1%). However, one study found 
that depressed older adults had a lower prevalence of 
alcohol use disorder (Merrick  et  al., 2008). These mixed 
findings warrant the need for further research in comorbid 
SUDs and psychiatric disorders among older populations.
5.2.4 Anxiety Disorders
Anxiety disorders have been found to co-occur with SUDs 
among the older adult population. For example, nearly 
30% of adults aged 50 years and older with anxiety had a 
cannabis use disorder within the past year (Choi, DiNitto, & 
Marti, 2016). In addition, the National Comorbidity Survey 
found that older adults with an alcohol use disorder were 
two to three times more likely to also have an anxiety 
disorder than those without a comorbid alcohol use 
disorder (Kessler et al., 1997). 
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Some studies have also investigated the extent to which 
alcohol use influences the risk for developing Alzheimer’s 
disease. While it might be plausible based on biological 
evidence, epidemiologic evidence does not support this 
relationship (Tyas, 2001). Additional research in this area 
is needed.
5.2.7 Multiple SUDs
The prevalence of having multiple SUDs is high among 
older adults, with comorbid tobacco and alcohol SUDs 
being the most common (Moore et al., 2009). In one study 
of older adults with SUDs, 4% had multiple SUDs, less than 
the 32% seen in the 18–64 age group (Chaput, Beaulieu, 
Paradis, & Labonte, 2011). Another study found that more 
than 60% of individuals who previously used cannabis and 
80% of those who used cannabis in the past year also had 
SUDs other than cannabis (Choi et al., 2016). Among the 
older population, cannabis use often precedes the use of 
other illicit drugs (Fergusson, Boden, & Horwood, 2006) 
and dependence occurs much faster in individuals who 
use cannabis than those who use alcohol or tobacco 
(Lopez-Quintero et al., 2011). Interestingly, older individuals 
are more likely to seek treatment if they have comorbid 
SUDs of cannabis and other drugs or tobacco use disorder 
(Choi et al., 2016). 
There is a risk of biological changes when using multiple drugs, 
which can increase the sedative effects of drugs such as 
benzodiazepines or opiates (Kuerbis et al., 2014). However, 
older adults might not be aware of such harmful drug–drug 
interactions, resulting in greater health repercussions. Little 
is known about the simultaneous use patterns of multiple 
substances in the older adult population. Given that older 
adults have high rates of psychiatric comorbidities with 
multiple drug–alcohol dependencies, developing treatments 
targeting this co-occurrence is important. 
Alcohol use disorders have consistently been shown to co-
occur with certain mood and anxiety disorders (National 
Institute on Alcohol Abuse and Alcoholism, 2016), with a 
study by Chou and colleagues (2011) finding that, over a 
three-year span, 2% of adults aged 60 years and older with 
alcohol use disorders had developed a new generalized 
anxiety disorder. Older age has also been implicated in 
the onset of alcohol dependence due to the social and 
medical complications that occur as people grow older 
(Brady & Sinha, 2005; Hurt, Finlayson, Morse, & Davis, 
1988). Interestingly, co-occurring anxiety and alcohol use 
disorders are seen in both older males and females (Byers, 
Yaffe, Covinsky, Friedman, & Bruce, 2010). 
The significant impacts of co-occurring SUDs and anxiety 
disorders on health outcomes warrant further research and 
treatment options for this population. 
5.2.5 Post-Traumatic Stress Disorder
Psychiatric disorders such as post-traumatic stress disorder 
(PTSD) are commonly treated with psychotropic drugs 
(predominantly benzodiazepines and antidepressants) to 
help with sleep abnormalities. With this treatment, there is 
an increased risk of developing an SUD given that older 
individuals might “abuse” prescribed or non-prescribed 
drugs (e.g., cannabis) to relieve the symptoms of PTSD 
(Brady & Sinha, 2005). Many veterans are found to have 
co-occurring PTSD and SUD, with 64 to 84% of those with 
PTSD meeting the criteria for lifetime alcohol use disorder 
and 40 to 44% meeting the criteria for nicotine dependence 
(Vorspan, Mehtelli, Dupuy, Bloch, & Lepine, 2015).
5.2.6 Alzheimer’s/Parkinson’s Disease
It is often reported that healthcare professionals 
underdiagnose, misdiagnose or undertreat older patients 
with symptoms related to SUDs by attributing them to 
Alzheimer’s or Parkinson’s disease. Although there is no 
literature investigating the prevalence of SUDs co-occurring 
with either disease, it is important to recognize the possibility 
of this comorbidity given the severe drop in blood pressure 
associated with the combination of alcohol and drugs 
prescribed for Parkinson’s disease (Lieber, 1991). Because 
of the sedative effects of substances such as alcohol 
(Hendler, Ramchandani, Gilman, & Hommer, 2013), those 
with cognitive impairment should not drink alcohol (Ridley, 
Draper, & Withall, 2013), despite evidence suggesting that 
light to moderate drinking prevents pre-existing cognitive 
impairment (Moore, Whiteman, & Ward, 2007). 
attributable risk of CHD due to tobacco smoking most 
prevalent among older women, as well as those with a 
history of myocardial infarction or diabetes (Steptoe, Kerry, 
Rink, & Hilton, 2001; Willett et al., 1987). 
Evidence also suggests that by quitting alcohol, older 
adults with CHD can reduce the risks of negative health 
outcomes, including death (LaCroix et al., 1991). Therefore, 
addressing the detrimental effects of co-occurring SUDs 
and CHD are critical to increasing awareness of these 
otherwise preventable conditions.
5.3.2 Cerebrovascular Disease
SUDs among older adults have commonly been found to 
predate ischemic stroke (Williams, Ghose, & Swindle, 2004). 
For instance, heavy alcohol consumption can increase risk 
or exacerbate hemorrhagic stroke and atherosclerotic 
cardiovascular disease in older adults (Kalla & Figueredo, 
2017; Reynolds et al., 2003). The risk of all forms of stroke 
is also increased with tobacco smoking and decreased 
with quitting smoking (Shah & Cole, 2010). Although 
smoking rates are generally lower among adults aged 
65 years and older (Shah & Cole, 2010), many biological 
and psychosocial mechanisms increase the mortality risk 
for smoking co-occurring with stroke. These mechanisms 
include impairments in immune functioning, cognitive and 
functional disability, poor nutrition and unemployment 
(Williams et al., 2004). Post-stroke depression can further 
exacerbate problematic substance use and contribute to 
increased long-term mortality in older adults (Williams et al., 
2004). Ultimately, biological and psychosocial mechanisms 
that drive greater risk among older adults with co-occurring 
SUDs and stroke should be further explored.
5.3.3 Diabetes
There is a high prevalence of alcohol use disorders in older 
adulthood, resulting in deficiencies in essential vitamins 
(e.g., thiamine, folate), mental health problems (e.g., mood 
disorders, short-term memory loss) and fatty liver disease 
(Ferreira & Weems, 2008). Among individuals with diabetes, 
heavier drinking of alcohol is associated with diabetic 
retinopathy (Young, McCulloch, Prescott, & Clarke, 1984) 
and neuropathy (McCulloch, Campbell, Prescott, & Clarke, 
1980). Given that alcohol suppresses energy metabolism 
in the liver, individuals with diabetes who consume alcohol 
without eating are also at high risk of hypoglycemia (Turner, 
Jenkins, Kerr, Sherwin, & Cavan, 2001). 
5.2.8 Conclusions
A large portion of older patients with psychiatric disorders 
use illicit drugs or misuse prescription drugs (Woo & 
Chen, 2010). Co-occurring SUDs ultimately worsen the 
severity and prognosis of primary mental illnesses. The 
high prevalence of positive urine screens in psychiatric 
emergency services provides evidence for the importance 
of determining treatment options and disposition for older 
adults with co-occurring SUDs and mental illnesses. In 
addition, the economic burden on healthcare systems 
resulting from co-occurring mental health and SUDs in older 
patients (e.g., prolonged hospital stays, frequent visits) 
highlights the importance of more research in this area. 
Patients are living longer but enduring several disorders 
requiring greater care, making improved diagnostic criteria 
and better treatment options critical to addressing this 
global issue.
5.3 Clinical Aspects of Substance Use 
Disorders with Medical Comorbidities 
in Older Adults
Certain medical problems found in older adult populations 
can be worsened with problematic substance use. During 
aging, the body develops a lower tolerance for substances; 
as a result, older adults might experience the effects of 
substances more quickly and severely than when they were 
younger. Older adults are also less likely to seek treatment 
for their substance use problems, given that co-occurring 
medical conditions diminish their ability to perform the 
basic activities of daily life. This lack of treatment can 
then exacerbate health problems such as heart disease, 
hypertension, diabetes and memory problems.
5.3.1 Coronary Heart Disease
Co-occurring SUDs and cardiovascular medical conditions 
such as heart disease can have detrimental effects on the 
physical health of older adults. While it is commonly reported 
that light to moderate alcohol consumption reduces the 
risk of coronary heart disease (CHD) and deaths, heavy 
alcohol use can worsen cardiovascular disease as well as 
diabetic neuropathy and retinopathy (Moore et al., 2007). 
In addition, among methadone maintenance patients aged 
50 and older, approximately 18% have a heart condition 
(Rosen, Smith, & Reynolds, 2008). Tobacco smoking is 
also a determinant of CHD among older adults, with the 
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5.3.5 Insomnia
SUDs involving benzodiazepines have commonly been 
related to greater rates of insomnia and anxiety within 
the older adult population (Egan, Moride, Wolfson, & 
Monette, 2000). One study found that 42% of older adults 
with insomnia have been prescribed benzodiazepines 
in primary care (Simon & Ludman, 2006). Another study 
found that benzodiazepines have been prescribed to 
31.4% of individuals 65 to 80 years of age versus 14.7% 
of those between 18 and 35 years of age, with twice the 
prescription rate among older females than males (Olfson, 
King, & Schoenbaum, 2015). This is not surprising given 
that the prevalence of insomnia increases with age; 
however, clinical guidelines have recommended non-
pharmacological options for treating insomnia, including 
sleep hygiene, stimulus control and relaxation, with 
benzodiazepines prescribed on a short-term basis (National 
Institute for Health and Care Excellence, 2004). Yet reports 
show that 24.3% of Canadian adults aged 65 years and 
older are using long-acting benzodiazepines (Preville et al., 
2012), which is alarming given the risks associated 
with the age-related changes in pharmacokinetics and 
pharmacodynamics with extended periods of action 
(Madhusoodanan & Bogunovic, 2004).
Chronic insomnia is defined as two or more weeks of trouble 
falling asleep or waking too early (Ford & Kamerow, 1989). 
Among older adults, a common misperception among 
those who use alcohol is that it helps them fall asleep. While 
this is plausible for younger individuals, tolerance rapidly 
develops and can lead to sleep interference and trouble 
staying asleep, resulting in disrupted sleeping patterns 
and insomnia in older adults (Roehrs & Roth, 2001). 
Interestingly, one study found that insomnia might be a 
potential causal factor of late-life alcohol problems as well 
as relapse (Oslin & Liberto, 1995). Additional research is 
warranted to determine whether the use of alcohol further 
worsens insomnia among older adults.
In contrast, a lower incidence of non-insulin-dependent 
diabetes in older adults is related to light to moderate use of 
alcohol (Djousse, Biggs, Mukamal, & Siscovick, 2007). In fact, 
some studies have demonstrated overall beneficial effects of 
moderate alcohol consumption in decreasing risk of death 
due to CHD among individuals with older-onset diabetes 
(Valmadrid, Klein, Moss, Klein, & Cruickshanks, 1999). 
Nonetheless, the increased risk of alcohol exacerbating the 
side effects and interfering with the therapeutic effects of 
diabetes medications makes additional research important 
to clear these inconsistent findings. 
There is also a high prevalence of diabetes among older 
adults taking methadone for the treatment of an SUD, 
with Rosen and colleagues (2008) finding that 11.4% of 
methadone maintenance patients aged 50 years and older 
had diabetes. 
5.3.4 HIV/AIDS
Nearly 50% of persons with HIV/AIDS have reported 
current or past histories of SUDs (Bing et al., 2001), while 
slightly more than half of HIV-positive women (51%) have a 
history of SUDs (Morrison et al., 2002). Co-occurring SUDs 
and HIV in older adults consist frequently of cannabis use 
disorders, with 13% of HIV-positive older adults commonly 
using cannabis (in medical or recreational forms) to enhance 
appetite and relieve persistent neuropathic pain (Rabkin, 
McElhiney, & Ferrando, 2004). Studies have also shown 
that alcohol and cocaine are heavily used by older adults 
with HIV/AIDS (Durvasula & Miller, 2014; Tobias, Lippmann, 
Pary, Oropilla, & Embry, 1989). 
In general, the co-occurrence of SUDs and HIV/AIDS results 
in immunosuppression (the reduction of the activation of 
the immune responses), increased risky sexual behaviour 
(e.g., not using condoms, having multiple sex partners) 
and high healthcare utilization (Chander, Himelhoch, & 
Moore, 2006). Older adults with HIV/AIDS and SUDs 
are also found to transmit the virus directly due to riskier 
sexual behaviours or the sharing of contaminated injection 
equipment (Klinkenberg & Sacks, 2004). Given that older 
adults with HIV/AIDS could have differential risks of SUDs, 
identifying this co-occurrence is important. 
Jane, a 67-year-old woman from Halifax, recently retired from the company where 
she worked for 37 years. Her husband passed away six months ago and her only 
daughter, Samantha, lives in Edmonton with her own two-year-old daughter. With 
Samantha having just gone through a messy divorce, Jane wanted to see both her 
daughter and granddaughter.
In the past, Jane had been treated by her family doctor for major depression, high 
blood pressure and type 2 diabetes. She recently developed anxiety and experienced 
panic attacks for the first time, likely brought on by having to take care of so many 
more commitments since her husband died. About four months ago, Jane’s family 
doctor gave her a monthly prescription for a benzodiazepine (lorazepam, 1 mg) to 
help with her sleep and anxiety problems. Even though Jane vowed to use the drugs 
only if she really needed them, she has taken this new medication virtually every day.
In her rush to make her flight to Edmonton, Jane forgot her medications. Because  
she and her husband were frequent business travellers, she was able to get an 
upgrade to business class. It was a turbulent flight and she admits to having “a few 
too many free drinks” to calm her nerves. Two days after arriving in Edmonton, Jane 
told Samantha she wasn’t “feeling right.” Within a few hours, she had a seizure and 
was rushed to a local emergency department. The attending doctor concluded that 
Jane had a sedative-hypnotic withdrawal-related seizure and admitted her to hospital 
for further observation.
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5.4 Evidence-based Treatment  
of Comorbidities in Older Adults
It is estimated that the percentage of the population aged 
50 years and older requiring substance use treatment will 
increase from 4% in 1995 to as high as 34% by 2020 (Wu & 
Blazer, 2011). In addition to the common underdiagnosis of 
SUD comorbidities in older populations, adults over the age 
of 60 are often excluded from clinical trials examining the 
safety and efficacy of existing or new treatments for SUDs. 
That said, the existing models of SUD treatment — including 
direct observation and methadone maintenance (in specific 
subgroups of individuals who use substances), motivational 
interviewing and cognitive behavioural therapy — have been 
shown to enhance adherence and reduce substance use in 
older outpatients (Durvasula & Miller, 2014). 
The effects of aging on the reward system and the 
psychological changes that occur with advancing age (e.g., 
greater wisdom, less risk taking) might have an influence on 
the types and patterns of SUDs experienced by older adults, 
as well as the effectiveness of behaviour change (Lim & Yu, 
2015). Existing comorbid medical and psychiatric disorders 
could also influence treatment choices and options. The 
distinctive biological and psychosocial characteristics of 
older adults that predispose them to addiction, along with 
other risk factors such as polypharmacy, must therefore be 
considered when using various treatment options. 
Treatment programs specific to older adults have been 
shown to have better retention rates in experimental 
groups compared to control groups (Kofoed, Tolson, 
Atkinson, Toth, & Turner, 1987). These programs include 
pharmacological options, psychosocial interventions and 
integrated approaches.
5.4.1 Pharmacological Options
Depending on the SUD, there are several pharmacological 
treatments available for older adults. Given the age-related 
pharmacokinetic and pharmacodynamic changes, the 
level of dosing required for older populations is generally 
lower than that of younger age groups. To date, most of 
the research in this area has focused on medications for 
treating tobacco smoking and alcohol use in older adults. 
Pharmacological treatments for tobacco use include 
5.3.6 Chronic Pain
Over the past decade, many older adults have reported 
the non-medical use of prescription drugs for chronic pain. 
The non-medical use of prescription drugs has become 
part of an invisible epidemic of polypharmacy in older 
adults (Kalapatapu & Sullivan, 2010). The drug used most 
often by baby boomers to relieve the symptoms of chronic 
pain and physical health conditions is cannabis (Lau et al., 
2015a). It is a common misperception that there is minimal 
risk in using cannabis, especially when compared to other 
illicit drugs or alcohol. Many older adults view cannabis as 
a safer alternative, with a low risk of addiction and less-
adverse side effects (Lau et al., 2015b). Yet trauma patients 
aged 50 years and older who test positive for cannabis 
have higher odds of hospital admissions, operations and 
stays than those who test negative. 
Most adults who smoke cannabis in later life have been doing 
so since their teens; this long-term use could be associated 
with the exacerbation of existing physical and mental 
health problems (Choi et al., 2016). A higher prevalence of 
older adults using cannabis today compared to previous 
generations could have implications for the healthcare 
system, such as increased healthcare costs resulting from 
longer hospital stays caused by cannabis-related adverse 
events (Pacula, Ringel, Dobkin, & Truong, 2008).
5.3.7 Conclusions
Medical conditions co-occurring with SUDs in older adults 
are highly prevalent. While healthcare providers can easily 
rule out serious physical problems such as heart conditions, 
diabetes, HIV/AIDS or chronic pain in younger patients, it 
is not as clear and straightforward in older patients. Given 
that common medical disorders can influence SUDs in the 
older adult population, better diagnostic and treatment 
options are needed. 
In individuals with SUDs and HIV/AIDS, gay-specific CBT 
and social support therapy (which contextualize treatment 
to the societal and interpersonal experiences of gay men) 
have resulted in two-fold decreases in substance use 
(Durvasula & Miller, 2014). Educational groups, which use 
similar concepts and processes as those found in CBT, 
have also been found effective in older adults with SUDs 
(Kuerbis et al., 2014). 
5.4.3 Integrated Care Approaches
In general, compared to younger adults, older patients have 
been found to engage well and over a longer duration of time 
in integrated treatment programs that include combinations 
of psychosocial and pharmacotherapy (Lemke & Moos, 
2003). For example, motivational interviewing has often 
been integrated into methadone maintenance programs, 
resulting in less risky sexual activity among individuals 
with HIV/AIDS and co-occurring SUDs (Durvasula & Miller, 
2014). However, the specific study demonstrating this 
result involved middle-aged individuals, signalling the need 
for additional research among older adults. 
Integrating screening and brief interventions for comorbid 
SUDs and physical or mental health disorders into mainstream 
primary care could result in decreases in healthcare costs 
in older populations. Currently, the availability of such 
approaches is limited in the older adult population, which 
highlights the importance of appropriately involving older 
adults in existing integrated approaches. 
In addition, given the age-related pharmacokinetic and 
pharmacodynamic changes, older adults might require 
lower drug doses compared to the general population. 
Future studies should therefore seek to include older adults 
for treatment trials.
smoking cessation aids such as varenicline, bupropion and 
nicotine replacement therapies, such as nicotine patches 
(Tait et al., 2007). For alcohol use disorder, naltrexone and 
disulfiram have commonly been used and are effective 
at both reducing drinking and preventing relapse (Oslin, 
Liberto, O’Brien, Krois, & Norbeck, 1997). Treatment of 
opioid use disorder has commonly included methadone 
and buprenorphine/naloxone (Gossop & Moos, 2008). 
Pharmacotherapies are less commonly used for SUDs co-
occurring with physical and psychiatric conditions in older 
adults due to the numerous potential interactions of these 
medications with the drugs already being taken to treat 
the comorbid conditions. Nonetheless, some studies have 
been conducted in comorbid populations, such as one 
looking at the use of lamotrigine in adults with HIV using 
crack cocaine (Margolin, Avants, DePhilippis, & Kosten, 
1998). Varenicline has also been shown to be effective 
in smoking cessation outcomes among patients with 
schizophrenia (Pachas et al., 2012; Williams et al., 2012) 
and bipolar disorder (Chengappa et  al., 2014). However, 
these studies were completed in populations with mean 
ages of approximately 46 years.
5.4.2 Psychosocial Interventions
Several psychosocial interventions have been proven to 
be effective in older adults with SUDs, with some of the 
less-intensive options including brief interventions (such 
as relatively unstructured counselling) aimed at reducing 
substance use (Fleming, Barry, Manwell, Johnson, & 
London, 1997). For instance, 10 to 30% of individuals who 
engage in problematic drinking have been found to reduce 
their drinking after just one to three brief intervention sessions 
(Fleming, Manwell, Barry, Adams, & Stauffacher, 1999). 
If brief interventions are not effective in older adults, 
motivational interventions should be considered. Such 
techniques evaluate an individual’s willingness to change 
their substance use (Purath, Keck, & Fitzgerald, 2014). 
Cognitive behavioural therapy (CBT) has also led to 
reductions in alcohol use in older adults with SUDs by 
helping them set goals and identify strategies for change 
(Morin et al., 2004). CBT has shown promise among older 
adults with co-occurring physical and psychiatric disorders 
(Edinger, Wohlgemuth, Radtke, Marsh, & Quillian, 2001). 
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and suicide. Also concerning is the prevalence of SUDs 
being under-reported due to stigma or underdiagnosis by 
healthcare professionals (DeMers, Dinsio, & Carlson, 2014; 
McGinty, Goldman, Pescosolido, & Barry, 2015). Clinicians 
treating older adults often overlook SUD diagnoses, 
resulting in a lower index of suspicion for comorbidities 
that might otherwise present covertly as falls or cognitive 
impairment. However, surveillance data indicate that 
one in 10 admissions among the older adult psychiatric 
population are associated with an SUD, underscoring the 
importance of better treatment programs and recognition 
of co-occurring diagnoses. 
Raising awareness of SUDs among older adults and their 
healthcare providers could help clinicians’ efforts to identify 
and treat these conditions. Knowing which mental health 
diagnoses are co-occurring with SUDs among older adults 
might also provide better risk prediction and decreased 
healthcare costs. The following chapter provides an in-
depth examination into the screening and assessment of 
problematic substance use among older adults. 
5.5 Conclusion
There is a clear need for specific programs that support 
older adults with SUDs. While alcohol is the primary 
problematic substance later in life, the increasing non-
medical use of prescription drugs (such as opioids and 
benzodiazepines) and the increasing use of illicit drugs are 
emerging issues that need to be addressed. 
By 2020, an estimated 56% of adults aged 50 years and 
older will have used drugs at some point during their 
lifetime — nearly double the rate (26%) reported in 2001 
(Gfroerer et al., 2003). Even more alarming, the number of 
older adults who will require treatment for illicit drug use is 
projected to increase by 500% between 1995 and 2020 
(Gfroerer & Epstein, 1999). With the world’s population of 
older adults expected to grow dramatically in the decades 
to come, the need for effective treatments and healthcare 
services targeting older adults with SUDs will likewise 
continue to grow. Furthermore, these numbers highlight 
the need to continue targeting younger populations, as 
doing so could help reduce the number of older adults with 
SUDs in the future. 
The high prevalence of SUDs in older populations raises 
concerns, especially considering the potential impact 
of comorbid diagnoses such as psychiatric illnesses, 
hypertension, anemia, dementia, diabetes, delirium 
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Detection, Screening 
and Assessment
06
CHAPTER AT A GLANCE
• While physicians and caregivers often overlook the possibility of problematic alcohol and 
substance use among older adult patients, there are also many barriers to detecting such 
use in this population. 
• Screening tools and processes should be tailored specifically to older adults and take into 
account their sensitivities, including concerns about stigma. 
• There is no consensus on the most appropriate and useful screening tools for older adults. 
• Screening for substance use should be carried out for all older adults during routine health 
examinations and hospitalizations, when certain physical or mental health problems arise, 
or if the person is experiencing a major stressful life event.
• Standard diagnostic criteria might have limited applicability for older adults.
• A comprehensive assessment of older adults is essential, including a full history of 
substance and medication use, comorbid medical and psychiatric illnesses, social and 
family history, and functional assessment and cognitive screening. 
• There is an urgent need for better training of healthcare professionals and students on the 
prevention, detection and care of older adults with substance use disorders.
CHAPTER
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With the number of older adults expected to rise rapidly 
over the coming decades, the prevalence of all disorders 
affecting older adults will also rise at a significant rate. The 
imminent legalization of non-medical cannabis, the rapid 
growth in the use of medical cannabis and the ongoing 
opioid crisis will also present significant challenges for 
Canadians of all ages.
Despite the evidence of harm related to the use of alcohol 
and other substances, there has been a lack of research and 
interventions aimed specifically at older adults (O’Connell, 
Chin, Cunningham, & Lawlor, 2003). Most individuals who 
misuse substances never receive appropriate treatment 
due to a number of barriers, with one of the most notable 
being a lack of detection. In fact, approximately two-thirds 
of all cases of problematic alcohol use in older adults remain 
undetected by physicians (Beullens & Aertgeerts, 2004).
6.2 Barriers to Identifying Substance 
Use in Older Adults
Researchers have noted numerous barriers to the detection 
of substance use disorders in older adults, with Koh 
and colleagues (2016) compiling a comprehensive list of 
potential barriers faced by both clinicians and older adults. 
Their findings are summarized in Table 1. 
6.1 Introduction
There is a common belief that problematic substance use 
is an issue that affects only young people. However, there 
is increasing evidence to suggest a growing number of 
older adults in many countries are experiencing substance-
related problems (Substance Abuse and Mental Health 
Services Administration, 2013; Office for National Statistics, 
2013; Hallgren, Hogberg, & Andreasson, 2010; Searby, 
Maude, & McGrath, 2015). 
Consider the “baby boomers,” who grew up in a time 
of greater acceptance of substance use. As they have 
aged, they have continued to use illicit drugs (especially 
cannabis), often combined with alcohol. As a result, it is 
projected that the number of older adults in the United 
States who misuse substances will grow from 2.5 million 
in 1999 to 5 million in 2020 (Gfroerer, Penne, Pemberton, 
& Folsom, 2003). In Canada, 72.1% of adults aged 65 and 
older drink alcohol, with 8.4% exceeding the limits set out 
in Canada’s Low-Risk Alcohol Drinking Guidelines (Health 
Canada, 2013). More specifically, 11% of Canadians aged 
65–74 are exceeding the recommended limits, along with 
3.7% of those 75 and older. 
Table 1: Clinician and older adult barriers to identifying substance abuse
Clinician’s barriers
• Age-related assumptions (e.g., belief that 
substance use is less prevalent in older age)
• Failure to recognize or attribute symptoms to 
substance abuse, which can be masked by other 
physical ailments
• Problems in effectively screening for substance 
abuse in older adults
• Discomfort with addressing substance abuse  
with older adult patients
• Absence of collateral information from family 
members and caretakers
Older adults’ barriers
• Symptoms are attributed to getting older  
or another illness
• Lack of insight into their substance use  
and failure to voluntarily seek help
• Stigma of seeking help and of the terms 
“addiction” and “substance abuse”
• Knowledge gap about how psychiatrists  
can help with substance abuse 
• Reluctance to report due to shame, denial, desire 
to continue using or pessimism about treatment 
and recovery
• Cognitive problems, including substance-induced 
amnesia or underlying dementia
• Family members and caretakers might not 
adequately report concerns about substance abuse
Source: Koh, Gorney, Badre, & Jeste (2016), adapted from Royal College of Psychiatrists (2011).
patients receive, causing such problems to be misdiagnosed 
or undetected. In comparison, a study looking at nursing 
students’ experiences following training on the use of a 
screening, intervention and referral tool noted that the 
students said the training had a positive impact on their 
attitudes and feelings of self-efficacy (Braxter et al., 2014).
6.3 Screening
The utility of screening programs is the subject of much 
debate. Any recommendations for screening must weigh the 
potential benefits of identifying a disorder and the treatability 
of a particular disorder versus any potential adverse effects 
from the screening process as well as cost considerations. 
One argument in favour of screening is that once a disorder 
is identified, there is evidence older adults can benefit from 
a variety of intervention programs. For example, a study by 
Fleming and colleagues (1999) found two brief counselling 
sessions that incorporated advice, education and a 
contract led to a 34% reduction in weekly alcohol use, a 
47% reduction in binge drinking episodes over a 12-month 
period and a 62% reduction in excessive drinking. 
In contrast, there is limited evidence on the harms of 
screening and subsequent behavioural counselling for 
substance use. Possible harms could include anxiety, 
labelling and discrimination, or interference with the doctor-
patient relationship. The United States Preventive Service 
Task Force concluded that the benefits of screening and 
brief counselling for alcohol misuse outweigh any risks 
among adults aged 18 or older in primary care settings 
(Moyer, 2013).
Some organizations recommend screening all older 
adults for substance use as part of a routine health check 
(Royal College of Psychiatrists, 2011). For example, 
the U.S. Substance Abuse and Mental Health Services 
Administration recommends that every person over the 
age of 60 be screened for problematic use of alcohol and 
psychoactive prescription drug use during their regular 
physical examination. Screening should also be done when 
certain physical symptoms are present, or if the older adult 
is undergoing major life changes or transitions. There are 
a number of physical symptoms that can be used as cues 
to conduct screening on older adults. These symptoms 
include sleep difficulties, cognitive impairment, seizures, 
malnutrition, muscle wasting, irritability, unexplained chronic 
pain, incontinence or other urinary problems, poor hygiene 
In their overview of detection of alcohol-related problems 
among older adults, Taylor and colleagues (2014) added 
societal factors to their list of barriers: societal attitudes 
and assumptions, ageism, stigma, governmental policies 
that focus only on younger people and a lack of research 
involving older adults. They also include organizational 
factors such as the lack of suitable detection tools, clinical 
guidelines and training opportunities for professionals 
related to the care of older adults. Another challenge 
to identifying substance use in older adults is that there 
is still significant debate about how to define “risky” and 
“problematic” use of certain substances such as cannabis 
(Casajuana et al., 2016).
6.2.1 Training and Education of Healthcare 
Practitioners
There is evidence of an overall lack of awareness and 
knowledge about alcohol and other substance use 
disorders among healthcare practitioners. In a literature 
review, Ram and Chisholm (2016) described the urgent 
need for improving substance use and addiction training, 
noting insufficient exposure to these topics in medical 
schools. Current training focuses mainly on transmitting 
knowledge with relatively little emphasis on the attitudes 
and skills that are vital to effective prevention and treatment. 
Given the gap between clinical need and physician 
education, increased training in medical schools will 
ultimately enhance the practice of evidence-informed care.
A study from Australia focused on the role of general 
practitioners, who are in a unique position to detect 
and manage patients with comorbid mental health and 
substance use disorders (Marshall & Deane, 2004). The 
study found that more than 30% of patients presenting 
to general practice have a diagnosable mental health 
disorder, with 12% having co-occurring mental health and 
substance use disorders. However, it is suggested that 
30–50% of these disorders go undetected in the general 
practice setting, likely due to limited education and training. 
The study’s authors also found significant deficiencies in 
the use of screening tools, provision of counselling and 
referral to specialist services, further emphasizing the need 
for additional training. 
Similarly, an Irish study of healthcare professionals working 
in emergency departments found low rates of detection of 
problematic substance use (Kelleher, 2007). Deficiencies in 
healthcare professionals’ knowledge and attitudes about 
substance use could have a negative influence on the care 
Substance Use In Canada—Improving Quality of Life: Substance Use and Aging Substance Use In Canada—Improving Quality of Life: Substance Use and Aging 
100 Canadian Centre on Substance Use and Addiction Canadian Centre on Substance Use and Addiction 101
Spotlight: Low-risk drinking guidelines 
for older adults
On behalf of the National Alcohol Strategy Advisory 
Committee, a group of independent experts from 
Canada and around the world developed Canada’s 
Low-Risk Alcohol Drinking Guidelines (LRDGs). The 
LRDGs are a key component of the National Alcohol 
Strategy and were informed by the technical report, 
Alcohol and Health in Canada: A Summary of Evidence 
and Guidelines for Low-Risk Drinking (Butt, Beirness, 
Gliksman, Paradis, & Stockwell, 2011). 
To reduce the long-term health risks of alcohol use, 
the LRDGs recommend no more than two drinks a 
day or 10 drinks a week for women, and no more 
than three drinks a day or 15 drinks a week for men, 
balanced with non-drinking days. As the LRDGs were 
designed for adults 25 to 65 years old, they do not 
recommend a specific lower level of drinking for older 
adults. However, CCSA (2017) recommends that 
older adults never exceed the limits prescribed in the 
LRDGs, noting that older adults might process alcohol 
more slowly, resulting in increased sensitivity to its 
effects and associated risks. 
In the United States, the National Institute on Alcohol 
Abuse and Alcoholism recommends a lower level of 
consumption for older adults: a maximum of seven 
drinks per week or three drinks in a single day. 
The Canadian Coalition for Seniors’ Mental Health has 
recently received funding to create guidelines for older 
adults related to four substances (alcohol, benzo-
diazepines, cannabis and opioids). These guidelines 
will be released in 2018 and may include specific 
recommendations for low-risk drinking. 
and self-neglect, unusual restlessness and agitation, blurred 
vision, dry mouth, unexplained nausea or gastrointestinal 
symptoms, tremor, motor incoordination, slurred speech, 
frequent falls and unexplained bruising (Substance Abuse 
and Mental Health Services Administration, 2012).
6.3.1 Screening Tools and Approaches 
With older adults, the screening process should be tailored 
to reflect the specific sensitivities of this population, including 
concerns about stigma. It should also take into account 
sensory, cognitive, cultural and environmental issues.
Screening for Alcohol
Taylor and colleagues (2014) provided an in-depth analysis 
of the various screening tools available for problematic 
alcohol use in older adults. One approach described was 
to ask about a patient’s alcohol history as a basic form of 
screening. Specifically, this involves asking patients if they 
have consumed alcohol within the past three months; if 
the answer is “yes,” the next step is to take their full 
alcohol history. This type of screening is easy to do as part 
of a clinical assessment and may be more sensitive than 
other screening methods, such as the CAGE questionnaire 
(see following page). 
Some primary healthcare professionals prefer to use one or 
two simple screening questions as a useful starting point. 
Recognizing the important role screening plays in primary 
care, in 2012 the Canadian Centre on Substance Use and 
Addiction (CCSA) and the College of Family Physicians of 
Canada produced Alcohol Screening, Brief Intervention 
and Referral: A Clinical Guide. Focused on alcohol use, 
this toolkit incorporates the recommendations set out in 
CCSA’s Canada’s Low-Risk Alcohol Drinking Guidelines.
focuses on dependence and not harmful use, and it looks 
at lifetime use and not current habits. In addition, fewer 
than half of those who screen positive on either the CAGE 
questionnaire or the Short Michigan Alcohol Screening 
Test — Geriatric (SMAST-G; see Table 2) screen positive 
on both measures, suggesting the two tests might be 
capturing different aspects of problematic alcohol use 
(Moore, Seeman, Morgenstern, Beck, & Reuben, 2002). 
As the full version of the SMAST can take about 10 minutes 
to administer, its usefulness in clinical practice is limited. 
The shorter version of the test, the SMAST-G, is preferred. 
Blow and colleagues (1998) found that the SMAST-G had 
a sensitivity of 85% and specificity of 97% compared with 
a Diagnostic and Statistical Manual of Mental Disorders 
diagnosis of alcohol abuse or dependence. 
A group supported by the World Health Organization 
developed the Alcohol Use Disorders Identification Test 
(AUDIT). In addition to being widely tested in multiple 
countries, this screening tool has been validated cross-
culturally, including in older adults. A 10-question tool that 
takes only a few minutes to complete, the AUDIT provides 
information on current quantity and frequency of drinking. Its 
strength lies in its ability to identify those who have problems 
with alcohol but might not yet be dependent (Berks & 
McCormick, 2008). However, the AUDIT was not developed 
specifically for older adults and has been found to perform 
poorly in older adults in some studies (Culberson, 2006). 
The widely used CAGE questionnaire is an acronym for 
the four questions it asks about cutting down on drinking, 
being annoyed by criticism about one’s drinking, having 
guilty feelings about drinking and starting the day with 
a drink (an eye opener) — making it easy to remember 
and administer (Ewing, 1984). Buchsbaum and colleagues 
(1992) found that one or more “yes” responses on the 
CAGE questionnaire had a sensitivity of 86% and specificity 
of 78% in medical outpatients over the age of 60. 
What are sensitivity and specificity?
The sensitivity of the CAGE questionnaire refers to 
the probability that the screening test will be positive 
among those who have problematic drinking.
In contrast, specificity reflects the probability that the 
screening test will be negative among those who do 
not have problematic drinking.
One study comparing the CAGE questionnaire with the 
Michigan Alcohol Screening Test (MAST) concluded 
that while both have low sensitivities in older adults, the 
CAGE questionnaire is more effective overall (Jones, 
Lindsey, Yount, Soltys, & Farani-Enayat, 1993). Some 
disadvantages of the CAGE questionnaire include the fact 
that it was not specifically developed for older adults, it 
Table 2. Short Michigan Alcoholism Screening Test — Geriatric
Scoring: Two or more “yes” responses indicates an alcohol problem
1. When talking with others, do you ever underestimate how much you drink? 
2. After a few drinks, have you sometimes not eaten or been able to skip a meal because you didn’t feel hungry?
3. Does having a few drinks help decrease your shakiness or tremors?
4. Does alcohol sometimes make it hard for you to remember parts of the day or night?
5. Do you usually take a drink to relax or calm your nerves?
6. Do you drink to take your mind off your problems?
7. Have you ever increased your drinking after experiencing a loss in your life?
8. Has a doctor or nurse ever said they were worried or concerned about your drinking?
9. Have you ever made rules to manage your drinking?
10. When you feel lonely, does having a drink help?
Source: University of Michigan Alcohol Research Center (1991).
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problematic or risky substance use through eight questions 
covering tobacco, alcohol, cannabis, cocaine, amphetamine-
type stimulants, inhalants, sedatives, hallucinogens, opiates 
and other drug use (Humeniuk  et  al., 2008). This tool is 
user-friendly and quick to administer, with the advantage 
of screening for multiple substances at the same time. 
Significant correlations with other measures of alcohol use 
disorders were found using the ASSIST in French geriatric 
outpatients (Khan et al., 2012).
The PDUQp was recently tested in patients aged 50 or older 
who went to an emergency department due to prescription 
opioid misuse and opioid use disorder (Beaudoin, Merchant, 
& Clark, 2016). The study’s authors concluded that it could 
be a viable instrument, but likely requires some modifications 
to increase its predictive value in the older adult population. 
The PDUQp also takes about 20 minutes to complete, which 
might limit its use in many clinical settings. 
The DAST-10 is a brief general screening tool for “drug 
abuse,” excluding alcohol and tobacco, and can be 
completed in under eight minutes (Skinner, 1982).
A recent Australian study used both the AUDIT-C and the 
ASSIST to screen for alcohol and substance use among 
older adults in both a geriatric hospital and community 
health setting (Draper  et  al., 2015). The results showed 
that 19.5% of participants screened positively for alcohol 
and substance use, with 17.1% positive for alcohol use, 
3.3% for non-medical benzodiazepine use and 1% for 
non-medical opioid use. Using the ASSIST, 12.4% were 
rated as medium-high risk. A score of five or higher on 
the AUDIT-C was used to determine risky alcohol use. 
The study’s authors concluded that, while many patients 
in geriatric health services have risky alcohol or substance 
use, there are few clinical features that distinguish them 
from other patients. As a result, they recommended routine 
screening of alcohol and substance use in these settings. 
Screening for inappropriate use of prescription drugs 
requires questions that focus on adherence, prescriptions 
from multiple physicians, where prescriptions are filled, and 
the use of over-the-counter and alternative medications. 
Simoni-Wastila and Yang (2006) listed a number of 
additional warning signs that could indicate inappropriate 
use of prescription drugs, including: 
• Excessive worry about whether psychoactive 
medications are working or about the supply  
and timing of medications;
The AUDIT-C is a shortened version of the AUDIT that uses 
only three questions: 
• How often did you have a drink containing alcohol 
in the past year?
• How many drinks did you have on a typical day 
when you were drinking this year?
• How often did you have six or more drinks on one 
occasion in the past year?
Each question is scored on a scale from 0 to 4, with a 
higher score assigned to heavier or more frequent alcohol 
use. For older adults, a total AUDIT-C score of 4 or higher 
(out of 12) could indicate problematic drinking (Aalto, Alho, 
Halme, & Seppa, 2011). The AUDIT-C has been shown to 
have nearly identical sensitivity as the full instrument in a 
general primary care population (Bradley et al., 2007).
Another tool, the Senior Alcohol Misuse Indicator (SAMI), 
is popular in some areas of Canada. The SAMI tool was 
designed to be sensitive to the feelings of older adults by 
asking questions in a nonjudgmental way, initially focusing 
on physical or emotional symptoms. It is also designed to 
provide for a collaborative discussion between clinician and 
patient with opportunities for education about the harmful 
effects of alcohol (Lum, 2005). 
In their overview of the available alcohol screening tools, 
Taylor and colleagues (2014) concluded there is a need for 
better detection tools for specific use in older adults. They 
suggest no one screening tool is adequate on its own and 
that no tool or questionnaire can be an adequate substitute 
for taking a full patient history of alcohol use. They also note 
the need for clinicians to consider the possibility of alcohol 
use disorders across a variety of different settings. For 
example, the Substance Abuse and Mental Health Services 
Administration (2012) recommends using the CAGE 
questionnaire and the MAST-G for screening for alcohol use 
among older adults, and the AUDIT for identifying alcohol 
problems among older adults in minority ethnic groups.
Screening for Other Substances
Screening tools for substances other than alcohol include 
the Alcohol, Smoking and Substance Involvement 
Screening Test (ASSIST), the Prescription Drug Use 
Questionnaire Patient Version (PDUQp) and the Drug 
Abuse Screening Test (DAST-10). 
The ASSIST, which was developed by the World Health 
Organization and validated in older adults, screens for 
• Where appropriate, a physical examination  
or blood and urine tests (or both); and
• Neuroimaging for individuals with recent  
head injuries or when there is evidence  
of cognitive impairment.
6.4.1 Diagnosing a Substance Use Disorder
A diagnosis of a substance use disorder can be made 
using the fifth edition of the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-5; American Psychiatric 
Association, 2013). However, unlike in DSM-IV, DSM-5 
does not separate the diagnoses of substance abuse and 
dependence. Instead, criteria are provided for substance 
use disorder accompanied by criteria for intoxication, 
withdrawal, substance/medication-induced disorder and 
unspecified substance-induced disorder. 
For the most part, the criteria for substance use disorder are 
identical to the combined DSM-IV diagnoses of substance 
abuse and dependence, but with two exceptions:
• First, the criterion of “legal problems” was  
deleted from DSM-5 and a new criterion of 
“craving or a strong desire or urge to use a 
substance” was added. 
• Second, the number of criteria required for a 
diagnosis of a substance use disorder is now  
set at two or more. The severity of the disorder  
is based on the number of criteria endorsed, with 
two or three criteria indicating a mild substance use 
disorder, four or five criteria indicating a moderate 
substance use disorder, and six or more criteria 
indicating a severe substance use disorder. 
Early remission is defined as at least three but less than 
12 months without meeting any criteria, while sustained 
remission is defined as at least 12 months without any 
criteria, except craving. 
Many of the DSM-5 criteria are more relevant to younger 
people, particularly those that focus on functional level 
(Farkas, 2014). In addition, these diagnostic items might 
not be especially relevant or useful for many older adults, 
especially those who are socially isolated and do not drive, 
work or volunteer. Observations of physical symptoms and 
changes in health are more appropriate when assessing 
this population, with poor sleeping and eating habits being 
common and often related to substance use in older adults. 
• Detailed knowledge about or attachment  
to a particular drug;
• Complaints about other physicians who refuse  
to write prescriptions;
• Excessive daytime sleepiness;
• Changes in personal grooming and hygiene; and
• Social withdrawal.
When considering which screening tool to use with older 
adults, it is important to keep in mind that each tool varies in 
terms of ease of use, sensitivity, specificity and applicability 
to different subsets of this population. Therefore, it might 
be useful to employ more than one tool to improve 
screening effectiveness (Moore  et  al., 2002; Koh  et  al., 
2016). Some laboratory tests, such as mean cell volume 
and liver function tests, can be used as a form of screening. 
These tests can show damage relating to alcohol use in 
older adults at lower levels of consumption, making it a 
more sensitive test in this population.
6.4 Assessment 
There is always a need for comprehensive assessment 
when evaluating older adults. A guide from the United 
Kingdom’s Royal College of Psychiatrists (2015) provides 
useful considerations about history-taking and systematic 
assessment in older adults. It emphasizes the need for 
a non-judgmental, non-ageist approach that takes into 
account the values and experiences of the patient. It is also 
points out that it is important to adjust the tempo of the 
assessment according to the needs of the patient. 
In the case of a possible diagnosis of a substance use 
disorder, considerable information must be gathered from 
the patient and often from providers of collateral information 
such as family members and caregivers. An essential 
biopsychosocial approach includes the following items:
• A full history of the patient’s medical  
and psychiatric illnesses;
• The patient’s use of medications  
and other substances;
• The patient’s personal and family history;
• A mental status examination, including  
cognitive screening;
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at least three times more likely than non-depressed older 
adults to have an alcohol use disorder (Caputo et al., 2012; 
Devanand, 2002). Older adults with generalized anxiety 
disorder are more than twice as likely as those without 
an anxiety disorder to have a substance use disorder 
(Mackenzie, Reynolds, Chou, Pagura, & Sareen, 2011). 
There is also a particularly high suicide rate among the older 
adult population, especially in men, with alcohol abuse and 
dependence being the second most common category of 
psychiatric disorder associated with completed suicide in 
this population (Blow, Brockmann, & Barry, 2004). 
Some older adults can have an early onset disorder that 
has been present throughout much of their adult life 
(Farkas, 2014). These individuals may have a history of 
multiple treatment attempts as well as multiple medical and 
psychiatric problems associated with their substance use. 
There is often a history of marital and family dysfunction 
and estrangement, and there might be associated 
homelessness in some cases. The prognosis for early 
onset clients is often worse because of their lack of social 
support, chronic physical problems (such as liver and 
cardiovascular illness) and cognitive impairment. 
In comparison, people with a late onset disorder are 
characterized by a history of more significant alcohol or drug 
use after mid-life. Some of these individuals may have been 
social drinkers. There is often a strong association between 
late onset of substance use and many of the mental and 
physical deficits associated with aging. Physicians might 
also unwittingly worsen the situation by prescribing 
additional medications that either interact with alcohol or 
lead to an additional substance use disorder. However, the 
prognosis for late onset substance use disorder is often 
good. When compared to those with early onset disorders, 
these individuals will typically have developed coping skills 
that do not involve the use of alcohol or other substances, 
and they often have stronger social support systems along 
with better physical and mental health (Farkas, 2014). 
6.4.3 Atypical Presentations in Older Adults
Detection and diagnosis in older adults can be difficult 
as the signs of problematic substance use and addiction 
can be confused with symptoms of aging and a variety of 
other health problems associated with older age such as 
dementia, depression, Parkinson’s disease, falls, sedation 
or insomnia. Changes in level of functioning can be 
attributed to other conditions or the aging process itself. 
6.4.2 Diagnostic Challenges  
of Co-occurring Disorders
The multiple overlapping medical problems often seen in 
older adults can create a complex diagnostic challenge for 
clinicians. In many cases, older adults will attribute health 
symptoms to their underlying medical conditions rather 
than substance use. The relationship between alcohol use 
and cognition in older adults is also complicated, as chronic 
alcohol use can lead to a variety of cognitive disorders 
such as alcohol-related dementia and Wernicke-Korsakoff 
syndrome. To complicate matters further, patients could 
present with evidence of mixed dementia, including 
features of vascular dementia and Alzheimer’s disease, in 
addition to a history of excessive alcohol use. 
Specific criteria for alcohol-related dementia have been 
proposed and validated in at least one study (Oslin & Cary, 
2003). It is important that clinicians use an appropriate 
standardized cognitive screening test during assessment, 
such as the Mini-Mental State Examination or the Montreal 
Cognitive Assessment (Folstein, Folstein, & McHugh, 1975; 
Nasreddine et al., 2005). In addition to cognitive screening, 
clinicians should evaluate the person’s ability to function, 
including basic functions (“activities of daily living”) and 
more complex tasks (“instrumental activities of daily living”; 
Lawton & Brody, 1969). It is also important to evaluate the 
presence of chronic pain, which is commonly associated 
with alcohol and other substance use. 
Delirium and withdrawal
In hospital inpatient units and emergency departments, 
it is especially important to rule out delirium. One 
common cause of delirium is delirium tremens related 
to acute alcohol withdrawal, which most commonly 
presents as a hyperactive delirium with agitation and 
visual hallucinations. The Confusion Assessment 
Method is a validated and easy-to-use screening 
instrument that is widely recognized for its use in 
detecting delirium (Inouye et al., 1990).
There is significant co-occurrence of substance use 
disorders and other mental health disorders. For example, 
the vast majority of older adults with a DSM-IV diagnosis 
of either alcohol abuse or alcohol dependence have a 
history of depression. Similarly, depressed older adults are 
require or incentivize medical schools to provide mandatory 
courses that will equip young healthcare professionals 
to address substance use and its consequences. 
Associations of clinical professionals are also encouraged 
to provide continuing education and training courses for 
those already in practice.
Ram and Chisholm (2015) reviewed the literature on the 
current inadequacies in substance use and addiction training 
in medical schools and suggested strategies to address 
this gap, focusing particularly on physician education. 
They emphasized that physicians often fail to adequately 
screen, diagnose and manage substance use disorders, 
with one study finding that less than one-third of primary 
care physicians carefully screened for substance abuse 
(O’Brien, 2008). Other studies have shown that physicians 
at outpatient clinics have a success rate in detecting 
individuals with substance use disorders of just 25–50% 
(Miller, Sheppard, Colenda, & Magen, 2001; Sillanaukee, 
Kaariainen, Sillanaukee, Poutanen, & Seppa, 2002). 
Many factors contribute to the lack of appropriate 
screening and diagnosis. In addition to feeling unprepared 
or lacking confidence, some physicians can have negative 
or pessimistic attitudes about substance use disorder 
treatment (Miller  et  al., 2001). Such attitudes make the 
training of medical students especially critical: medical 
school represents the most formative time in a physician’s 
career and exposure to the culture of medicine at that time 
can have a significant impact on professional identity. 
Studies have suggested that, on average, U.S. medical 
schools devote only 12 hours of curricular time to 
substance use and addiction. In one survey, 119 of 125 
accredited medical schools in the U.S. reported providing 
some education in substance use and addiction. However, 
only 12 had a separate required course in the curriculum 
and only 45 offered a separate elective course (Yoast et al., 
2008). In addition, much of this training is focused on 
the biology of addiction, with relatively little education on 
appropriate attitudes such as respect, compassion and 
integrity, or on the treatment skills necessary to care for 
individuals who use substances. 
Based on their findings, Ram and Chisolm (2015) 
suggested that medical schools expand the focus of 
their curricula to include information about evidence-
informed substance use treatments, foster humanistic 
and professional attitudes, and provide students with 
opportunities to practice evidence-based treatment skills 
through standardized patients or clinical simulations. 
The signs of problematic alcohol or other substance use 
could also present differently from one older adult to the 
next, and might include a number of mental and cognitive 
health issues, behavioural changes, or physical signs and 
symptoms. Cognitive presentations can include signs of 
memory difficulty, delirium or even dementia, and there is 
sometimes an overlap between cognitive disorders and 
inappropriate substance use. Some patients could present 
with symptoms of depression or irritability. Behavioural 
changes could include isolation, lack of self-care and loss 
of interest or motivation. Physical changes could include 
weight loss or malnutrition, ataxia (lack of muscle control), 
falls, bruising, urinary incontinence or increasing frailty. 
Depending on the setting, atypical presentation of 
substance use in older adults could include substance 
withdrawal states. Although alcohol withdrawal is the most 
common form, it is also possible for individuals to present 
with benzodiazepine or opioid withdrawal. Some patients 
who present with significant cognitive impairment could also 
have alcohol-related dementia or the associated Wernicke-
Korsakoff syndrome (Oslin & Cary, 2003). Symptoms can 
include ataxia, confusion, vision changes (e.g., abnormal 
eye movements, double vision, drooping eyelids), 
significant short-term memory dysfunction, hallucinations 
and confabulation (distorted or misinterpreted memories). 
Finally, as polypharmacy (the use of multiple pharmaceutical 
medications) is prevalent among older adults, the risk of 
misusing prescription and over-the-counter medication 
rises with aging. Clinicians should always consider the 
possibility that patients are using excessive amounts of 
medication related to either misuse or prescribed amounts, 
often by multiple physicians.
6.5 Training Needs for Healthcare 
Professionals
A recent report on alcohol, drugs and health by the Surgeon 
General of the United States stated that integration of 
mental health and substance use disorder care into general 
health care will not be possible without a workforce that is 
competently cross-educated and trained in all areas (U.S. 
Department of Health and Human Services, 2016). The 
report notes that only 8% of American medical schools 
require students to take a separate course on addiction 
medicine, while only 36% offer an elective course on that 
topic. Minimal or no professional education on substance 
use disorders is available for other health professionals. The 
report recommends that federal and state policies should 
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Abuse (2005). The core curriculum is focused on screening, 
brief intervention and referral to treatment, and can then 
be adapted by residency programs to meet their individual 
needs. The curriculum also encourages direct observation of 
family medicine residents to ensure the core competencies are 
learned adequately. Project Mainstream’s core competencies 
for family medicine residents are summarized in Table 3 below. 
It should be noted that the implementation of such a 
curriculum on a broad scale would require a new faculty 
development initiative to train supervisors, as well as a 
series of workshops to create a network of trained faculty.
6.6 Conclusion
Following the assessment and formal diagnosis of a 
substance use disorder, the next challenge for clinicians is 
to develop a treatment plan that includes full consideration 
of the wide variety of options. For older adults, the 
options for treatment are both pharmacological and non-
pharmacological in nature, and can involve detoxification, 
short-term treatment and maintenance treatment. 
Chapter 7 of this report provides more details on the 
available prevention and treatment options for older adults, 
taking into account the effective interventions and unique 
considerations for this population.
6.5.1 Training Programs and Curricula
Despite the lack of formal training in substance use offered 
by medical schools, there are a number of innovative 
teaching programs currently in place, including a four-
day service elective at homeless shelters; a web-based 
program focused on screening, brief intervention and 
referral to treatment; and a course that includes 14 web-
based video modules with associated faculty development 
training (Packer, Carnell, Tomcho, & Scott, 2010; Tanner, 
Wilhelm, Rossie, & Metcalf, 2012; MedU, n.d.). 
Other successful programs include Project Engage at 
Christiana Care Health System (one of the largest healthcare 
providers in the U.S.), which trains nurses to screen all 
patients about their substance use patterns. A positive 
screening results in a referral to behavioural counsellors for 
a brief intervention in the emergency department, as well 
as a referral for further treatment. Initial results suggest this 
program has had a positive impact on nurses’ screening 
and referral behaviours — and also on their attitudes 
toward screening and referral (Pecoraro et al., 2012). 
In their review of curriculum improvements in family medicine 
residency programs, Seale and colleagues (2010) described 
an eight-module curriculum based on the substance abuse 
core competencies defined by Project Mainstream of the 
Association for Medical Education and Research in Substance 
Table 3. Core competencies in substance abuse for family medicine residents
Residents will:
• Perform age-, gender- and culture-appropriate screening for unhealthy substance use
• Effectively assess patients with unhealthy substance use
• Provide brief interventions to patients with unhealthy substance use
• Demonstrate effective counselling methods to help prevent unhealthy substance use
• Refer patients with substance use disorders to treatment settings that provide pharmacotherapy  
or psychosocial counselling for relapse prevention
• Recognize, treat or refer comorbid medical and psychiatric conditions in patients with substance use conditions
• Refer patients with substance use disorders to appropriate treatment and supportive services
• Be aware of the ethical and legal issues around physician impairment from substance use and the resources for 
referring potentially impaired colleagues, including employee assistance programs, hospital-based committees, 
physician health programs and licensure boards
• Identify the legal and ethical issues involved in the care of patients with unhealthy substance use
• Provide pharmacologic withdrawal to patients with substance dependence
• Provide or refer to treatment for relapse prevention (both pharmacotherapy and psychosocial counselling) in patients 
with substance use disorders
Source: Seale, Shellenberger, & Clark (2010).
Barbara, an 81-year-old retired teacher, fell at home and fractured her hip, requiring 
surgery at her local hospital. She has a history of hypothyroidism, hypertension, urinary 
incontinence, cholecystectomy and high cholesterol. She also experienced mid-life 
depression and has taken citalopram for almost 20 years. When asked about her 
alcohol intake, Barbara said she was only a social drinker. She also told her doctor  
that she stopped taking her antidepressant several months earlier as she felt she didn’t 
need it any longer. 
On the third day after surgery, Barbara suddenly became agitated and disoriented,  
with vivid visual and tactile hallucinations, paranoid delusions and day/night reversal 
with severe insomnia. She was also experiencing tremors and a sensation of bugs 
crawling on her skin. Terrified and demanding to leave the hospital, Barbara was treated 
with haloperidol (5 mg intramuscular) and briefly put in physical restraints. A diagnosis 
of post-operative delirium was made but the cause was uncertain: blood work was 
normal with no evidence of infection. She scored 18 out of 30 on the Mini-Mental State 
Examination, and was unable to correctly place the numbers and hands when asked to 
draw a clock set to 10 past 11. When her daughters arrived, they said Barbara enjoys 
several large martinis every evening — and has been drinking significantly more since 
her husband died. They also reported some evidence of forgetfulness and told the 
doctor that Barbara had at least three falls during the past four months. 
Barbara’s presentation is classic for acute alcohol withdrawal. Delirium tremens 
generally occurs two to four days after a person’s last alcoholic drink. During 
hospitalization, this diagnosis is often overlooked as many individuals lie about their 
alcohol intake. In this case, information from the family provided the essential details 
about Barbara’s increased alcohol intake. Screening tools for substance use disorders 
are useful only when individuals provide an honest estimate of their intake. 
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Substance Use Treatment 
for Older Adults
07
CHAPTER AT A GLANCE
• As the number of older adults with substance use disorders increases, it will become 
particularly important for treatment centres to offer age-specific services.
• Older adults face societal barriers as well as unique complexities in their physical 
and mental health, all of which make it difficult to identify and treat substance use 
disorders in this population.
• Physicians play a key role in increasing older adults’ awareness of the relationship 
between substance use and health outcomes.
• A variety of patient-centred approaches and techniques can be incorporated into 
clinical practice to help identify, refer and treat substance use in older adults.
• Although age-specific services can lead to better treatment outcomes in older adults, 
the availability of such services in North America is limited.
CHAPTER
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7.2 Recognizing Substance  
Use Disorders in Older Adults
The most important step toward recognizing SUDs in 
older adults is simply accepting that such disorders are 
possible in this population (Taylor & Grossberg, 2012). 
The U.S. Substance Abuse and Mental Health Services 
Administration recommends yearly screening for all 
adults ages 60 and older as part of their regular physical 
examinations, as well as additional screening when 
experiencing changes in health status, major life events or 
transitions (e.g., loss of a partner or spouse, retirement, 
move to new home or location), a decrease in cognitive 
or behavioural functioning, or before prescribing new 
medications (Blow, 1998). 
While some older adults will acknowledge their problematic 
use of alcohol or other drugs on their own, it is also 
common for the problem to be identified by concerned 
family or friends. In some cases, an SUD is identified while 
a patient is hospitalized for another health issue, usually 
because the sudden lack of access to alcohol or drugs 
causes withdrawal symptoms to emerge. For this reason, 
medical professionals, particularly primary and emergency 
care personnel, are especially well positioned to identify 
SUDs in older adults. (See Chapter 6 for more information 
on the various methods used to assess substance use in 
older adults.)
The low percentage of older adults in treatment for SUDs 
could be due partly to the fact that the symptoms of an 
SUD in older adults often mimic or are complicated by 
other health conditions. Comorbid health conditions 
common to the aging process (such as diabetes, high 
blood pressure, chronic pain, insomnia and gastrointestinal 
distress) can mask the signs of an SUD, making it more 
difficult to identify. Emotional and cognitive challenges such 
as dementia, Alzheimer’s disease and depression can also 
mask the symptoms of an SUD, complicating assessment 
and treatment. 
Due to the natural aging process, older adults experience 
unique complexities in their physical and mental health 
that make them more vulnerable to the effects of alcohol 
and medications. This increased vulnerability puts them at 
greater risk for harmful drug interactions, cognitive decline, 
injury, sleep problems, memory problems, liver disease, 
cardiovascular disease and mental health issues (Blow, 
1998; Barry, 1997; Kirchner  et  al., 2007; Oslin, 2000; 
Maree, Marcum, Saghafi, Weiner, & Karp, 2016; Simoni-
7.1 Introduction
The baby boomer generation grew up in the 1960s when 
permissive attitudes toward drugs and alcohol were 
common. As a result, today’s cohort of older Canadians 
have higher rates of past or current substance use disorders 
than previous cohorts (Gfroerer, Penne, Pemberton, & 
Folsom, 2003). As this generation continues to age, the 
number of older adults in need of substance use treatment 
services is expected to grow exponentially (Ialomiteanu, 
Hamilton, Adlaf, & Mann, 2013; Rotondi & Rush, 2012). 
Historically, older adults have not participated in treatment 
programs as often as younger adults. There also remains 
a common societal misconception that problematic 
substance use and substance use disorders in older adults 
either do not exist or are not worth treating. However, there 
is a growing body of evidence that addiction treatment for 
older adults can reduce or stop substance use — improving 
both health outcomes and quality of life (Whitlock, Polen, 
Green, Orleans, & Klein, 2004; Kuerbis  et  al., 2015; 
Schonfeld et al., 2015; Ettner et al., 2014; Satre, Mertens, 
Areán, & Weisner, 2004; Oslin, Pettinati, & Volpicelli, 2002).
Older adults face unique barriers that contribute to the failure 
to identify and treat of substance use disorders (SUDs). For 
example, ageist beliefs cause older adults and healthcare 
professionals alike to internalize false stereotypes about aging 
(Butler, 1969; Blow, 1998; Morgan, Brosi, & Brosi, 2011). 
It is also common to see permissive attitudes toward older 
adults’ use of alcohol and drugs. Caregivers, family, friends 
and medical professionals often view these substances as 
“one of the last few pleasures” for older adults, so they let 
the behaviour continue under the assumption that addiction 
cannot be treated in later life. While they might recognize 
problematic substance use among older adults, they choose 
not to address it (Klein & Jess, 2002; Benshoff, Harrawood, 
& Koch, 2003). Other barriers such as gender, religious 
beliefs, diminished social support and a lack of financial 
resources also contribute to the low levels of identification 
and treatment of SUDs in the older adult population. 
Society’s lack of understanding that addiction is not a 
choice but a chronic disease further contributes to the 
stigma and shame that often prevents older adults from 
seeking treatment for SUDs (U.S. Department of Health 
and Human Services [DoHHS], 2016). For others, the 
treatment options are limited or not specific to older adults. 
Issues related to diagnostic classification also lead to the 
underdiagnosis or misdiagnosis of SUDs in older adults. 
7.3 Treatment Options for Older Adults
Depending on the type and severity of an SUD, the 
American Society of Addiction Medicine recommends 
that treatment begins with the least intensive option and 
then progress to more intensive options (David, 2013). The 
different levels of care available include:
• Outpatient care (weekly individual  
or group counselling);
• Intensive outpatient care (daily individual or  
group counselling over a longer period of time);
• Residential care (24-hour supervision and  
clinical monitoring); and
• Medically managed inpatient care (treatment 
services in a supervised medical or psychiatric 
hospital setting). 
While many older adults benefit from low-intensity 
interventions, others do not. However, unless there is 
significant impairment, active suicidal ideation or other 
acute health concerns, older adults must be free to choose 
their preferred method of treatment. In general, older adults 
prefer a gentler motivational approach to a confrontational 
approach. Table 1 compares and contrasts these two 
treatment approaches. 
Wastila & Yang, 2006). Although some individuals use 
psychoactive prescription medications to “get high,” many 
unintentionally develop a substance use disorder due to 
pain, anxiety, depression or insomnia (Simoni-Wastila & 
Yang, 2006; Blow et al., 2006). 
7.2.1 Co-occurring Mental Health Issues
Major life changes that are, in some cases, unique to 
the aging process (such as the loss of a loved one, 
retirement and health issues) can all cause or worsen 
existing depression and anxiety — and increase the use 
of alcohol or drugs to cope with the stress. Studies show 
that older adults with SUDs have high rates of co-occurring 
psychiatric illnesses (ranging from 21% to 66%) and are 
associated with poorer health outcomes, higher health 
care utilization, social dysfunction, higher rates of suicide 
ideation, heightened mortality and poorer prognosis of 
mental illness when compared to individuals with either an 
SUD or psychiatric illness alone (Blow, 1998; Devanand, 
2002; Salmon & Forrester, 2012; Blow, Loveland Cook, 
Booth, Falcon, & Friedman, 1992; Brennan, Schutte, & 
Moos, 2005; Blazer & Williams, 1980; Jinks & Raschko, 
1990; U.S. DoHHS, 1999; Jeste et al., 1999). 
A study by Blixen and colleagues (1997) found 38% 
of older adults admitted to a psychiatric hospital had 
both a psychiatric disorder and an SUD. This finding 
highlights the importance of systematic screening and 
specialized treatment for both substance use and comorbid 
psychiatric conditions.
Table 1. Substance abuse treatment preferences for older adults
Motivational approach Confrontational approach
• De-emphasis on labels
• Gentle, warm and caring
• Emphasis on personal responsibility
• Elicit concern
• Meet resistance with reflection
• Individual identifies goals
• Strategies are negotiated
• Accept self as addict
• Assertive
• Judgmental and controlling
• Present evidence of problem
• Meet resistance with correction
• Goals are prescribed
• Strategies are prescribed
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Initial treatment for alcohol withdrawal should include 
fluids, electrolytes, thiamine and magnesium. Depending 
on the severity, medication assisted therapy (MAT) can 
be used to alleviate the discomfort associated with 
withdrawal symptoms, although  few studies have 
examined the use of MAT for alcohol withdrawal in 
older adults. Sedative hypnotics, such as shorter-acting 
benzodiazepines (lorazepam, alprazolam or oxazepam) 
have been recommended for delirium and seizures, but 
there is little information on dosing for older adults (Kraemer, 
Conigliaro, & Saitz, 1999; Taheri et al., 2014).
Studies of middle-aged adults have shown that anti-craving 
medications such as acamprosate and oral naltrexone can 
reduce return-to-drinking rates. However, none of these 
studies have focused on older adults (Jonas et al., 2014). 
Naltrexone, an opioid antagonist approved by both Health 
Canada and the U.S. Food and Drug Administration 
(FDA), has been shown to reduce alcohol cravings 
and has some efficacy in preventing relapse to heavy 
drinking (O’Malley  et  al., 1992). Evidence of its safety 
and effectiveness in older adults is limited (Srisurapanont 
& Jarusuraisin, 2005; Barrick & Connors, 2002; Oslin, 
Liberto, O’Brien, Krois, & Norbeck, 1997). Naltrexone can 
be administered orally or via injection on a monthly basis 
for patients who are unable to adhere to a daily regimen 
(Ciraulo, Dong, Silverman, Gastfriend, & Pettinati, 2008). 
There have been no studies conducted on the safety and 
efficacy of injectable naltrexone in older adults. Naltrexone 
is not recommended for individuals who use opioids for 
pain management or those with acute disorders of the liver. 
Acamprosate has also been approved by Health Canada 
and the U.S. FDA for the treatment for alcohol use disorder 
due to its ability to reduce alcohol craving in adults. Unlike 
naltrexone, acamprosate can be used by patients with liver 
issues or those who are on opioids for pain, but it cannot be 
used by those with inadequate renal function (Jonas et al., 
2014). Once again, no studies have assessed its efficacy or 
safety in older adults. As a result, acamprosate is seldom 
used in the long-term treatment of alcohol use disorders 
among older adults (Sass, Soyka, Mann, & Zieglgansberger, 
1996; Pelc et al., 1997; Anton et al., 2006). 
7.3.1 Acute Care: Intoxication and Withdrawal
An SUD cannot be fully addressed until the individual has 
been stabilized from a medical and psychiatric perspective 
(Bommersbach, Lapid, Rummans, & Morse, 2015). Once 
the individual has been identified as at-risk for an SUD, 
assessments for acute intoxication and potential for 
withdrawal are needed. 
Older adults tend to have more medical and psychological 
comorbidities that go unrecognized than younger patients. 
They also have greater clinical risks associated with 
withdrawal and medical stabilization, especially if they have 
been taking a very high dose or have prolonged use of 
alcohol or other drugs. In these cases, detoxification in a 
medical setting is suggested. For safety, acutely intoxicated 
older adults should be referred to a medically monitored or 
managed setting. Under hospital supervision, clinicians are 
able to work on a safe detoxification and withdrawal process, 
while also managing medical and psychiatric comorbidities 
to minimize the chance of severe complications. Inpatient 
treatment could also be needed for individuals who are 
experiencing suicidal ideation, are frail, are experiencing 
relapse or are addicted to multiple substances. 
The substances of most concern for older adults are alcohol, 
tobacco and psychoactive prescription medications, 
primarily benzodiazepines, sedatives and opioids used to 
treat sleep, pain and anxiety issues.
Treatment for Alcohol Use Disorder
Although clinicians can use their discretion in determining 
the setting for care, inpatient detoxification is generally 
recommended for older adults with alcohol use disorder. If 
the patient’s history is well known and the symptoms are 
mild, outpatient monitoring might be appropriate as long as 
close daily monitoring is possible. However, it is important to 
note that even at lower daily intake, older adults experience 
an increased sensitivity to alcohol detoxification symptoms. 
They are more likely to have more severe and longer 
lasting alcohol withdrawal symptoms than their younger 
counterparts. Common symptoms of alcohol withdrawal in 
older adults include tremors, anxiety, insomnia, tachycardia 
(rapid heart rate) and diaphoresis (excessive sweating). 
Untreated symptoms can bring about serious complications 
such as seizures, delirium tremens (rapid onset of confusion), 
hallucinations and death (Goodson, Clark, & Douglas, 2014). 
who want to eventually abstain from opioids, but is less 
useful for those who need long-term pharmacotherapy 
or have chronic pain. For these patients as well as those 
with recurring opioid relapse, buprenorphine maintenance 
therapy is a better option. Buprenorphine can be more 
convenient than methadone, which requires daily 
administration at a supervised clinic. It is also associated 
with pain relief and, when compared to methadone, is 
more cost-effective and carries less risk for overdoses and 
harmful drug–drug interactions in older adults.
Treatment for Benzodiazepine Dependence
Although it is rare for individuals to experience a non-
intentional benzodiazepine overdose, the risk is higher in 
older adults due to age-associated changes in medication 
metabolism. In the event of an overdose, the benzodiazepine 
antagonist flumazenil can be safely administered to 
older adults at low doses. Psychotherapy, along with a 
medically supervised stepped withdrawal schedule and 
education about benzodiazepine use, is the preferred initial 
approach for benzodiazepine withdrawal (U.S. DoVA & U.S. 
DoD, 2015; Gould, Coulson, Patel, Highton-Williamson, & 
Howard, 2014). 
Withdrawal symptoms can be similar to those of alcohol 
withdrawal, including anxiety and sleep disturbances, as 
well as life-threatening complications such as seizures. 
The risk of such complications emphasizes the importance 
of a gradual, tapered approach to treatment. Tapering 
can last from four to 12 weeks and, on occasion, can be 
combined with additional medications such as trazodone, 
which is used to treat sleep disturbances. It is also, more 
rarely, combined with carbamazepine, which is used to 
treat seizures (Rickels  et  al., 1999; Markota, Rummans, 
Bostwick, & Lapid, 2016). Tannenbaum and colleagues 
(2014) found that a 22-week tapering protocol and 
minimum intervention strategy was associated with 27% 
of individuals discontinuing benzodiazepines within six 
months compared to just 5% in the control group. Similar 
results were noted by Paquin and colleagues (2014), 
whose literature review of 28 studies found success rates 
of 32% among older adults who did tapering alone, 32% 
with tapering plus cognitive behavioural therapy and 36% 
with tapering plus medication substitution. 
It is recommended that all patients on MAT keep an 
emergency naloxone kit in case of overdose. They should 
also attend community-based mutual help meetings such 
as Narcotics Anonymous. 
Treatment for Opioid Use Disorder
When an older adult undergoes an opioid overdose, it 
should be treated as a life-threatening emergency. Due 
to the physiological changes that are part of the aging 
process, older adults experience higher concentrations 
of opioid metabolites in their systems. Older adults with 
pulmonary disorders also have an increased likelihood of 
pulmonary suppression during an overdose. Naloxone, 
starting at lower doses, has been shown to be an effective 
treatment for opioid overdoses in older adults.
Once the individual has been stabilized, a controlled 
environment such as a hospital or intensive outpatient 
program might be necessary to reduce the risk of 
uncomfortable withdrawal symptoms (David, 2013; U.S. 
Department of Veterans Affairs [DoVA] & U.S. Department 
of Defense [DoD], 2015). Because older adults are more 
likely to have comorbid chronic pain, the severity of opioid 
withdrawal can be magnified by the effect of worsening 
pain, causing the individual significant discomfort. 
To help alleviate extreme withdrawal symptoms, 
antipsychotics such as quetiapine can be used, but only 
on a short-term basis. Benzodiazepines are not 
recommended for older adults undergoing opioid 
detoxification due to their sedating and cognitive side 
effects. In addition, benzodiazepines combined with 
opioids increase the chances of overdose and death. In 
most cases, a tapered approach, which incorporates 
careful monitoring along with the use of clonidine or 
gabapentin to reduce the severity of withdrawal symptoms, 
is most effective for opioid detoxification (Le Roux, Tang, 
& Drexler, 2016). Buprenorphine and methadone, at low 
doses, can also be used for opioid detoxification in older 
adults. Buprenorphine is preferred as it is the safer choice 
over methadone and can also have an antidepressant 
effect (Karp et al., 2014). 
Once stabilized, the individual and their clinician must 
agree on a treatment plan. Due to the high relapse rates 
among this population, older adults have more success with 
opioid maintenance therapy compared to detoxification 
without maintenance therapy (Northrup  et  al., 2015; 
Sees et al., 2000).
Three types of maintenance medications are used for older 
adults with opioid use disorder: naltrexone, methadone 
and buprenorphine. Naltrexone can be given to patients 
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Although many older adults feel it is “too late” to quit 
smoking, studies show they are indeed able to quit and 
actually have higher success rates of smoking cessation 
than younger adults (Abdullah & Simon, 2006). Nicotine 
replacement therapy is the most widely studied smoking 
cessation treatment for older adults, with evidence showing 
it is both safe and effective, especially when combined 
with behavioural counselling (Cawkwell  et  al., 2015). 
Other treatments, such as bupropion (an antidepressant) 
and varenicline (which alleviates nicotine cravings), have 
advanced rapidly and been shown to be safe and effective 
in the general population (Cohen, Haglund, & Mooney, 
2016). However, there remains a lack of high-quality data 
specific to older adults on ideal dosing, adherence and 
adverse events related to bupropion and varenicline. 
Treatment for Nicotine Dependence 
Tobacco use disorders are the most common and 
harmful SUD among all age groups. In its 2016 Canadian 
Community Health Survey, Statistics Canada estimated 
that approximately 9.5% of adults aged 65 years and 
older are daily or occasional smokers (Statistics Canada, 
2017). Older adult smokers are at increased risk of chronic 
obstructive lung disease, lung cancer and Alzheimer’s 
disease (Burns, 2000; Peters et al., 2008). They also have 
lower scores on cognitive function tests and experience 
an accelerated rate of cognitive decline (Mons, Schöttker, 
Müller, Kliegel, & Brenner, 2013; Cawkwell, Blaum, & 
Sherman, 2015; Zhong, Wang, Zhang, Guo, & Zhao, 2015). 
As there is a shortage of residential treatment programs 
designed for older adults, there have been few studies on 
the effectiveness of such programming for this population. 
Slaymaker and Owen (2008) studied 67 alcohol dependent 
older adults in a residential treatment program designed 
for older adults. The program, which had a mean duration 
of 26 days, was based on a 12-step model and included 
detoxification and stabilization, individual and group 
therapy, lectures, and attendance at community meetings. 
Therapeutic approaches included a combination of 
motivational enhancement and cognitive behavioural therapy. 
Special seminars were also offered on topics unique to older 
adults such as continuing care, grief, life-stage transitions, 
leisure and recreation. Results showed that 71% of the older 
adults were abstinent at six months and 60% were abstinent 
12 months after leaving the program. 
Outpatient Treatment
Outpatient treatment is the most commonly studied 
treatment for older adults. As part of a case-management 
model of care, non-traditional settings for SUD treatment 
(such as community-based agencies and primary care 
settings) are an effective way to engage older adults 
in treatment and connect them to resources within the 
community (Kuerbis, Sacco, Blazer, & Moore, 2014). 
The PRISM-E study compared an integrated care model, 
where participants received services in a primary care clinic, 
to an enhanced specialty referral model, which provided 
referrals from primary care to a specialty mental health or 
substance use clinic. Results from both treatment groups 
found significant reductions in frequency and quantity of 
binge drinking over six months, despite lower levels of 
engagement (Oslin et al., 2006). 
7.3.2 Behavioural Treatments
One of the primary goals of addiction treatment is to 
educate and motivate individuals to engage in their 
recovery (Le Roux  et  al., 2016). Older adults do best in 
programs that offer age-appropriate care with clinicians 
who understand the unique issues and complexities of 
older adults (MacFarland, 2014; Lemke & Moos, 2003; 
Kuerbis & Sacco, 2013; Rothrauff, Abraham, Bride, & 
Roman, 2011). Programs must be individualized, easily 
accessible and open to the involvement of the older adult’s 
friends and family. They should also have structure, but not 
be overly strict (U.S. DoHHS, 1999; Holland et al., 2016; 
Kashner, Rodell, Ogden, Guggenheim, & Karson, 1992). 
Treatment for Cannabis Use Disorder
As the landscape shifts regarding cannabis legalization 
and the social acceptance and availability of marijuana 
increases, clinicians can expect to see more older adults 
with cannabis use disorders. 
Discontinuing cannabis after long-term use can lead to 
withdrawal (Gorelick  et  al., 2012), with symptoms that 
include irritability, anxiety, depression, sleeping difficulties 
and dysphoria, all of which can complicate cessation and 
lead to relapse (Budney, Novy, & Hughes, 1999; Budney, 
Roffman, Stephens, & Walker, 2007). There is a lack of 
evidence on how best to manage cannabis use disorder 
in both the general population and in older adults. Most 
studies are adaptations of alcohol interventions and include 
psychological interventions that consist of motivational 
enhancement therapy, cognitive behavioural therapy and 
contingency management. While most adults respond 
well to these interventions, many have problems similar 
to those who are dependent on other illicit drugs (Moore 
& Budney, 2003). Reduced use of cannabis, but not 
total abstinence, is the most common outcome of many 
randomized control trials. 
To date, there have been few pharmacological interventions 
for cannabis use disorder. One promising study found that 
oral THC (the psychoactive component of cannabis) reduced 
withdrawal symptoms associated with cannabis cessation 
(Haney et al., 2004). More studies on pharmacotherapies for 
cannabis use disorder are needed as well as interventions 
designed specifically for older adults. 
Inpatient Residential Treatment
Before they are able to safely and successfully detoxify, 
some individuals need to be placed in inpatient residential 
treatment settings to stop their continual access to alcohol 
and drugs. These individuals could have a lack of social 
support in stopping their alcohol or drug use, or could 
be dealing with social isolation that would make 
detoxification on their own too difficult or dangerous. 
Residential treatment can also be a good option for 
individuals who do not have the mobility to get to and from 
treatment appointments, or who have no other options 
to receive specialized care. Inpatient residential treatment 
programs can be delivered in settings such as group 
homes, halfway houses, extended care facilities, nursing 
homes and specialized rehabilitation programs. 
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severe substance use disorders, to engage in additional or 
more intensive treatment programs (Miller & Rollnick, 2012; 
Barry & Blow, 1999). For clinicians and staff in fast-paced 
healthcare settings who have limited time with patients, 
they represent a cost-effective and efficient way to provide 
immediate attention to individuals who are at risk for or 
experiencing substance use problems. 
Rooted in cognitive and social psychology, brief 
inter ventions are based on the transtheoretical model 
of change, which conceptualizes behaviour change as 
a movement through five stages: precontemplation, 
contemplation, preparation, action and maintenance 
(Prochaska & DiClemente, 1986). To help patients progress 
through these stages, clinicians seek to motivate them to 
identify their own intrinsic desire to change. This identification 
is done when the clinician, using a conversational style, 
illustrates the discrepancy between the patient’s personal 
goals and priorities and their current behaviours. 
Most brief interventions are based on the principles of 
motivational interviewing, which is a non-judgmental, 
patient-centred approach to discussing substance use and 
encouraging positive goals and life changes (Miller & Rollnick, 
2012). In motivational interviewing, clinicians ask open-
ended questions that help the patient explore and identify 
both the positive and negative aspects of their substance 
use. The clinician summarizes and reflects back to the 
patient the key motivational points, then gives feedback on 
how to develop a plan for change. For older adults, possible 
motivations for behaviour change might include the desire 
to maintain independence as well as optimal health and 
mental capacity (Blow, Walton, Chermack, Mudd, & 
Brower, 2000; Blow, Walton, Barry, et al., 2000). Studies 
have shown that brief interventions are acceptable for older 
adults and effective across treatment settings, especially 
in primary care or health clinic settings (Whitlock  et  al., 
2004; Kuerbis et al., 2015; Schonfeld et al., 2010, 2015; 
Ettner et al., 2014; Havard, Shakeshaft, & Sanson-Fisher, 
2008; Moore et al., 2011; Mowbray & Quinn, 2015). 
Screening, Brief Intervention and Referral to Treatment
Screening, brief intervention and referral to treatment 
(SBIRT) is a simple, consistent and time-sensitive technique 
designed to be incorporated into clinical practice within 
existing screening and intake procedures (Barry & Blow, 
1999). The key aspect of SBIRT is the integration of its four 
components — screening, brief intervention, referral and 
In general, older adults prefer treatment approaches that 
offer:
• Structured but flexible programs;
• Gender-specific treatment;
• A focus on building self-esteem;
• Written materials with large print;
• Staff who specialize in elder issues;
• An available sliding scale;
• Individualized attention or counselling;
• Optional family or friend involvement;
• Accommodations for physical disabilities;
• Group-based treatment;
• Transportation;
• Peer support;
• Food, clothing or shelter;
• Counsellors who practise good self-care;
• A focus on coping skills;
• Counsellors who genuinely care
• Linkages to outside services; and
• Accommodations for sensory declines or deficits. 
Two treatment modalities that have been adapted 
specifically for older adults are cognitive behavioural 
therapy (CBT) and supportive therapy models (STM). Both 
techniques take a psychotherapeutic and psychosocial 
approach, focusing on building social support, improving 
self-esteem and developing ways to cope with one’s 
substance use — and both have been shown to lead to 
improved outcomes in older adults (Kuerbis & Sacco, 
2013; Schonfeld et al., 2000; Schonfeld & Dupree, 2002). 
CBT is especially useful for older adults given its highly 
structured and individualized approach (U.S. DoHHS, 
1999). CBT models for SUD treatment help the individual 
focus on the way they think and behave so they can better 
manage their choices (Walters & Rotgers, 2012).
Brief Interventions
Brief interventions typically comprise one to five sessions 
ranging from a few minutes to an hour in duration. 
These sessions are designed to increase an individual’s 
motivation to change their behaviours (specifically, to 
reduce or eliminate substance use) and, for those with 
older at-risk drinkers in treatment, possibly because it 
seeks to reduce stigma by taking a broader approach to 
overall health (Blow, 1998).
Contingency Management
Another strategy for the treatment of SUDs in older adults is 
contingency management: the systematic reinforcement of 
desired behaviours and the withholding of reinforcement (or 
punishment) of undesired behaviours (Higgins, Silverman, & 
Washio, 2008). Contingency management is based on the 
principle that rewarded or reinforced behaviours are likely 
to reoccur. As an abstinence-based approach, treatment 
programs using contingency management can involve urine 
drug screens with monetary rewards or other incentives 
given for “clean” tests. By improving an individual’s ability 
to remain abstinent, contingency management allows 
them to take fuller advantage of other components of their 
treatment program. As such, it is meant to be a platform 
for other treatments rather than a stand-alone strategy 
(Prendergast, Podus, Finney, Greenwell, & Roll, 2006). 
treatment — into a network of diagnostic, early intervention 
and referral services within the community (Saitz, 2007; 
Babor et al., 2007). 
As the initial approach to treatment, SBIRT is a comprehensive 
model designed for medical settings to screen and intervene 
early with individuals who are at risk of or have developed an 
SUD. It takes a non-judgmental and motivational approach 
that is based on the public health principles of universal 
systematic screening, integrated into the normal routines at 
medical facilities and community settings. 
Case and Care Management
Case and care management models (CMM) are offered in 
non-traditional settings such as community agencies and 
primary care. The CMM approach to SUD treatment takes 
a comprehensive approach to addressing an individual’s 
overall health instead of focusing solely on their substance 
use. It also aims to connect the individual to resources 
within the community such as Alcoholics Anonymous or 
Narcotics Anonymous. There is some evidence that the 
CMM approach is effective at engaging and maintaining 
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In the United States, the Substance Abuse and Mental 
Health Services Administration and the Center for 
Substance Abuse Treatment have developed the 
Treatment Improvement Protocol (TIP) series to help guide 
the treatment of substance use disorders. TIP 26, which 
focuses on older adults, recommends that people aged 
65 and older consume no more than one standard drink 
per day or seven standard drinks per week (Blow, 1998). 
However, these limits might not be appropriate for the 
majority of older adults due to their increased likelihood of 
taking alcohol-interactive medications. One study showed 
that 77.8% of older adults who drank alcohol were also 
using alcohol-interactive medications, emphasizing 
the need for primary care providers to discuss the risks 
of combining any amount of alcohol use with these 
medications (Breslow, Dong, & White, 2015). 
As older adults often find it difficult to acknowledge 
their problematic substance use, clinicians can help by 
informing their older patients about age-related changes 
in metabolism and how alcohol can interact with sedatives 
and anti-anxiety medications. Discussions about the 
relationship between alcohol and drugs and other health 
problems (such as falls, hypertension and depression) can 
also increase older adults’ awareness of the connections 
between substance use and health outcomes (Blazer & 
Wu, 2009; Atkinson, 1999).
7.3.4 Prescribing Practices
It is critical that clinicians thoroughly understand how 
their prescribing behaviours contribute to the problem of 
non-medical use of prescription drugs. Many older adults 
unintentionally misuse prescription drugs due to a lack of 
knowledge about them, including their high potential for 
addiction and the effects of improper dosing. This type 
of misuse is particularly common among individuals with 
chronic pain, who tend to find the diagnosis of a prescription 
drug use disorder difficult to accept — resulting in them 
seeking to obtain opioids through various legal or illegal 
methods rather than seeking treatment, putting them at a 
high risk of accidental overdose (Fischer & Argento, 2012; 
Volkow & McLellan, 2011). 
Contingency management is an effective approach 
for treating SUDs (Prendergast  et  al., 2006; Higgins & 
Silverman, 1999; Petry, Tedford, & Martin, 2001; Petry, 
Martin, Cooney, & Kranzier, 2000; Dutra et al., 2008). While 
there is some evidence that the approach works well in 
older adults, more studies are needed (Weiss & Petry, 
2013; Petry et  al., 2000). Because the magnitude of the 
therapy’s effects decline slowly over time after the individual 
leaves contingency management, this approach should be 
used only as a supplement to other treatment methods — 
as a way to motivate the individual to remain abstinent 
and engage more productively in addiction treatment 
(Prendergast et al., 2006).
7.3.3 Addiction Treatment in Primary Care
Older adults seeking treatment for problematic substance 
use often face difficulties navigating the various treatment 
services and supports. Most primary care practices have 
an acute care orientation, with limited time and resources 
to detect and treat SUDs among older adults. While it is 
not expected that primary care providers will have the 
resources available to treat older adults with SUDs, they 
must develop linkages to and have knowledge of the 
available resources within the community for doing so 
(McLellan, Lewis, O’Brien, & Kleber, 2000). As part of their 
continuum of care, providers should be prepared to write 
referrals to treatment providers and then follow up with 
patients to determine if the referral was successful (Crome, 
Wu, Rao, & Crome, 2014). 
The Canadian Centre on Substance Use and Addiction has 
developed a series of care pathway guides, including one 
focused on older adults, to guide treatment for prescription 
drug use disorders (Canadian Centre on Substance Abuse, 
2016). These pathways outline the continuum of care 
that should be followed to provide better, more efficient 
support to people experiencing harms from problematic 
substance use, moving from awareness and screening to 
assessment, treatment options, and recovery and relapse 
prevention. At each stage in the pathway, the guides help 
providers identify their own roles, apply the right tools and 
help patients navigate the treatment system. 
7.4 Conclusion
It is well established that SUDs in older adults are 
underdiagnosed and undertreated. As the number of 
older adults with SUDs and problematic substance use 
increases, greater efforts aimed at screening and treating 
problematic substance use with a specific focus on older 
adults will be needed. In particular, it will become even more 
important to be able to accurately identify SUDs among the 
older adult population and for treatment centres to offer 
age-specific services. 
Older adults face unique barriers that contribute to the lack 
of identification and treatment of SUDs. Yet older adults 
are more likely than younger adults to complete treatment 
programs. They also have comparable or better treatment 
outcomes than younger adults, including reduced or 
eliminated substance use as well as improvements to 
overall health and quality of life. While evidence shows 
age-specific services can lead to better outcomes in older 
adults, the availability of such services remains limited 
across North America. 
In Ontario, accidental deaths related to prescription opioids 
doubled between 1994 and 2004 and continue to rise 
(Dhalla et al., 2009). Although older adults have a higher 
prevalence of chronic conditions that leads to an increased 
use of prescription drugs, clinicians have a responsibility 
to periodically evaluate the appropriateness of prescribed 
medications, including their dosing. However, the 2008 
Canadian Survey of Experiences with Primary Health Care 
found that only 48% of older adults with chronic conditions 
had their regular prescription medications reviewed by a 
doctor in the previous 12 months (Canadian Institute for 
Health Information, 2009). 
National guidelines, such as the Beers Criteria, can help 
educate physicians on specific medications that are 
potentially inappropriate for older adults (Steinman et al., 
2015). Efforts such as the Opioid Safety Initiative have also 
significantly affected the way clinicians prescribe opioids 
and helped individuals learn about drug-free methods 
for pain management (U.S. DoVA, 2014). Clinicians can 
also use strategies such as the “brown bag” approach, 
in which the patient brings all of his or her over-the-
counter preparations, supplements and medications in a 
bag to their clinical visit, to gain reliable information about 
medication use. Finally, prescription monitoring programs 
have been developed throughout Canada to promote 
the safe and effective use of controlled prescription 
medications. Although these programs have met with some 
success, they have high variability in their management, 
types of substances monitored and prescribing definitions 
(Furlan et al., 2014). 
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Robert retired at age 65, selling the hardware store he had owned with his wife, Jean, for 
36 years. They had planned to travel and enjoy their “twilight” years together; however, 
shortly after selling the business, Robert injured his back doing yard work. Now 70, 
Robert is plagued by chronic back pain that limits his mobility and daily activities.
Because the couple’s lives had revolved almost entirely around the hardware store 
and family activities, they had little time left for friends. Now that Robert is retired, his 
days feel empty and he is irritable from the chronic back pain. He has a lot more time 
on his hands but hasn’t developed many outside interests because he’s limited in the 
activities he can do. 
ROBERT
While he was a drinker in his 20s, 30s and early 40s, Robert’s use of alcohol was 
limited to when he was watching Sunday football games and during family meals. 
He had to cut back on his drinking due to high blood pressure and gastritis. Now, 
however, he finds that drinking helps alleviate some of the pain and stress from his 
chronic pain and boredom. He generally has about three drinks a day. 
Robert came to the clinic at the retirement complex for a follow-up on his 
hypertension and a flare-up of his gastritis. When asked how he was feeling, he said, 
“I guess I’m fine for an old man with a bad back. Not sure if it really matters how I feel 
at this age, nothing can be done for me.” He was also asked about what he does with 
his spare time, through which it was discovered that he has trouble sleeping, takes 
over-the-counter sleep medications and uses alcohol in excess.
Robert’s clinician is concerned about his alcohol intake, as well as his mixing of 
alcohol with sleep and other alcohol-interactive medication. Robert was counselled 
on his alcohol intake and the risks of mixing alcohol with his medications, and was 
given a referral to a pain specialist for his back. He was also provided with a monthly 
schedule for activities at the local senior centre.  
Robert began doing physical therapy on his back three times a week and takes anti-
inflammatory medication for it. He and his wife started attending activities at the senior 
centre, and ended up making new friends. Robert enjoys playing cards with a group 
of friends twice a week, and going out with them for weekly lunch and coffee outings. 
Robert’s pain and sleep have improved and his alcohol intake has decreased. 
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A Call to Action
08
CHAPTER AT A GLANCE
• Healthcare providers, caregivers, family members and the general public need  
to be more aware of the issue of substance use in the older adult population.
• Healthcare professionals require more education and training on how to effectively 
prevent, detect, assess and treat substance use in older adults.
• Tailored guidelines and recommendations should be developed for substance  
use in older adults, reflecting the unique nature of this demographic. 
• Age-specific services for the treatment of substance use disorders need to  
be made available and accessible to older adults.
• Guidelines for substance use and available treatments for substance use  
disorders in older adults should be communicated to healthcare professionals  
and the general public.
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8.1 Introduction
Older adults constitute the fastest growing subgroup of 
the Canadian population: by 2036, approximately one-
quarter of the people in this country will be over the age 
of 65. It is imperative that strategies to promote positive 
aging outcomes be brought to the forefront of healthcare 
initiatives  and resources dedicated to minimize and buffer 
the adverse impact this demographic change could have 
on the Canadian healthcare system.
This report focuses on substance use within the older 
adult population, an issue that will only become more 
important as this demographic continues to grow. The 
expectation that the issue will become more prevalent 
in the coming years reinforces the need for action now. 
Several chapters in this report suggest there is a need to 
differentiate within the broad category of “adults” because 
older adults have unique physiological, psychological and 
socio-environmental characteristics that differentiate them 
from younger adults. 
Although substance use is less common in older adults than 
younger adults, the effects of substance use can be more 
pronounced and problematic when it does occur. Similar to 
the period of rapid neurodevelopmental change seen during 
adolescence, aging is associated with several anatomical 
and physiological changes that increase a person’s 
vulnerability to the effects of substances. In particular, older 
age is associated with decreased homeostatic reserves 
(the capacity to adapt and bounce back physiologically) to 
compensate for the adverse effects of drugs on the brain 
and other organs, such as the liver and kidneys. 
Older adults are also prescribed more medications 
than younger people and, given the high rates of sleep 
abnormalities and pain in the older adult population, 
they can develop dependence to medications such as 
benzodiazepines and opiates. This tendency increases 
the risk for drug interactions with alcohol and other drugs. 
Even “moderate drinking” by older adults, as defined by 
Canada’s Low-Risk Alcohol Drinking Guidelines, can 
result in health consequences severe enough to lead to 
hospitalization, further emphasizing the need to revise 
these definitions and guidelines specifically for older adults.
Drug use in older adults can also result in consequences 
that mimic certain age-related trends such as cognitive 
decline, the development of mental health issues and 
increases in physical falls. Not only do the similarities 
intensify the consequences of substance use, they can also 
contribute to the under-recognition, under-diagnosis and 
under-reporting of substance use disorders in older adults. 
Many older adults have chronic health conditions that can 
complicate the diagnosis of substance use disorders. 
Social barriers also play a role, with false stereotypes 
about aging and age-related stigma affecting the reporting 
of substance use disorders in this population as well as 
proper diagnosis and treatment.
This call to action seeks to address the issues of under-
diagnosis and under-reporting of substance use disorders 
in older adults. It also points to the need to raise awareness 
of the growing issues associated with substance use 
by older adults. Raising awareness includes increasing 
healthcare professionals’ capacity and skills for screening 
and diagnosing these issues. This call to action advocates 
for clinical guidelines and recommendations that are tailored 
for the diagnosis and treatment of substance use disorders 
in older adults. Finally, it underlines the need to communicate 
effectively this information to the general public, healthcare 
professionals, decision makers and older adults.
8.2 Recommendations
There is a need for increased awareness of 
substance use in older adults among healthcare 
providers, caregivers and older adults. 
First and foremost, there is a need for increased awareness 
of substance use problems in the aging population. 
Throughout this report, it has been established that 
substance use disorders are under-diagnosed and under-
treated in older adults for a number of reasons, including 
the stigma faced by older adults and the under-recognition 
of the issue by healthcare professionals, who often confuse 
signs of substance use with signs of aging. To effectively 
address this issue, a greater acknowledgement and 
understanding of substance use disorders among older 
adults as well as their healthcare providers is needed.
Raising awareness
The Canadian Longitudinal Study on Aging is an 
ongoing research initiative funded by the Canadian 
Institutes of Health Research that will help raise 
awareness of substance use in older adults and help 
bridge the knowledge gaps that exist in this area.
Ageist social attitudes about substance use also need 
to be shifted. Doing so will require more research on 
substance use that focuses specifically on older adults. 
This population should also be included and taken into 
consideration in government policies, which tend to focus 
on the needs of younger populations. Healthcare providers 
can help facilitate this attitudinal shift by increasing their 
knowledge of the physical and mental health conditions 
that tend to co-occur alongside substance use disorders 
in older adults (e.g., depression, anxiety, insomnia, chronic 
pain). And if providers are encouraged or incentivized to 
identify and treat substance use disorders and co-occurring 
conditions more actively, it could help improve the quality of 
life of older adults while decreasing the costs to Canada’s 
healthcare system. 
There is a need for more education and training 
for healthcare professionals and students on 
substance use disorders in older adults.
From a healthcare standpoint, there is an urgent need to 
improve the training offered in educational programs for 
medical and paramedical professionals for the prevention, 
diagnosis and treatment of substance use disorders 
among older adults. Students and practising healthcare 
professional alike need more education and training to 
better integrate mental health and substance use care 
into general health care. Policies that require or incentivize 
schools to provide mandatory courses on both substance 
use disorders and mental health are recommended. 
Although some healthcare providers explore the possibility 
of problematic substance use with older adults, many 
do not. Because of such variable practices, there is a 
need to have this exploration incorporated into standard 
practice. Screening for substance use — using a non-
judgmental, non-ageist approach that takes into account 
the unique values, experiences and sensitivities of older 
adults — should be part of routine health checks. Such 
assessment tools will also need to disentangle symptoms 
of harmful substance use from symptoms of aging. While 
there is sufficient knowledge among healthcare providers 
to implement these changes, this need must be recognized 
and addressed in a standardized way across the entire 
system. Furthermore, initiatives related to professional 
development should be ongoing and flexible enough 
to adapt to the fast-growing aging population and their 
access to an expanding choice of drugs.
There is a need for guidelines and recommendations 
on substance use in older adults tailored to the 
unique nature of this demographic. 
Another important thread running through this report is the 
need for a nuanced and tailored approach to guidelines 
and recommendations on substance use in the older adult 
population. Although there is widespread recognition that 
the aging population requires unique guidelines, these 
must continue to evolve and adapt such that they can be 
standardized, consistent with existing evidence, and take 
into consideration how the definition of “aging” will change 
as the number of older adults continues to increase. To 
reflect this changing overall definition, there is a need to 
better define the different stages of aging and the nuances 
within the broad spectrum of the aging population. 
National guidelines
The Canadian Coalition for Seniors’ Mental Health  
recently received funding from Health Canada to 
develop guidelines for the prevention, assessment 
and treatment of alcohol, opioid, benzodiazepine and 
cannabis use disorders. These evidence-informed 
guidelines will help healthcare professionals, older 
adults and their families recognize and manage issues 
related to substance use.
As the older adult population grows in the years to come, it 
will be increasingly important to acknowledge the differences 
among individuals in the “older adult” demographic as 
well. To reflect the uniqueness of each stage of life and 
its variability, the process of aging must be looked at as a 
continuum rather than categorically. Although it can be 
useful to divide age groups into discrete categories, an 
individualized approach would better reflect the aging 
process and provide more effective results. Because the 
degree to which the older adult population is met with 
tailored guidelines and recommendations varies widely, 
there is a need to standardize the definition of “older adult” 
as well as the classifications used for other demographic 
groups, without obscuring the nuances and interacting 
factors that can differ on a case-by-case basis. The creation 
of age-specific recommendations for substance use must 
begin with a more precise and non-ageist understanding of 
the stages of development in older adulthood.
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pointing to a problematic gap in the system of care. There 
should be an increase in the number of tailored treatment 
programs for older adults, as the need for such programs 
will only increase in the years to come as the number of older 
adults with substance use disorders continues to grow. 
When creating age-specific treatment programs, healthcare 
providers should actively take the perspectives of older 
adults into account. As discussed previously in this report, 
older adults’ perception of “successful aging” aligns with 
the risk and protective factors associated with problematic 
substance use. This alignment means that interventions 
designed to promote successful aging, as defined by older 
adults, could also reduce problematic substance use. 
The tools necessary for age-specific treatment of 
substance use disorders already exist; it is just a matter 
of implementing them. Doing so will require harnessing 
the information and evidence that is out there and making 
age-specific treatment programs more widely available and 
accessible, as well as incorporating such programs and 
therapies into current treatment facilities.
Guidelines and treatments for older adults need to 
be communicated to healthcare professionals and 
the general public.
In addition to establishing guidelines for substance use 
and treatment programs for substance use disorders that 
are customized to the specific needs of the older adult 
population, it is important to effectively communicate 
information about those guidelines and programs to 
healthcare professionals, older adults and their caregivers, 
and the general public.
The issues raised throughout this report should be 
disseminated to healthcare professionals to ensure they 
are prepared to overcome the barriers to identifying and 
diagnosing substance use disorders in older adults. To 
effect positive change throughout the healthcare system, 
it will also be important to convey the information from the 
existing research to medical students, students in health-
related disciplines and policy makers. 
One factor that often leads to problems of substance use 
in older adults is misinformation communicated between 
clinician and patient or a lack of communication. For 
example, only about half of older adults with chronic 
health conditions had their regular prescriptions reviewed 
by a doctor within the past year. Older adults are also 
There is a need to improve the availability and 
accessibility of age-specific substance use 
disorder treatments and individualized care.
A greater number of treatment services and programs 
designed specifically to support older adults with substance 
use disorders is required. Although older adults face unique 
complexities in their physical and mental health that make 
them more vulnerable to the effects of substances, they are 
often excluded from clinical trials examining the safety and 
efficacy of new or existing treatments for substance use 
disorders. Treatments need to be designed that specifically 
cater to the older adult population. This need is intensified 
by the fact that older adults who require substance use 
treatment are increasing in needs and numbers, making 
it essential that future studies include older adults in 
treatment trials or conduct trials specific to this population. 
Considering the host of unique factors at play when 
discussing the older adult population, it is not surprising 
that age-specific care options have been found to lead to 
better treatment of substance use disorders. As put forth in 
this report, various patient-centred approaches and elder-
specific techniques can be integrated into clinical practice 
to help identify and treat substance use disorders in the 
older adult population. For example, older adults tend to 
do better when social engagement and the involvement 
of family and friends are integrated into their treatment 
programs. Thus, age-specific programs where healthcare 
providers move beyond questions of physical health to 
develop a more individualized, interpersonally focused 
treatment (e.g., supportive therapy models) should provide 
optimal results. 
Pathways to better treatment
The Canadian Centre on Substance Use and Addiction 
has developed care pathways to guide the treatment 
of prescription drug harms in older adults. Based on 
peer-reviewed literature as well as experiential evidence 
from subject-matter experts, these pathways outline 
the continuum of care for providing quality treatment to 
older adults experiencing harms from substance use.
However, despite the evidence indicating that age-specific 
services lead to better treatment for older adults, the 
availability of such programs is limited in North America, 
often unaware of the side effects and interactions of their 
medications. An increased emphasis on interpersonal 
communication could help address this issue. Similarly, 
it is important to provide older adults and caregivers 
with information about what they should do in particular 
situations related to substance use, along with information 
on the resources and programs that are available and how 
older adults can access them. 
8.3 Conclusion
This report seeks to bring to the forefront the increasingly 
significant consequences of substance use in the older 
adult population. It highlights how the increasing prevalence 
of substance use disorders among older adults, coupled 
with the increasing numbers of this population, is making 
substance use in older adults particularly relevant and 
consequential to Canada’s healthcare system and society 
as a whole. 
Thus, this call to action calls for increased awareness 
of the occurrence of substance use disorders in older 
adults, specifically through the training of healthcare 
professionals and the development of standardized 
screening tools. This training should take into consideration 
the specific needs, values and characteristics of older 
adults that distinguish them from other demographic 
groups. Similarly, there is a need for age-specific clinical 
guidelines and recommendations for substance use, as 
the unique attributes of older adults do not fit with blanket 
recommendations for adults in general. Likewise, age-
specific treatment programs that have already proven to 
be effective should be made more widely available and 
accessible. Finally, these recommendations need to be 
widely disseminated to the public as well as to relevant 
healthcare professionals and decision makers so the 
findings in this report can be used in an effective way. 
These recommendations aim to mitigate adverse 
consequences to the healthcare system that might be 
brought on by the growing issue of substance use in 
older adults. Creating age-specific services and providing 
professional training to address the under-diagnosis of 
substance use disorders in older adults are effective and 
important ways in which the issues related to problematic 
substance use in older adults can be controlled and 
decreased. By doing so, we will help not only the growing 
and vulnerable population of older adults, but also deliver 
benefits to our healthcare system and society as a whole. 


